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General introduction and 





Epidemiology of obesity and type 2 diabetes mellitus
The prevalence of overweight and obesity is increasing dramatically in countries 
throughout the world.  Since 1980, worldwide obesity has nearly doubled. The World 
Health Organization (WHO) defines overweight as a body mass index (BMI, calculated 
as bodyweight in kilograms divided by the square height in meters (kg/m2)) of 25 kg/
m2 or higher; obesity is defined as a BMI of 30 kg/m2 or more. In 2008, worldwide more 
than 1.4 billion adults were overweight, of whom around 500 million were obese (WHO 
‘Obesity and overweight’ factsheet). If past trends continue, the number of overweight 
and obese adults is projected to reach around 2.2 billion and 1.1 billion respectively by 
the year 2030 (1).
Obesity is a major risk factor for developing type 2 diabetes mellitus (T2DM). It 
therefore comes as no surprise to find that the increasing prevalence of overweight and 
obesity is accompanied by an increase in prevalence of T2DM. Nowadays, diabetes is 
one of the most common chronic diseases in almost every country. In 2000, the global 
prevalence of diabetes was 2.8%. Estimations of the prevalence of diabetes in 2030 
range from 4.4% to 6.4%, indicating the magnitude of this public health problem (2,3). 
The prevalence of T2DM is on the rise in low-to-middle income countries, which 
is attributed to a shift in infrastructure, technology and food supply that promotes 
over-nutrition and sedentary lifestyles. Especially striking is the increasing incidence 
worldwide of T2DM in people of South Asian descent (4). South Asians originate from 
the Indian subcontinent and represent one fifth of the total world’s population. Not only 
is the prevalence of T2DM higher in this population, South Asians are younger and tend 
to have a lower BMI when they develop the disease compared to Caucasians, and dis-
ease severity is higher. Although currently a topic that is attracting great interest in the 
literature, no explanation has yet been found for the increased incidence and severity of 
T2DM in the South Asian population.
Pathogenesis of T2DM and end-organ damage
Diabetes mellitus is a chronic disease characterized by disturbances in glucose ho-
meostasis, eventually leading to hyperglycemia. Normally speaking, blood glucose 
concentrations are maintained within a narrow range, since both low and elevated 
blood glucose levels are detrimental to the body. Diabetes has negative consequences 
for almost all organs. Well known complications involve the cardiovascular system, 
(central) nervous system, kidneys and eyes. Around 50% of patients with diabetes die 
from cardiovascular disease (5). 
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The pathogenesis of T2DM and cardiovascular complications involves multiple 
pathways that are tightly interlinked. Although it is impossible to dissect the individual 
contributions of the multiple endogenous and exogenous disruptors (such as cytotoxic 
chemotherapy), and to establish causal relationships between the many pathological 
phenomena observed in T2DM, the main pathogenetic phenomena identified in T2DM 
are related to lipid dysfunction, inflammation and glucotoxicity. 
Cardiovascular complications
The pathogenesis of cardiovascular complications in T2DM is complex, but a major role 
is attributed to ectopic accumulation of triglycerides (TG) in organs that normally do not 
store fat, such as skeletal muscles, liver and heart. Ectopic fat accumulation is closely as-
sociated with the generation of toxic intermediates of lipid oxygenation, mitochondrial 
dysfunction and activation of inflammatory pathways, all of which contribute to organ 
dysfunction (6-10). Cardiac ectopic fat includes myocardial and pericardial fat accumu-
lation. Both are associated with impaired myocardial function (11-13) and increased 
cardiovascular disease (CVD) risk (14). 
South Asians are at an increased risk of developing CVD compared to Caucasians 
(15). The mean age of first acute myocardial infarction is approximately five years earlier 
in South Asians than in Caucasians (16,17) and CVD in this population is more aggres-
sive and has higher mortality rates at younger ages (15,17-19). The differences in CVD 
prevalence and severity between both ethnicities cannot be explained by traditional 
risk factors. As South Asians represent over 20% of the world’s population, uncovering 
the underlying mechanisms involved in the higher prevalence of T2DM and CVD in this 
group deserves urgent attention.
Pulse wave velocity
Aortic pulse wave velocity (PWV) is a surrogate marker for arterial stiffness and a power-
ful independent predictor of cardiovascular events (20). Insulin resistance and T2DM 
are known to compromise aortic elastic function. Although the precise underlying 
mechanisms remain unclear, it is known that prolonged exposure to elevated insulin 
levels can have direct and indirect trophic effects on smooth muscle cells (21), which 
contribute to increased arterial wall thickness, and hence to increased arterial stiffen-
ing. Furthermore, the formation of advanced glycation end products (AGEs) on vascular 
walls causes collagen cross-linking, leading to the loss of collagen and a subsequent 
reduction in arterial compliance.
Type 1 DM (T1DM) is also associated with end-organ damage in various organs. 
The arterial vessel wall also exhibits structural changes in patients with T1DM, which 
results in stiffening of the aortic wall (22). This stiffening occurs early in the diseases 
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process in T1DM and is already evident at a young age (23). In patients with T1DM, PWV 
is an independent predictor of cardiovascular morbidity (24,25) and mortality (26). 
Furthermore, aortic stiffness is also reported to be associated with systolic and diastolic 
left ventricular (LV) dysfunction (27,28). 
Brain
Although DM is not primarily a brain disease, it is associated with cerebral atrophy, white 
matter hyperintensities and infarctions as well as decreased cognitive functioning (29-
31). Various pathophysiological mechanisms have been suggested to contribute to the 
brain alterations in patients with DM. Both hyperglycemia and vascular complications 
have been proposed as underlying mechanisms in DM associated declined cognitive 
functioning and volume loss, but the pathogenesis is complex and incompletely un-
derstood (32-35). Aortic stiffening may play a central role in the development of brain 
injury (36). Previous studies have shown that aortic stiffness is a contributing factor in 
the development of generalized white matter atrophy in T1DM patients (37). Aortic stiff-
ness may contribute to microvascular brain injury by exposing the small vessels to high 
pressure fluctuations in the cerebral circulation (38). The brain is particularly vulnerable 
to high pressure fluctuations, because it is perfused at high volume flow and has very 
low vascular resistance. In addition to white matter injury, T1DM is also associated with 
gray matter density changes in general (35) and focal cortical regions, the left thalamus 
(39,40) and the hippocampus (41,42). However, there are no data on the volumes of 
subcortical structures, including the basal ganglia and amygdala, in T1DM. Recent de-
velopments in magnetic resonance imaging (MRI) techniques enable a more in-depth 
investigation of brain damage in T1DM patients. 
Caloric restriction
Lifestyle, and in particular dietary intervention, is the most powerful intervention to 
prevent and treat T2DM (43). Over 80% of T2DM patients are overweight or obese, 
and therefore weight loss remains the hallmark of their treatment. Weight loss in over-
weight/obese T2DM patients has several beneficial effects, including improved insulin 
sensitivity (44), improved diastolic cardiac function (45) and a less stiff aorta (46). Very 
low calorie diets (VLCD) can be used to induce substantial weight loss. Obese subjects 
lose on average 20 kg in 12 to 16 weeks. 
As mentioned earlier, a major role in the pathogenesis of cardiovascular complica-
tions in T2DM is attributed to ectopic accumulation of TG in organs that normally do 
not store fat. This ectopic fat can be modulated by dietary interventions in healthy 
subjects (47) as well as in obese subjects (48-51). Prolonged caloric restriction in obese 
patients with T2DM without established coronary atherosclerosis leads to a decrease in 
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ectopic fat, including hepatic, myocardial and pericardial fat and improves myocardial 
function (45,52). Furthermore, in these obese T2DM patients a decrease in pericardial 
fat was observed immediately after the diet (52). However, long-term maintenance of 
weight loss is extremely difficult. Short-term dietary interventions can be sufficient to 
induce changes in cardiac function. For example, changes in cardiac diastolic function in 
healthy young males (53,54) have been reported after a 3-day high fat high caloric diet 
(HFHC) and after 3 days of caloric restriction. Short-term caloric restriction is therefore 
an attractive method to study the susceptibility of patients with DM to long term dietary 
interventions and may also be suitable for studying underlying mechanisms of ectopic 
fat accumulation and cardiovascular dysfunction in patients with obesity or DM, includ-
ing the differential response between ethnicities.
Bariatric surgery results in sustained weight loss (55). Furthermore, bariatric surgery 
leads to diabetes remission in 70-80% of T2DM patients (56) and is associated with a 
decreased incidence of diabetes (57) and cardiovascular events (58), as well as a long-
term reduction in overall mortality (59) in obese subjects. Bariatric surgery and the 
subsequent weight loss may be an alternative treatment for T2DM. 
As described before, exogenous disruptors, such as cytotoxic chemotherapy, are 
associated with adverse metabolic and cardiovascular consequences. Treatment with 
cisplatin-based chemotherapy in testicular cancer (TC), for example, has been found to 
induce metabolic perturbations, such as changes in serum lipid levels (60). Additionally, 
3 years after chemotherapy, higher incidences of hypercholesterolemia, hypertension, 
microalbuminuria, obesity, elevated insulin-glucose ratio, and even metabolic syndrome 
have been reported (13,61,62). The acute effects of chemotherapy, defined as effects 
occurring 3 months after the start of chemotherapy, on these risk factors are largely 
unknown. The aforementioned indirect risk factors are all independently associated 
with a higher risk of cardiovascular disease and may contribute to the overall increased 
risk of cardiovascular complications after treatment with cisplatin-based chemotherapy. 
The increased risk of cardiovascular disease in cured TC patients after cisplatin-based 
chemotherapy is probably a combination of direct toxic effects on the cardiovascular 
system and indirect effects of chemotherapy (13,63).
MR assessment techniques  
MRI techniques are ideally suited for assessing various aspects of cardiovascular anatomy 
and systolic and diastolic cardiac function. MRI provides the gold standard for cardiac 
chamber volume assessment. As mentioned before, PWV is a surrogate marker for aortic 
stiffness. PWV is defined as the velocity of the systolic pulse wave front propagating 
through the aorta, which reflects the elastic properties of the aortic vessel wall. MRI in 
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combination with velocity-encoded MRI is a non-invasive, accurate, validated technique 
for measuring PWV globally and regionally in the aorta.
Ectopic fat can be visualized by magnetic resonance spectroscopy (1H-MRS) and MRI 
(10,12,64,65). 1H-MRS enables an accurate assessment of myocardial and hepatic TG. We 
used MRI to measure the abdominal and paracardial fat compartments. The use of MRI 
to measure paracardial fat with MRI is relatively new, and so far, no consensus has been 
reached on the ideal way to study this fat compartment with MRI. However, the method 
developed at our department has been shown to produce interesting and reproducible 
results. 
The introduction of relatively new methods to investigate brain structure, volume 
and integrity enables the effects of diabetes on the brain to be explored in more detail.
Diffusion Tensor Imaging (DTI) is used for measurement of white matter microstructure 
(66) and voxel-based morphometry (VBM) enables the identification of subtle gray mat-
ter alterations (67).
The field of MRI is developing rapidly, as higher magnetic field strengths continue 
to be implemented in human imaging. The 7 Tesla (T) MRI scanners might contribute 
to increasing image quality and more detailed assessment of end-organ damage. In the 
future, this could lead to earlier recognition and maybe even earlier treatment of end-
organ damage in patients with DM. For example, high field imaging of the carotid vessel 
wall is an area of increasing development in MRI, driven by the continued clinical inter-
est in non-invasive imaging modalities to assess the carotid artery vessel wall (68,69). 
Given the promising results when previously carotid vessel wall imaging was com-
pared between 1.5T and 3T (70), ultrahigh field 7T might offer great potential for carotid 
vessel wall imaging. However, as these imaging techniques must still be optimized, 
imaging at a high magnetic field strength remains, at present, beset by challenges.
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OUTLINE OF THE THESIS
The aim of this thesis was to assess end-organ damage in individuals with metabolic 
syndrome and diabetes mellitus using  MRI and 1H-MRS. In addition, safety, feasibility 
and implementation of innovative MR techniques at higher field strengths for assess-
ment of cardiovascular disease, were evaluated.
The first part of this thesis focuses on the end-organ damage in patients with T1DM 
studied with relatively new imaging methods.
Since aortic stiffness is an independent predictor of cardiovascular morbidity (24,25) 
and mortality (26), we investigated whether an increased aortic PWV, as assessed by MRI, 
is associated with subclinical LV diastolic dysfunction and decreased left atrial (LA) com-
pliance, as assessed with speckle tracking strain analysis in patients with T1DM. Speckle 
tracking strain analysis allows the assessment of myocardial deformation providing use-
ful parameters describing LV diastolic function and LA function (71-74). These relatively 
new indices are sensitive to early detection of subtle alterations in LV diastolic function 
and have described LV diastolic dysfunction at early stages of the disease process (75). 
The results of this study are described in Chapter 2. 
Diffusion Tensor Imaging (DTI) is a validated brain imaging technique with MRI, which, 
in contrast to conventional methods, enables the measurement of white matter micro-
structure (66). In Chapter 3, we assessed a possible association between aortic PWV 
and brain white matter integrity assessed with DTI in patients with T1DM . Voxel-based 
morphometry (VBM) is a relatively novel and sophisticated analysis technique, which 
allows regional differences in brain volume to be tested for. VBM enables subtle gray 
matter alterations to be identified (67). As regional specific reductions in gray matter 
density in areas responsible for language processing and memory have been found in 
T1DM (39), we performed in-depth gray matter studies in patients with T1DM, using 
VBM. This study is described in Chapter 4. 
Prolonged caloric restriction in obese patients with T2DM without established coronary 
atherosclerosis leads to a decrease in ectopic fat, including myocardial and pericardial 
fat, and improves myocardial function (45,52). Because of their increased cardiovascular 
risk, it is important to establish whether T2DM patients with a history of cardiac disease 
also benefit from prolonged caloric restriction. We therefore studied the effects of 16 
weeks caloric restriction on ectopic fat accumulation and cardiovascular function in 
overweight patients with T2DM and coronary artery disease (CAD). In Chapter 5, the 
effects of a 16-week (V)LCD on cardiovascular function and ectopic fat depositions in 
overweight patients with CAD and T2DM are described.
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Long-term maintenance of weight loss after a low caloric diet is challenging. Al-
though bariatric surgery certainly results in sustained weight loss, it is largely unknown 
whether cardiac ectopic fat depots can also be mobilized by bariatric surgery in the 
same way or to the same extent as a 16-week VLCD was found to achieve (76). TG can be 
stored in the myocardium or in pericardial fat, the adipose tissue surrounding the heart. 
In Chapter 6 the effects of bariatric surgery on pericardial ectopic fat depositions and 
cardiovascular function are studied. 
In Chapter 7, we used MRI and 1H-MRS techniques to determine whether differences in 
cardiac dimensions, cardiovascular function, and myocardial TG content are present be-
tween young, healthy South Asians and matched Caucasians. A short-term high fat diet 
has been shown to decrease diastolic function in healthy Caucasians (53). If the higher 
risk of CVD in South Asians is indeed related to a higher metabolic risk, the effects of a 
HFHC-diet on cardiovascular function might be stronger for this ethnic group. To assess 
whether possible functional differences can be attributed to alterations in metabolism 
and fat depositions in South Asians, we subjected 12 healthy lean South Asians and 12 
matched Caucasians to a 5-day HFHC-diet. Chapter 8 describes the effects of this 5-day 
HFHC-diet on insulin sensitivity in the participants.
Chapter 9 focuses on cardiovascular function in middle-aged overweight South 
Asians compared with Caucasians, and the response to short-term caloric restriction. 
To assess whether cardiovascular function in middle-aged overweight South Asians is 
impaired compared to Caucasians and whether metabolic and functional cardiovascular 
flexibility in response to caloric restriction is compromised in South Asians, we subjected 
middle-aged, overweight South Asians and age-, sex- and BMI-matched Caucasians to 
an 8-day VLCD. 
Treatment of TC with cisplatin-based chemotherapy is associated with subacute 
changes in cardiac function (77,78), and with long-term cardiovascular disease (62,79). 
Because of the increasing number of survivors with a long life expectancy, gaining an 
understanding of and the prevention of short-term and long-term cardiovascular effects 
of chemotoxicity are of utmost importance. Little is known about the acute effects of 
cisplatin-based chemotherapy on metabolic parameters and cardiac function. Therefore 
we performed a study, described in Chapter 10, in which we assessed the acute changes 
in cardiac function and myocardial TG, in relation to body fat distribution and metabolic 
parameters 3 months after start with cisplatin-based chemotherapy.
The introduction of the ultrahigh field 7T MRI scanners is an exciting and promising 
development. However, many challenges must be overcome before 7T MRI can be 
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implemented in regular clinical care. Given the promising results previously seen in 
comparisons between carotid vessel wall imaging at 1.5T and at 3T magnetic field 
strengths (70), ultrahigh field 7T might offer great potential for carotid vessel wall 
imaging. However, only limited data are available on the feasibility of 7T carotid MRI. 
We therefore objectively compared quantitative parameters related to image quality of 
carotid vessel wall imaging performed at 7T and 3T, which is described in Chapter 11. 
There is only limited data available on the feasibility of cardiovascular MRI in patients 
with cardiovascular disease at 7T. However, before clinical cardiovascular MRI at 7T can 
be performed, coronary stent safety has to be determined. The static magnetic field 
of the MR system exerts a force during patient positioning on ferromagnetic objects, 
possibly causing displacement of coronary artery stents. Furthermore, medical implants 
can potentially interact with the rapidly changing RF field, thereby inducing unwanted 
currents and heating of surrounding tissue. Chapter 12 describes the data of the 
tested coronary stent safety at 7T MRI. Furthermore, the initial clinical feasibility of 7T 
cardiovascular MRI in healthy volunteers and patients with cardiovascular disease is 
demonstrated.
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Diabetes mellitus type 1 (T1DM) is associated with aortic stiffening and left ventricular 
(LV) diastolic dysfunction, but the relationship with LV diastolic dysfunction in T1DM 
patients is still largely unknown. The purpose of this study was to evaluate whether an 
increased aortic stiffness, expressed by increased aortic pulse wave velocity (PWV), is 
associated with subclinical LV diastolic dysfunction and decreased left atrial (LA) compli-
ance as assessed with speckle tracking strain analysis in patients with T1DM.
Methods
Aortic PWV was assessed with cardiovascular magnetic resonance imaging (MRI) in 41 
T1DM patients. Patients underwent echocardiography for assessment of conventional LV 
diastolic function indices and LV and LA longitudinal strain and strain rate were assessed 
with speckle tracking strain analysis. LV strain rate during the isovolumic relaxation pe-
riod (SRIVR) and LA strain were recorded and the E-wave velocity to SRIVR velocity ratio 
(E/SRIVR) was calculated. Independent samples t-test and multivariate linear regression 
analyses were used for statistical analyses.
Results
Aortic PWV significantly correlated with SRIVR (β=-0.71, p<0.001), E/SRIVR (β=0.61, 
p=0.002) and LA strain (β=-0.47, p=0.014), but not with conventional echocardiographic 
markers of diastolic function (all p>0.10).
Conclusions
In T1DM patients, aortic stiffness is inversely associated with sensitive markers of LV 
diastolic function and decrease in LA compliance as measured with echocardiographic 
speckle tracking strain analysis. 
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INTRODUCTION
Diabetes mellitus (DM) is a chronic disease, which leads to microvascular and macro-
vascular complications. The arterial vessel wall reveals structural changes in patients 
with DM which results in stiffening of the arterial vasculature, including the aortic wall 
(1). This stiffening occurs early in the disease process in type 1 DM (T1DM) and is even 
evident at a young age (2). In patients with T1DM, the pulse wave velocity (PWV), a sur-
rogate marker of aortic stiffness as measured by means of ultrasonography or cardiovas-
cular magnetic resonance imaging (MRI), is an independent predictor of cardiovascular 
morbidity (3,4) and mortality (5). Furthermore, aortic stiffness has been described to be 
associated with systolic and diastolic left ventricular (LV) dysfunction (6,7). 
MRI techniques are well suited for assessing various aspects of cardiovascular func-
tion. MRI provides the gold standard for cardiac chamber volume assessment. MRI in 
combination with velocity-encoded MRI is a non-invasive validated technique for 
measuring PWV globally and regionally in the aorta by using the transit-time method 
(8). Furthermore, recent developments in speckle tracking strain analysis have permit-
ted the assessment of myocardial deformation providing useful parameters describing 
LV diastolic function and left atrial (LA) function (9-12). These new indices are sensitive 
to early detection of subtle alterations in LV diastolic function and have described LV 
diastolic dysfunction at early stages of the disease process (13).
Therefore, our hypothesis is that an increase in aortic PWV in T1DM patients is as-
sociated with early alterations in sensitive markers of LV diastolic function and with a 
decrease in LA compliance. To our knowledge, no previous study has evaluated the re-
lationship between aortic PWV assessed with MRI and LV diastolic function parameters 
assessed with speckle tracking strain analysis. Accordingly, the purpose of this study was 
to evaluate whether increased aortic stiffness, expressed as an increased aortic PWV, 
is associated with subclinical LV diastolic dysfunction and decreased LA compliance as 
assessed with speckle tracking strain analysis in T1DM patients.
METHODS
Subjects
This study was approved by the local medical ethics committee and the study was 
conducted according to the principles in the Declaration of Helsinki. All subjects gave 
informed consent.
Consecutive patients with T1DM were recruited from the local outpatient clinic. All 
subjects were within the age range of 30-80 years and underwent MRI imaging between 
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February 2008 and January 2010. Forty-one patients with T1DM were included in the 
study (25 men and 16 women; mean age ± standard deviation 50 ± 9 years). 
Exclusion criteria for the patients with T1DM were congenital aortic/heart disease, 
known history of cardiovascular disease, evidence of aortic valve stenosis or insuf-
ficiency and general contraindications to MRI. This patient group was partly included 
in a previous study describing an association between aortic stiffness and systolic LV 
function in patients with T1DM (7). 
T1DM is defined as fasting blood glucose ≥ 7.0 mmol/l according to WHO criteria (14). 
The duration of DM was calculated as the time (in years) between the reported age of 
diagnosis and the MRI examination. Heart rate and blood pressure were measured using 
a semiautomated sphygmomanometer (Dinamap, Critikon, Tampa, Fla, USA). Mean arte-
rial pressure (MAP) was calculated by adding one-third of the pulse pressure to diastolic 
blood pressure. Body mass index, smoking status (nonsmoker or current smoker) and 
glycated hemoglobin (HbA1c) were determined. All patients underwent MRI evaluation 
and transthoracic echocardiography including speckle tracking strain analysis. Further-
more, all patients were in sinus rhythm and had adequate echocardiographic image 
quality for speckle tracking analysis.
MR imaging protocol
MRI was performed on a 1.5T MRI scanner (NT 15 Gyroscan Intera; Philips Medical 
Systems, Best, the Netherlands). The aorta was imaged in a double-oblique parasagit-
tal scout view. Aortic PWV was assessed using the transit-time method as previously 
described (8) from two consecutive one-directional through-plane velocity-encoded 
MRI acquisitions with high-temporal resolution performed in the ascending aorta at 
the level of the pulmonary trunk and 7.5 cm beneath the diaphragm in the abdominal 
aorta (Figure 1, left panel). Scan parameters were: TR 5.0ms, TE 2.9ms, flip angle 20º, 
FOV 300mm, 128×115 acquisition matrix, slice thickness 8mm, with maximal number 
of phases reconstructed ensuring high (6-10ms) effective temporal resolution. True 
temporal resolution is defined as 2 times TR = 10ms. 
Flow rate-graphs were determined by automated contour segmentation on the veloc-
ity maps using the in-house developed FLOW software package (Figure 1, right panel). 
Pixelwise integration of the aortic velocity over the lumen area of the aorta results in the 
flow rate per cardiac phase. Propagation of the systolic flow wave front (which defines 
the PWV) was determined by the transit-time between the two measurement sites, as 
shown in Figure 1. This transit-time is determined by the time difference in the arrival of 
the systolic flow wave front at each measuring site, which is automatically assessed by the 
intersection of the horizontal diastolic flow and the upslope of the flow wave, modeled 
by linear regression of all data points between 20% and 80% of the range of flow values 
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along the slope. The distance between the two measurement sites was manually deter-
mined by drawing a poly-line in the center of the aorta as defined in a double-oblique 
parasagittal aortic scout view, using the in-house developed software package MASS. 
The acquisition time amounted to approximately 4 min per plane at a heart rate of 60 
beats per minute. Due to the automated contour detection in the velocity maps and the 
automated transit-time detection from the flow graphs, image analysis per patients was 
under 5 minutes for an experienced user.
To determine LV volumes, function and mass, the LV was imaged in short-axis orien-
tation in 10-12 consecutive slices, by using electrocardiographically gated breath-hold 
segmented cine fast gradient-echo imaging with steady-state free-precession as previ-
ously described (15). Imaging parameters were: TR 3.3ms, TE 1.7ms, flip angle 35º, FOV 
400×320mm, and slice thickness 10mm. Using software package MASS, endocardial and 
epicardial LV contours were manually drawn in the end-systolic and end-diastolic phases 
of the short-axis data. Left ventricular ejection fraction (LVEF), stroke volume (SV), LV 
end-diastolic volume (LVEDV), LV end-systolic volume (LVESV) and LV end-diastolic mass 
(LVED mass) were assessed. Volumes and mass were indexed (i) for body surface area 
(BSA, calculated according to the Mosteller formula).
Figure 1. Aortic PWV determination with MRI. The left panel shows a double-oblique parasagittal image 
of the aorta. The red and blue lines represent the acquisition planes for velocity-encoded MRI which are 
positioned perpendicular to the aorta. Δx = the path length of the aorta determined along the centerline 
of the aorta. The right panel shows the flow rate-time curves for the proximal and distal aorta. Δt = transit-
time between time-of-arrival of flow wave in the proximal and distal aorta, respectively. Aortic PWV is 
defined as Δx/Δt (in m/s).
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Echocardiography
Transthoracic echocardiography was performed in the left lateral decubitus position us-
ing a commercially available ultrasound transducer and equipment (M4S probe, Vivid 7, 
GE-Vingmed, Horten, Norway). All images were analyzed off-line with Echo Pac version 
110.0.0 (GE-Vingmed).
Conventional parameters of LV diastolic function
Several parameters of LV diastolic function were assessed by conventional echocardiogra-
phy. Trans-mitral diastolic early wave (E) velocity, E-wave deceleration time (DT) and late 
diastolic wave (A) velocity were measured by applying pulsed-wave Doppler at the tip 
of the mitral leaflets in the apical 4-chamber view (16). Isovolumic relaxation time (IVRT) 
was assessed from the apical 5-chamber view, using continuous-wave Doppler with the 
sample volume positioned in the LV out-flow tract, at the level of the mitral valve (16). Tis-
sue Doppler imaging (TDI) was recorded with high frame rate (≥100 frames/second) from 
the apical 4-chamber view to assess myocardial velocities. Peak annular early diastolic 
velocity (E´) was measured in 2 basal LV segments (septal and lateral) and averaged to 
calculate the mean early diastolic velocity (E´mean). The ratio of peak trans-mitral E-wave 
to E´mean (E/E´mean) was calculated, as a validated estimate of LV filling pressure (17).
In addition, maximal LA volume was calculated according to the American Society of 
Echocardiography guidelines, at end-systole, just before mitral valve opening, and was 
indexed to body surface area (18). Based on current recommendations (16), LV diastolic 
dysfunction was graded as follows: normal, grade I, grade II and grade III.
LV diastolic function indices by speckle tracking strain analysis
Measures of LV diastolic function were obtained with two-dimensional (2D) speckle 
tracking strain and strain rate (SR) analysis. Strain rate during isovolumic relaxation 
period (SRIVR) was measured as previously described (19). SRIVR is a load- and angle- 
independent parameter that is strongly related to LV relaxation (20). Briefly, the endo-
cardial border was manually traced on LV apical 4-, 2-, and 3-chamber views and the 
region of interest width was adjusted to include the entire myocardium. Longitudinal 
SR-values over the cardiac cycle were automatically obtained for each apical view. The 
peak SR-value during LV isovolumic relaxation was measured and averaged from the 3 
apical views (Figure 2) (19). The ratio of peak trans-mitral E-wave to SRIVR (E/SRIVR) was 
calculated as an index of LV filling pressures (20). LA peak strain was measured during LV 
systole as an index of LA compliance (9,21). For this measure, LA endocardial border was 
identified in the apical 4-chamber view and a region of interest was adjusted to include 
the entire LA wall. LA strain curves over the cardiac cycle were generated. The peak LA 
positive strain during ventricular systole (LAs) was subsequently measured (Figure 2) (9).
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Figure 2. Parameters of LV diastolic function and LA compliance. The evaluation of peak strain rate 
during left ventricular isovolumic relaxation period (SRIVR) from the apical 4-chamber view is displayed 
in panel A. A region of interest which includes the entire left ventricular wall is first obtained. The 
software consequently displays the changes in longitudinal strain rate over the cardiac cycle. Left 
ventricular isovolumic relaxation occurs in diastole, starting immediately after the aortic valve closure 
and terminating with the beginning of the diastolic early (E) wave. The peak strain rate value during 
isovolumic relaxation period (SRIVR) is consequently measured. The assessment of left atrial peak systolic 
strain (LAs) is shown in panel B.
Statistical analysis
Statistical analysis was performed with SPSS (SPSS, Chicago, Illinois, USA), version 17. 
Data are expressed as mean ± standard deviation (sd), unless stated otherwise. Categori-
cal variables were presented as frequencies and percentages. Multivariate linear regres-
sion analyses were performed to analyze the association between aortic PWV and the 
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echocardiographic parameters, adjusted for the confounding factors age, gender and 
MAP. The β-regression coefficients and p-values are reported. Significance was reached 
when p<0.05 (two-tailed).
Besides evaluating associations between aortic PWV and echocardiographic param-
eters, patients were also classified according to their age-related PWV. Normal values 
for age-related PWV were taken from a study by Westenberg et al. (22), in which linear 
regression was performed for PWV vs. age-relation, using the same imaging technique 
as in the current study: PWV=A×AGE+B, with A ± standard error (SE)=0.07 ± 0.01m/s/
year and B ± SE=2.32 ± 0.23m/s (Pearson R=0.93 (p<0.001)). PWV as assessed in the 
patients in the current study was classified as normal if PWV≤2×SE of normal age-related 
PWV or increased if PWV >2×SE of normal age-related PWV. Between-group differences 
concerning classified aortic PWV and continuous variables were calculated using in-
dependent samples t-test. The chi-square test was used to calculate the difference in 
categorical variables between groups.
RESULTS
Twenty-four (59%) of the patients with T1DM were on antihypertensive treatment, 
consisting of ACE inhibitors, β blockers, calcium antagonists, diuretics, angiotensin II 
inhibitors or a combination of the aforementioned medications. Retinopathy, mostly 
minimal background retinopathy, was present in 32 (78%) of the patients. Only 5 (12%) 
patients had nephropathy. Table 1 describes the clinical characteristics of the total study 
population and per subgroup, classified according to normal (n=28) versus increased 
PWV (n=13). There were no significant differences between both groups: no differences 
in age, T1DM duration or blood pressure were shown.
The associations between aortic PWV and MRI and echocardiographic parameters 
are shown in Table 2. After adjustments for age, gender and MAP, multivariate linear 
regression analysis showed that aortic PWV was significantly correlated with SRIVR 
(β=-0.71, p<0.001), E/SRIVR (β=0.61, p=0.002) and LA strain (β=-0.47, p=0.014). The 
significant correlations are shown in Figure 3. 
The mean aortic PWV in the subgroup with normal PWV was 6.0 ± 0.8m/s and in the 
group with increased PWV 9.9 ± 2.1m/s. Mean values of echocardiographic parameters 
between both subgroups are displayed in Table 3. Among the conventional echocar-
diographic parameters of LV function, the E/A-ratio was the only statistically different 
parameter between both subgroups. In contrast, all indices of LV diastolic function 
assessed by speckle tracking (SRIVR, E/SRIVR and LA strain) were statistically significant 
different between subgroups with normal versus increased PWV.
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Table 2. Association between aortic PWV and MRI and echocardiographic parameters
PWV
mean ± sd β p-value
MRI parameters
LVEF (%) 59.0 ± 6.1 -0.35 0.067
LVSV (i) (ml/m²) 45.8 ± 7.9 -0.22 0.253
LVEDV (i) (ml/m²) 77.7 ± 10.6 -0.41 0.820
LVESV (i) (ml/m²) 31.9 ± 6.3 0.20 0.265
LVED mass (i) (g/m²) 50.5 ± 9.4 -0.01 0.955
Conventional echocardiographic parameters
LA volume (i) (ml/m²) 22.2 ± 6.0 -0.02 0.942
IVRT (ms) 83.0 ± 18.3 0.33 0.101
E/A 1.13 ± 0.37 -0.21 0.275
DT (ms) 249.9 ± 73,9 -0.05 0.798
E´ (cm/s) 8.0 ± 2.2 -0.14 0.379
E/E´mean 9.53 ± 2.62 0.01 0.957
Speckle tracking parameters
SRIVR (1/s) 0.49 ± 0.20 -0.71 <0.001*
E/SRIVR (cm) 175.6 ± 83.6 0.61 0.002*
LA strain (%) 35.9 ± 6.9 -0.47 0.014*
Data are presented as mean ± standard deviations (sd). β regression coefficients (β) and p-values are 
reported for the association with aortic PWV in multivariate analysis with the confounders age, gender 
and mean arterial pressure. PWV: pulse wave velocity, LVEF: left ventricular ejection fraction, LVSV: 
left ventricular stroke volume, LVEDV: left ventricular end-diastolic volume, LVESV: left ventricular end 
-systolic volume, LA: left atrial, IVRT: isovolumic relaxation time, E: Trans-mitral diastolic early wave, 
A: late diastolic wave, DT: E-wave deceleration time; E´: peak early diastolic velocity, SRIVR: strain rate 
during isovolumic relaxation period. i: indexed for body surface area. *p-value <0.05. 
Table 1. Patient characteristics







Male gender, n (%) 25 (61) 17 (61) 8 (62) 0.960
Age (years) 49.9 ±  9.0 48.9 ± 8.4 52.1 ± 10.1 0.288
Diabetes duration (years) 26.2 ± 13.5 26.2 ± 13.6 26.3 ± 14.0 0.984
BMI (kg/m²) 26.4 ±  3.2 25.9 ± 2.7 27.7 ± 3.8 0.098
Systolic blood pressure (mmHg) 138 ±  20 135 ±  19 146 ± 20 0.094
Diastolic blood pressure (mmHg) 76 ±  10 75 ± 10 77 ± 10 0.508
Mean arterial pressure (mmHg) 96 ±  11 95 ± 10 100 ± 13 0.164
Heart rate (beats/min) 67 ± 11 67 ±  11 66 ± 13 0.793
Current smokers, n (%) 8 (20) 6 (21) 2 (15) 0.650
On antihypertensive treatment  24 (59) 15 (54) 9 (69) 0.344
ACE inhibitors 11 (27) 6 (21.4) 5 (41.7) 0.189
β blockers 5 (12) 1 (3.6) 4 (30.8) 0.013*
Calcium antagonists 2 (5) 2 (7.1) 0 (0) 0.323
Diuretics 10 (24) 6 (21.4) 4 (30.8) 0.517
Angiotensin II inhibitors 11 (27) 8 (28.6) 3 (23.1) 0.712
HbA1c (%) 7.9 ±  1.1 7.8 ± 1.1 8.0 ± 1.1 0.658
Data are presented as mean ± standard deviations or n (%). BMI: body mass index, HbA1c: glycated 
hemoglobin.
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Table 3. MRI and echocardiographic parameters between PWV-groups
Normal PWV (n=28) Increased PWV (n=13) p-value
MRI parameters
LVEF (%) 60.2 ±  5.7 56.4 ± 6.5 0.068
LVSV (i) (ml/m²) 46.9 ±  7.6 43.5 ± 8.4 0.205
LVEDV (i) (ml/m²) 78.0 ±  11.1 76.9 ± 9.8 0.745
LVESV (i) (ml/m²) 31.2 ±  6.6 33.3 ± 5.5 0.300
LVED mass (i) (g/m²) 49.9 ±  8.2 51.8 ± 11.8 0.564
Conventional echocardiographic parameters
LA volume (i) (ml/m²) 21.6 ±  5.3 23.5 ± 7.4 0.350
IVRT (ms) 80.7 ±  14.7 87.9 ± 24.3 0.251
E/A 1.21 ±  0.38 0.95 ± 0.31 0.043*
DT (ms) 246.5 ±  67.9 257.3 ± 88.0 0.668
E´ (cm/s) 8.5 ±  1.9 7.1 ± 2.5 0.065
E/E´mean 9.21 ±  2.08 10.21 ± 3.52 0.350
Diastolic grade 
Normal, n (%) 17 (60.7) 5 (38.5) 0.165
Grade I, n (%) 9 (32.1) 8 (61.5)
Grade II, n (%) 2 (7.1) 0 (0)
SRIVR (1/s) 0.59 ±  0.15 0.28 ± 0.10 <0.001*
E/SRIVR (cm) 136.6 ±  44.6 256.5 ± 90.6 <0.001*
LA strain (%) 38.4 ±  6.7 30.5 ± 3.5 <0.001*
Data are presented as mean ± standard deviations. PWV: pulse wave velocity, LVEF: left ventricular 
ejection fraction, LVSV: left ventricular stroke volume, LVEDV: left ventricular end-diastolic volume, 
LVESV: left ventricular end-systolic volume; LA: left atrial; IVRT: isovolumic relaxation time; E: Trans-mitral 
diastolic early wave, A: late diastolic wave, DT: E-wave deceleration time, E´: peak early diastolic velocity, 
SRIVR: strain rate during isovolumic relaxation period. *p-value <0.05.
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Figure 3. Correlations between pulse wave velocity (PWV) and the echocardiographic parameters. Panel 
A shows the correlation between PWV and strain rate during isovolumic relaxation period (SRIVR), panel B 
the correlation between PWV and E-wave velocity to SRIVR velocity ratio (E/SRIVR), panel C the correlation 
between PWV and left atrial strain (LA strain). Blue squares represent patients with normal age-related 
PWV and red triangles represent patients with increased age-related PWV.
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DISCUSSION
The main findings of our study are: first, aortic PWV varied from normal to increased in 
T1DM patients with similar clinical characteristics. Secondly, a strong correlation was 
found between aortic PWV and LV diastolic function parameters as well as LA strain as 
assessed by speckle tracking strain analysis, irrespective of age.
Aortic PWV is a surrogate marker of vascular stiffness (23), which has been identified 
as a strong predictor of cardiovascular events and all-cause mortality (24). The defini-
tion of normal values of aortic PWV is challenging since the ageing process should be 
taken into consideration. Previous studies have demonstrated that patients with T1DM 
present with higher aortic PWV than age-matched healthy volunteers indicating that 
T1DM patients have increased aortic stiffness (1,2,25). Still, there is a gray zone between 
clearly normal and obvious abnormal PWV. Aortic PWV measurements falling in this gray 
zone may be considered as a starting point in the cardiovascular stiffening continuum. 
The present study group of T1DM patients showed a wide range of aortic PWV values. 
Therefore, this patient cohort may be well-suited as a model for assessment of early 
changes in diastolic function, not confounded by other risk factors. In our study, we used 
the definition of normal values for age-related PWV as described in a previous publica-
tion (22), where aortic PWV was assessed using the same technique. After classifying 
patients according to their age-related normal PWV-values, diastolic function indices 
were different between patients with normal versus increased PWV, illustrating the ef-
fect this stiffening continuum has on cardiovascular pathology.
Age and hypertension are well-known major independent risk factors for aortic 
stiffness in subjects with and without T1DM. Abnormal glucose metabolism may play a 
relative minor role in the development of increased arterial stiffness (26,27). In our study, 
patients with normal and increased PWV had a similar duration of T1DM and a similar 
cardiovascular risk profile. 
Previous studies have shown that in patients with T1DM, aortic stiffness is related to 
cardiovascular disease (4,5). The correlation between aortic stiffness and impaired LV 
diastolic function can be caused by two possible separate mechanisms. First, increased 
aortic stiffness can directly affect LV diastolic function by higher end-diastolic pressure 
and increased afterload (28). Secondly, the advanced glycation products that form due 
to DM and cause cross linking of collagen molecules both in the myocardium and vessel 
walls can simultaneously affect both the myocardium and the aortic wall (29).
Such an association between aortic stiffness and impaired LV diastolic function has 
been reported in patients with T2DM, hypertension or both (30,31). However, only one 
previous study by Karamitsos et al. has investigated the relationship between aortic 
stiffness and LV diastolic dysfunction in patients with T1DM (3). They assessed LV func-
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tion and aortic stiffness in 66 T1DM patients using conventional echocardiography 
and showed that LV diastolic function and aortic wall stiffness were correlated. In our 
study, we assessed aortic PWV using velocity-encoded MRI, which has some advantages 
over ultrasonography. In contrast to ultrasonography, PWV-assessment with MRI is not 
limited to the availability of suitable acoustic windows along the aorta. Furthermore, the 
true aortic path length, needed for PWV-calculations, can be accurately determined with 
MRI. With ultrasonography, only an estimation of the aortic path length can be obtained, 
usually from the sternal-notch to pubis distance measurement over the patient’s body 
surface (32,33).
Traditionally, LV diastolic function is assessed by mitral inflow waveform analysis 
using echocardiographic Doppler techniques. Although these techniques are clinically 
useful, they have some limitations that can influence their accuracy (20). An important 
limitation of this technique is that the regional measurement assumes correspondence 
with global LV relaxation over the entire LV (20). Furthermore, the mitral inflow pattern 
can only be evaluated in the direction of the ultrasound beam. Speckle tracking allows 
for the assessment of angle independent LV myocardial deformation of the entire left 
ventricle, which represents the performance of all myocardial segments and therefore 
might provide a more sensitive evaluation of global LV diastolic function. It is especially 
more accurate than the conventional methods in patients with normal LV ejection frac-
tion or regional dysfunction (20,34). Moreover, speckle tracking strain analysis is highly 
sensitive for early detection of alterations in LV diastolic function (10,13,20,34).
Furthermore, speckle tracking strain analysis permits a concise evaluation of LA 
compliance in patients with preserved LV ejection fraction (11). Generally, LA strain is 
dependent on LV systolic function. In our cohort, LV systolic function was preserved, so 
the impaired LA strain is most likely caused by LA myocardial stiffening. Interestingly, 
our results show a significant association between aortic stiffness and LA strain which 
has not been reported by previous studies. It has been reported, though, that stiffen-
ing of the aorta can result in increased afterload (28). This results in higher LV pressure, 
which potentially leads to LV hypertrophy, decreased LV compliance and eventually to 
structural changes in the LA (35). Our results are in line with the hypothesis that in-
creased aortic stiffness can eventually lead to diminished LA compliance. This could be 
a risk factor for atrial fibrillation (36,37). The potential contribution of aortic stiffening 
in causing atrial stretch and atrial fibrillation is a hypothesis that warrants further in-
vestigation. Our study had some limitations. The design of the study is cross-sectional, 
therefore a causal relationship between aortic PWV and LV diastolic function cannot be 
determined. Longitudinal studies are required to assess the prognostic value of the cor-
relation between aortic PWV and LV diastolic function. In this study we did not analyze 
aortic stiffness directly by means of aortic distensibility. For a proper calculation of the 
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aortic distensibility, an invasive aortic pressure assessment is required, which cannot 
be obtained in clinical routine. However, PWV assessed with velocity-encoded MRI has 
proven to be a useful surrogate marker for aortic stiffness and is pressure independent 
(38). Furthermore, we used normal age-related PWV values derived from the age relation 
described by Westenberg et al. (22), to determine whether PWV-values in our patient 
group were normal or increased. The age of the volunteers in the study by Westenberg 
et al. was slightly lower than in our patient population (18-65 years vs. 31-69 years). We 
have used the linear regression model from that study to extrapolate the normal values 
for the present evaluation. However, other studies reported approximately similar val-
ues in patient groups with broader age range (39). Therefore we considered the normal 
age-related PWV values we used applicable for our study.
In conclusion, aortic PWV, assessed with velocity-encoded MRI, is inversely associated 
with LV diastolic function indices and reduced LA compliance, assessed with speckle 
tracking strain analysis in patients with T1DM. These results suggest that aortic PWV 
can be used as an integrated marker for LV diastolic function and LA compliance in this 
patient group. Further study is required to assess the potential clinical and prognostic 
implication of our findings.
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The objective was to assess the association between aortic pulse wave velocity (PWV), 
as a marker of arterial stiffness and diffusion tensor imaging (DTI) of brain white matter 
integrity in patients with type 1 diabetes (T1DM) using advanced magnetic resonance 
imaging (MRI) technology. 
Methods
Forty-one patients with T1DM (23 men, mean age 44 ± 12 years, mean diabetes duration 
24 ± 13 years) were included. Aortic PWV was assessed using through-plane velocity-
encoded MRI. Brain DTI measurements were performed on 3 Tesla MRI. Fractional an-
isotropy (FA) and apparent diffusion coefficient (ADC) were calculated for white and 
gray matter integrity. Pearson correlation and multivariable linear regression analyses 
including cardiovascular risk factors as covariates were assessed. 
Results
Multivariable linear regression analyses revealed that aortic PWV is independently as-
sociated with white matter integrity FA (Beta= -0.777 p=0.008) in patients with T1DM. 
This effect was independent of age, gender, mean arterial pressure, body mass index, 
smoking, duration of diabetes and glycated hemoglobin levels. Aortic PWV was not 
significantly related to gray matter integrity.
Conclusions
Our data suggest that aortic stiffness is independently associated with reduced white 
matter integrity in patients with T1DM. 
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INTRODUCTION
Type 1 diabetes (T1DM) is a common chronic metabolic disorder, which is associated 
with diverse comorbidity. Although diabetes mellitus is not primarily a brain disease it 
may be associated with cerebral atrophy, white matter hyperintensities and infarctions 
as well as decreased cognitive functioning (1-3). 
Besides well-recognized risk factors in patients with T1DM, like chronic hyperglyce-
mia and alterations in insulin metabolism, vascular risk factors are thought to contribute 
to the occurrence of brain abnormalities. Aortic stiffening may play a central role in the 
development of brain injury. Of note, previous studies have shown that aortic stiffness 
is associated with generalized white matter atrophy and cerebral small vessel disease in 
T1DM (4,5). Aortic stiffness may contribute to microvascular brain injury by exposing the 
small vessels to the high pressure fluctuations and flow in the cerebral circulation (6). 
The brain is vulnerable in particular to high pressure fluctuations, because it is perfused 
at high volume flow and has very low vascular resistance. Pulse wave velocity (PWV) is a 
widely used surrogate marker for arterial stiffness. It is defined as the propagation speed 
of the systolic flow wave front traveling along the aorta, reflecting the elastic properties 
of the aortic vessel wall. PWV is estimated by dividing the distance between anatomical 
locations over the aorta by the time difference between the arrival of flow waves at the 
two locations. Higher PWV (m/s) corresponds to higher arterial stiffness (7).
Diffusion Tensor Imaging (DTI) is a validated technique of brain imaging with MRI, 
which, in contrast to conventional methods, enables measurement of white matter mi-
crostructure (8). DTI is based on diffusivity of water, providing two parameters of tissue 
integrity, namely the apparent diffusion coefficient (ADC) which reflects the magnitude 
of diffusion and fractional anisotropy (FA) which is a measure of the directionality of 
the diffusion and flow of water molecules in the brain tissue. Early detection of tissue 
injury reflected by an increase in ADC and reduction in FA has been observed in normal 
aging and cerebral small vessel disease (1). Moreover, Kodl et al. showed white matter 
microstructural deficits in patients with longstanding T1DM using this technique (8). 
Interestingly, increased pulse pressure, an indicator of arterial stiffness, was found to 
be associated with lower FA in healthy volunteers (9). There are no previous publications 
that explored the possible relationship between aortic stiffness and diffusion tensor 
imaging of the brain in patients with T1DM using well-validated MRI techniques. Ac-
cordingly the purpose of this study was to assess the association between aortic pulse 
wave velocity, and diffusion tensor imaging of brain white matter integrity in patients 




This study was approved by the local medical ethics committee and all subjects gave 
written informed consent. Between February 2008 and January 2010 consecutive 
patients with T1DM were recruited from the local outpatient clinic. Characteristics of 
the study population are detailed in Table 1. Forty-one patients with T1DM (23 men 
and 18 women) were included with a mean age of 44 ± 12 years. Mean duration of the 
T1DM was 24 ± 13 years. All patients were treated with insulin. One patient was using 
an ACE-inhibitor in combination with an angiotensin II-antagonist for the presence of 
albuminuria. None of the other patients with T1DM were using blood pressure lowering 
medication. Statins were used by 11 (26%) patients. 
Information about the characteristics of T1DM was obtained by standardized inter-
views and physical and laboratory examinations. Exclusion criteria for all participants 
were congenital aortic/heart disease, a clinical history of hypertension or cardiovascular 
disease, evidence of aortic valve stenosis or insufficiency, any other systemic disease 
than diabetes and general contraindications to MRI. At MRI examination duration of 
diabetes in years was estimated from self-reported year of diagnosis. Blood pressure 
and heart rate were measured using a semiautomated sphygmomanometer (Dinamap, 
Critikon, Tampa, Fla, USA) after MR imaging. Pulse pressure was defined as systolic blood 
pressure minus diastolic blood pressure. Mean arterial pressure (MAP) was estimated by 
adding up one-third of the pulse pressure to diastolic blood pressure. Body mass index 
and smoking status (nonsmoker or current smoker) were determined. High-density 
lipoprotein (HDL), total cholesterol, triglycerides, creatinine and glycated hemoglobin 
(HbA1c) were also determined. 
This patient group was partly included in a previous study describing the predic-
tive value of cerebral blood flow and aortic stiffness on generalized white matter brain 
atrophy in T1DM (4).
MRI protocol
MR imaging of the aorta and brain were performed at the same day. Aortic imaging was 
performed, as previously described, using a 1.5T MRI scanner (NT 15 Gyroscan Intera; 
Philips Medical Systems, Best, the Netherlands) (10). In short: a scout image of the aorta 
was acquired using a five-element phased array cardiac surface coil. Aortic PWV was 
assessed according to the transit-time method from two one-directional through-plane 
velocity-encoded MRI acquisitions with high-temporal resolution performed in the aorta 
at two predefined levels: at the level of the pulmonary trunk in the ascending and in the 
abdominal descending aorta (10). Scan parameters were: repetition time (TR) 5.0ms, 
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Table 1. Clinical characteristics and MR findings of patients with type 1 diabetes
Patients with type 1 diabetes
(n=41)
Clinical characteristics
Age, years 44 ± 12
Male gender, n (%) 23 (55)
Body mass index, kg/m2 25.3 ± 2.9
Systolic blood pressure, mmHg 128 ± 19
Diastolic blood pressure, mmHg 73 ± 10
Pulse pressure, mmHg 55 ± 14
Mean arterial pressure, mmHg 91 ± 12
Heart rate, beats/min 66 ± 10
Current smoker, n (%) 6 (15%)
Alcohol use yes, n (%) 23 (56%)
Laboratory markers
HbA1c, % 7.6 ± 1.0
HDL-cholesterol, mmol/l 1.7 ± 0.5
Total cholesterol, mmol/l 4.8 ± 1.0
Triglycerides, mmol/l 1.2 ± 0.6
Creatinine, umol/l 75 ± 11
MRI findings
Aortic PWV, m/s (median, IQR) 6.2 (5.2-7.6)
Stroke volume, ml/heart beat (median, IQR) 87 (81-105)
Periventricular WMHs, n (%) 7 (17)
Subcortical WMHs, n (%) 2 (5)
Gray matter brain volume, mL 574 ± 60
Gray matter FA 0.171 ± 0.008
Gray matter ADC 0.00042 ± 0.00002
White matter brain volume, mL 564 ± 69
White matter FA 0.344 ± 0.017
White matter ADC 0.00036 ± 0.00001
Total brain volume, mL 1139 ± 121
Total brain FA 0.252 ± 0.010
Total brain ADC 0.00040 ± 0.00001
Data are presented as mean ± standard deviations unless otherwise stated. BMI: body mass index, 
HbA1c: glycated hemoglobin, HDL: high-density lipoprotein, PWV: pulse wave velocity, IQR: inter 
quartile range, FA: fractional anisotropy, ADC: apparent diffusion coefficient.
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echo time (TE) 2.9ms, flip angle (FA) 20º, field of view (FOV) 300mm, 128×115 acquisition 
matrix, slice thickness 8mm, with maximal number of phases reconstructed ensuring 
high (6-10ms) effective temporal resolution. Aortic velocity maps were analyzed using 
the in-house developed FLOW software package. 
The aortic PWV is defined by the propagation of the systolic flow wave front, and was 
determined by the distance between the aortic measurement sites and the transit-time 
of the systolic flow wave front (Figure 1). This transit-time is assessed by the time differ-
ence in arrival of the systolic flow wave front at each level, automatically assessed by 
definition of the intersection between the horizontal diastolic flow and the upslope of 
the flow wave, modeled by linear regression of all data points between 20% and 80% of 
the range of flow values along the slope. The aortic path length between the measure-
ments sites was measured by manually drawing a centerline in the aorta as defined in 
the aortic scout view, using the in-house developed software package MASS (Medis, 
Leiden, the Netherlands). Aortic vessel wall contour segmentation was performed by a 
researcher unaware of the subjects’ conditions and obtained data with brain MRI. Figure 
2 shows the flow chart for the processing data.
 
∆x
Figure 1. Aortic pulse wave velocity assessment. The left panel shows an oblique sagittal scout view 
of the aorta. Velocity mapping was obtained at the level of the pulmonary trunk and in the abdominal 
descending aorta. The aortic path length (x) between both levels was measured, indicated by the 
polyline following the centerline of the aorta. The right panel illustrates the flow curves in the ascending 
(red line) and descending (blue line) aorta. The transit time of arrival of the pulse wave (t) was divided 
by the aortic path length (x) to calculate aortic PWV (in meters per second).
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For the assessment of systolic LV function, the LV was imaged in short-axis orientation 
as previously described (11) by using a retrospectively-gated breath-hold segmented 
gradient-echo sequence with steady-state free-precession. Ten to twelve consecutive 
slices of 10mm thickness and without gap were obtained with one signal average and 
40 reconstructed phases. Scan parameters: echo time TE 1.7 ms, repetition time TR 3.3 
ms, flip angle 50°, acquisition matrix 256×194, acquisition voxel size 1.7×1.7×10mm3. 
Using the software package MASS, end-systolic and end-diastolic LV volumes were ob-
tained using manual contour definition of the endocardial borders in these multi-slice 
Figure 2. Flow chart of the processing of pulse wave velocity.
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and multi-phase datasets. Left ventricular end-systolic and -diastolic volume, cardiac 
output and stroke volume were assessed (12).
All brain MRIs were performed on a 3.0 Tesla (Achieva; Philips Medical Systems, Best, 
The Netherlands). Brain MRI consisted of a 3 dimensional T1 (3D T1) sequence for brain 
volume assessment. Diffusion tensor imaging was performed to assess FA and ADC. 3D T1 
acquisition parameters were: TR 9.8ms, TE 4.6 ms, FA 8º, FOV 224mm, 192×152 acquisition 
matrix, 256×256 reconstruction matrix, slice thickness 1.2mm, 120 slices, no slice gap). 
For DTI, a single-shot echo-planar sequence was applied with 32 measurement directions 
having the following scan parameters: TR 10,004ms, TE 56ms, FOV 220×220×128 with an 
acquisition matrix of 112×110, 2.00mm slice thickness, transversal slice orientation, slice 
gap = 0, FA 90°, single reconstruction voxel dimensions were 1.96×1.96×2.00mm, number 
of slices = 64, B factor = 1,000, halfscan factor = 0.61. Parallel imaging (SENSE) was used 
with a reduction factor of 2, NSA = 1 and fat suppression was applied. DTI acquisition time 
was 6.55min.
MRI post processing
Evaluation of cerebral small vessel disease was evaluated on a spin-echo T2-weighted 
and fluid-attenuated inversion recovery (FLAIR) sequences. White matter hyperintensities 
(WMHs) were defined as areas of brain parenchyma with increased signal on T2-weighted 
and FLAIR images without mass effect. Lacunes defined as areas of more or less complete 
focal tissue destruction are not included in the rating of WMHs. WMHs were classified ac-
cording to Fazekas et al (13,14) and subdivided into either periventricular or subcortical. 
Periventricular lesions were defined as starting directly at the ventricular border. When 
these abnormalities extend > 1cm into the adjacent white matter, this by convention indi-
cates damage to both the periventricular and deep white matter. Deep WMH are character-
ized by a rim of normal appearing tissue which separates them from the periventricular 
region. Subjects were divided into those with normal [0] vs abnormal [1] amounts of WMHs. 
Fazekas scores of 0 and 1 were considered normal, a score of 2 was considered abnormal 
below the age of 75 years, and a score of 3 was considered abnormal in any age group. 
All T1-weighted scans were analyzed using software provided by FMRIB’s Software 
Library (FSL) (15). Total brain tissue volume was estimated with SIENAX (16,17). This 
program extracts brain and skull images from the single whole-head input data (18). 
The brain images were then affine-registered to MNI152 space, using the skull images 
to determine the registration scaling with 7 degrees of freedom (FSL-FLIRT). FSL’s FAST 
was used to create GM and WM tissue segmentations. A visual inspection of all registra-
tions was performed and of the final segmentations 20 % were selected at random and 
visually inspected for accuracy. ADC and FA reconstructions were performed direct after 
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data acquisition using software provide by the manufacturer (Philips Medical Systems, 
Best, The Netherlands). To correct for possible partial volume effects in ADC and FA 
data, especially from CSF, an eroded mask of GM and WM segmentations was created 
by removing one voxel in plane for all above named VOIs. FA and ADC reconstructions 
were then registered to the eroded whole brain, WM and GM volumes, using the same 
transformation matrix obtained from the original linear registration of the T1-w volume 
to MNI space. Finally, mean ADC and FA values were calculated for (eroded) whole brain, 
(eroded) WM and (eroded) GM. The researcher who obtained the FA and ADC data was 
unaware of the subjects’ conditions and pulse wave velocity data.
Statistical analysis
Statistical analysis was performed with SPSS (SPSS, Chicago, Illinois, USA), version 17. Con-
tinuous variables are expressed as mean ± standard deviation (sd) unless otherwise stated. 
Categorical variables were presented as frequencies and percentages. Aortic PWV and 
stroke data were non-normally distributed and therefore were log-transformed for further 
analyses. Regression analysis, corrected for age and gender was used to test whether 
subjects with white matter hyperintensities have a different PWV than subjects without. 
The correlation between aortic PWV and between stroke volume with brain integrity was 
tested by Pearson correlation analysis. Multivariate linear regression analyses were per-
formed to adjust for confounding factors, defined as age, gender, mean arterial pressure, 
body mass index, smoking, duration of diabetes and HbA1c. These covariates were entered 
simultaneously into a multivariable linear regression model. The β-regression coefficients 
and p-values are reported. Significance was reached when p<0.05 (two-tailed).
RESULTS 
PWV did not differ between patients with or without periventricular WMHs (p=0.250) 
but was higher in subjects with subcortical WMHs (Beta=0.235, p=0.008). There were 
significant correlations between the aortic PWV and white matter integrity FA (r=-0.529, 
p<0.001) and ADC (r=0.406, p=0.009). The correlation between PWV and white matter FA 
is shown in Figure 3. For gray matter integrity a significant correlation was found for ADC 
(r=0.518, p=0.001) but not for FA (r=0.016, p=0.923). Stroke volume correlated with gray 
matter integrity FA (r=0.342, p=0.029) and ADC (r=-0.368, p=0.018) and with white matter 
FA (r=0.326, p=0.038). Multivariable linear regression analyses showed that aortic PWV 
is independently associated with WM integrity expressed as FA (Beta=-0.777, p=0.008) 
in patients with T1DM (Table 2). This effect was independent of age, gender, MAP, BMI, 
smoking, duration of diabetes and HbA1c levels. In a similar multivariable linear regression 
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model for the prediction of gray matter (GM) integrity no significant effect of aortic PWV 
was observed. Lipid lowering drugs (used by 26% of the patients) may reduce arterial stiff-
ness. Therefore further adjustment for the use of statins was performed but this did not 
yield different results for the association between PWV and WM integrity (FA Beta=-0.798, 
p=0.006, ADC Beta=0.555, p=0.203). No significant association between stroke volume 
and integrity was found in multivariable linear regression analyses.
Figure 3. Correlation between  pulse wave velocity (PWV) and fractional anisotropy (FA), a DTI parameter 
of the white matter. 
Table 2. Results of multivariable linear regression analyses performed in patients with type 1 diabetes 
(n=41) to assess independent predictors of WM and GM integrity
White matter integrity Gray matter integrity
ADC FA ADC FA
Beta p-value Beta p-value Beta p-value Beta p-value
Age, years -0.068 0.859 0.111 0.731 0.252 0.444 -0.157 0.700
Female gender (n=19) -0.166 0.418 0.123 0.474 -0.230 0.192 0.091 0.676
Mean arterial pressure, mmHg -0.048 0.830 0.064 0.731 -0.245 0.202 0.044 0.850
Body mass index, kg/m2 0.079 0.666 -0.057 0.712 0.039 0.804 -0.100 0.607
Current smoker -0.037 0.831 0.149 0.319 -0.015 0.922 0.253 0.182
Duration of diabetes, years -0.078 0.753 -0.058 0.781 0.313 0.146 -0.052 0.844
HbA1c, % -0.112 0.600 -0.011 0.949 -0.166 0.363 -0.203 0.357
Aortic PWV, m/s 0.532 0.111 -0.777 0.008* 0.270 0.338 -0.098 0.778
ADC: apparent diffusion coefficient, FA: fractional anisotropy, HbA1c: glycated hemoglobin, PWV: pulse 
wave velocity. *p-value <0.05.
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DISCUSSION
The main finding of our study is the observation, that aortic stiffness is associated with white 
matter integrity independently of other potential confounders in patients with T1DM. 
So far few studies have reported on white matter integrity in T1DM. White matter 
microstructural deficits have been observed in patients with type 2 diabetes (19,20) inde-
pendent of age and blood pressure levels. Kodl et al. showed white matter microstructural 
deficits expressed as reduced FA in 25 patients with longstanding T1DM, as compared 
to 25 age- and gender-matched healthy volunteers (8). The patients in our study have a 
similar age and a somewhat shorter duration of diabetes (24 ± 13 years vs. 30 ± 11 years).
As hypothesized we found that arterial stiffness was associated with white matter mi-
crostructure expressed as reduced FA in patients with T1DM. The association with PWV 
was not found for ADC. Possibly this may be due to the fact that ADC reflects general 
diffusional properties, therefore being a more heterogeneous white matter measure 
than FA, which reflects organizational aspects. Crucial in this analysis was to incorporate 
age as a covariate as it is known that measures of diffusion such as FA and ADC, as well 
as arterial stiffness are dependent on age (19,21). Aortic PWV is a surrogate marker for 
arterial stiffness and has been shown to be an independent predictor for stroke, cerebral 
small vessel disease (5,6,20,21) and might be a predictor for cognitive decline (22). Fur-
thermore in T1DM aortic PWV measured with MRI has been demonstrated a predictor 
of white but not gray matter atrophy (4). In line with this study we could not show an 
independent association for aortic PWV with gray matter integrity. 
It is known that the blood flow in the white matter is substantially lower compared to 
the blood flow in gray matter. White matter may be more susceptible to subtle pressure 
fluctuations than gray matter, because of the vulnerable end-arterioles penetrating the 
white matter (23). It has been hypothesized that in particular “watershed” areas of the 
brain may be sensitive to arterial stiffness (24). In line, PWV has been associated with 
processing speed and memory, cognitive functions represented in these watershed loca-
tions (25). To the best of our knowledge we are the first to show an association between 
PWV and white matter integrity in patients with T1DM as evaluated by MRI techniques. 
In agreement with our study, a relation between pulse pressure, another marker of arte-
rial stiffness, and white matter deficits has been observed (9). However that relationship 
was studied in healthy normotensive subjects. Furthermore aortic PWV is considered 
to be a more accurate method for assessing arterial stiffness than the measurement of 
pulse pressure made in the peripheral vessels which does not always accurately reflect 
the actual central pulse pressure and which may be unreliable in older subjects. 
In diabetes mellitus both glucose toxicity and abnormal insulin metabolism have 
been suggested to contribute to brain pathology (26,27). Up to now few studies 
54 Chapter 3
investigated the relationship between clinical parameters of disease severity and mi-
crostructural white matter changes in diabetes. In patients with type 2 diabetes disease 
duration rather than HbA1C was related to DTI assessed white matter changes when 
investigated simultaneously (19). Interestingly we did not observe associations between 
white matter microstructure and clinical parameters such as disease duration or HbA1c. 
This is in contrast to an earlier study that identified a significant relationship between FA 
and HbA1c and between FA and disease duration in T1DM. However in that study no ad-
justments for age were performed. Furthermore those authors did not report on blood 
pressure while we investigated patients with T1DM without a history of hypertension. 
Since high blood pressure was shown to be associated with a decrease in FA (28) and is 
frequently occurring in diabetes it is not clear to which degree this may have influenced 
these previous results. 
MR-DTI is a technique that allows early detection of white matter damage even in 
regions that appear normal on conventional anatomical images.
Despite a limited understanding the exact pathophysiology, DTI changes could be of 
clinical relevance. In children DTI assessed structural integrity is associated with higher 
IQ and loss of integrity in normal aging is associated with cognitive decline (29,30). In 
addition in patients with T1DM white matter deficits were associated with performance 
on neurocognitive tests (8). In order to develop targeted treatments to prevent brain 
damage it is important to understand the underlying mechanisms that cause subtle 
brain alterations. Our findings support the role of vascular mechanisms leading to a 
decline in white matter microstructure in T1DM, which adds to current knowledge. 
Smoking is known to increase arterial stiffness (31-33) consequently we adjusted for 
smoking in the linear regression analyses. Alcohol consumption may have a divergent 
effect on arterial stiffness and may also directly affect the brain, however as the number 
of alcohol units were not registered we were not able to explore the effect of alcohol. 
Furthermore this was an explorative study and associations already detected in this small 
patient group need to be confirmed in a larger population. Given the cross-sectional 
design of this study no insight into the changes over time or a causal relationship be-
tween aortic PWV and white matter damage can be determined. Another limitation of 
our study is that we did not include cognitive testing in the current study. Longitudinal 
studies are needed to assess the impact of our findings on cognitive decline and to as-
sess the prognostic and therapeutic implications.
In conclusion we found that aortic stiffness is independently associated with reduced 
white matter integrity in patients with T1DM, which suggests a vascular contribution to 
early subtle microstructural deficits. Future prospective studies are needed to improve 
knowledge of the prognostic and therapeutic implications of these microstructural 
changes.
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Type 1 diabetes mellitus (T1DM) is associated with brain damage, such as white matter 
hyperintensities and early development of cerebral atrophy, and impaired cognitive 
functioning. Metabolic factors, like hyperglycemia, and vascular complications have 
been proposed to affect the brain in T1DM. Cortical gray matter and the thalamus and 
hippocampus, two subcortical structures, are affected in patients with T1DM. No studies 
have yet investigated the effects on other subcortical gray matter structures. Our ob-
jective was to assess, with the advanced magnetic resonance imaging (MRI) technique 
voxel-based morphometry (VBM), whether volumes of the basal ganglia differ between 
patients with longstanding T1DM and healthy controls. 
Methods
62 patients with T1DM and 62 age- and gender-matched healthy controls underwent 
MRI of the brain. Volumes of the basal ganglia, amygdala, hippocampus and thalamus 
were assessed with VBM. 
Results
T1DM patients showed volume loss of all of these gray matter areas, except for the 
amygdala. Furthermore, after correcting for potential confounding factors, the thala-
mus, hippocampus and putamen were still significantly smaller. 
Conclusions
Using MRI VBM technique, volume loss of the basal ganglia, hippocampus and thalamus 
is observed in patients with T1DM compared to controls.
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INTRODUCTION
Type 1 diabetes mellitus (T1DM) is associated with micro- and macrovascular complica-
tions (1,2). It has become increasingly clear that T1DM also affects the brain (3,4). Several 
structural brain abnormalities such as white matter hyperintensities, brain infarctions and 
the early development of cerebral atrophy (5-7) have been observed with magnetic reso-
nance imaging (MRI). Cross sectional studies have demonstrated that generalized white 
and gray matter volume loss in patients with T1DM is associated with cognitive function-
ing and even dementia (8). Both hyperglycemia and vascular complications have been 
proposed as underlying mechanisms in T1DM associated declined cognitive functioning 
and volume loss, but the pathogenesis is complex and incompletely understood (7,9-11).
Although previous studies have shown that T1DM is associated with gray matter density 
changes in general (7) and focal cortical regions and the left thalamus (12,13) and hip-
pocampus (14,15), there are no data on the volumes of subcortical structures including 
the basal ganglia and amygdala in T1DM. Since the thalamus and the hippocampus are 
subcortical structures, we hypothesized that other subcortical structures, like the basal 
ganglia and the amygdala could also be affected in patients with T1DM.
Voxel-based morphometry (VBM) is a relatively novel and sophisticated analysis 
technique which enables to test for regional differences in brain volume. VBM enables to 
identify subtle gray matter alterations (16). As regional specific reductions in gray mat-
ter density in areas responsible for language processing and memory have been found 
in T1DM (12) we set out to perform in-depth gray matter studies in T1DM, using VBM. 
We hypothesized that subcortical structures differ between patients with longstanding 
T1DM and healthy controls. 
METHODS
Study participants
Patients with T1DM were recruited from the local outpatient clinic between February 
2008 and January 2010. For inclusion, patients had to be older than 18 years and diag-
nosed with T1DM. A total of 62 patients (34 men, 28 women; mean age 51.6 ± 12.4 years) 
gave written informed consent to participate in the study. Healthy volunteers were 
recruited by advertisement in local newspaper. Sixty-two age- and gender-matched 
controls were enrolled in the study. Exclusion criteria for all participants were congenital 
aortic/heart disease, evidence of aortic valve stenosis or insufficiency, a history of stroke 
and general contraindications to MRI, like claustrophobia or a pacemaker. T1DM was 
defined according to WHO criteria (17).
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Medical data were obtained in all participants by standardized interviews and physi-
cal and laboratory examinations. Duration of T1DM in years was estimated as the time 
passed between the reported age of diagnosis and the MRI examination. Blood pressure 
and heart rate were measured using a semiautomated sphygmomanometer (Dinamap, 
Critikon, Tampa, Fla, USA). 
Hypertension was defined as: systolic blood pressure > 140 mmHg and/or diastolic 
blood pressure > 90 mmHg, on repeated physical examination before antihypertensive 
therapy was instituted and according to the criteria of the European Society of Hyper-
tension (18), or a blood pressure > 140/90 mmHg at time of MR imaging. Furthermore, 
smoking status (i.e. nonsmoker or current smoker), body mass index (BMI) and high-
density lipoprotein (HDL), total cholesterol, triglycerides, creatinine, glycated hemoglo-
bin (HbA1c) in T1DM and fasting glucose in controls were determined. Renal function 
defined as estimated glomerular filtration rate (GFR) was calculated with the Modifica-
tion of Diet in Renal Disease (MDRD) equation: 186 * (serum creatinine µmol/L / 88.4)-1.154 
x (age)-0.203 (x 0,742 if female)). Retinopathy was diagnosed based on fundoscopy.
This study was approved by the local medical ethics committee and was conducted 
according to the principles in the Declaration of Helsinki. 
MRI protocol 
All brain MRIs were performed on a 3.0 Tesla (Achieva; Philips Medical Systems, Best, 
The Netherlands). Brain MRI consisted of a 3 dimensional T1 (3D T1) sequence for brain 
volume assessment. 3D T1 acquisition parameters were: repetition time (TR) 9.8 ms, 
echo time (TE) 4.6 ms, flip angle (FA) 8º, field of view (FOV) 224 mm, 192x152 acquisition 
matrix, 256x256 reconstruction matrix, slice thickness 1.2 mm, 120 slices, no slice gap). 
MRI post processing 
All MRI scans were analyzed using different tools of FSL (FMRIB Software Library) (19). 
Whole brain volume, gray and white matter volumes were calculated using the FSL-tool 
SIENAX (Structural Image Evaluation, using Normalization, of Atrophy) (20,21). SIENAX 
starts by extracting brain and skull images from the single whole-head input data (22). 
The brain image is then affine-registered to MNI152 space (19), using the skull image to 
determine the registration scaling. This is primarily done in order to obtain the volumet-
ric scaling factor, to be used as a normalization for head size. Next, tissue-type segmen-
tation with partial volume estimation is performed to calculate total volume of brain 
tissue, including separate estimates of volumes of gray matter and white matter (23). To 
determine the volume of the subcortical twin structures nucleus accumbens, amygdala, 
caudate nucleus, hippocampus, pallidum, putamen and thalamus FMRIB’s Integrated 
Registration and Segmentation Tool (FIRST) was used. FIRST starts by registering all im-
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ages to MNI152 templates. Secondly it fits models for all different structures (meshes) to 
the images and finally applies boundary correction for the volumetric output.
A visual inspection of all registrations was performed and all final segmentations 
were visually inspected for accuracy. 
Statistical analysis
Statistical analysis was performed by using SPSS (SPSS, Chicago, Illinois, USA), version 
20. To compare clinical characteristics between T1DM and age- and gender-matched 
controls paired samples t-test for continuous variables with a normal distribution and 
nonparametric tests for non-normally distributed variables were used. Furthermore the 
McNemar test for dichotomous variables was used. Continuous variables are expressed 
as mean ± standard deviation (sd) or if non-normally distributed as median (interquartile 
range) and categorical variables were presented as frequencies and percentages.
The left and right volumes of the subcortical structures including the basal ganglia, 
the hippocampus and thalamus were added up and divided by 2 in order to obtain 
mean volumes. 
Multivariate linear regression analyses were performed to assess the independent 
contribution of T1DM to the volumes of subcortical structures, by controlling for the 
following confounders: age, gender, GFR, smoking, BMI, hypertension, HDL-cholesterol 
and triglycerides. The β-regression coefficients and p-values are reported. Significance 
was reached when p<0.05 (two-tailed).
RESULTS
Three-dimensional T1-weighted MRI of the brain was performed in 62 patients with 
T1DM and 62 age- and gender-matched volunteers (52 ± 12 years, 55% male). Mean 
T1DM duration was 27.4 ± 12.7 years, all patients used insulin and diabetic retinopathy 
was present in 47 (76%) diabetic patients. The clinical characteristics of the study popu-
lation are shown in Table 1. There were no differences between groups with respect to 
smoking, BMI and triglycerides. Cholesterol was lower and HDL higher in patients with 
T1DM compared to controls (p= 0.011 respectively 0.006). Twenty eight (45%) T1DM 
patients and 1 control subject used lipid lowering medication. Patients with T1DM were 
more often diagnosed with hypertension (37% vs 5%, p<0.001) and used more often 
blood pressure lowering drugs (34 % vs 2 %, p<0.001). Renal function estimated by GFR 
was higher in T1DM (92.3 ± 19.4 ml/min/1.732) compared to healthy volunteers (82.4 ± 
12.4 ml/min/1.732, p<0.001)
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Table 1. Clinical characteristics





Male sex, n (%) 34 (54.8) 34 (54.8) 1.000
Age, years 52 ±  12 52 ±13 0.381
Type 1 diabetes duration, years 27.4 ±  12.7 -
Hypertension, n (%) 23 (37.1) 3 (4.8) <0.001*
Current smoker, n (%) 8 (12.9) 8 (12.9) 1.000
Body mass index, kg/m2 25.3 ±  3.3 25.4 ±3.4 0.791
ACE inhibitors, n (%)  10 (16.1) 0 (0) 0.004*
AT2 antagonist, n (%)  11 (17.7) 0 (0) 0.125
Ca antagonist, n (%)  5 (8.1) 0 (0) 0.125
Diuretics, n (%)  7 (11.5) 0 (0) 0.016*
B blocker, n (%)  6 (9.7) 1 (1.6) 0.125
Use of statin, n (%) 28 (45.2) 1 (1.6) <0.001*
Retinopathy, n (%) 47 (77) -
HbA1c, % 7.7 ±  1.1 - -
HbA1c, mmol/mol 60.9 ±  11.7  
Fasting plasma glucose, mmol/l - 5.22 ±0.86 -
Creatinine, mmol/l 74.8 ±  12.4 81.6 ±11.8 0.001* 
Estimated GFR (MDRD), ml/min 92.3 ±  19.4 82.4 ±12.4 <0.001*
Total cholesterol, mmol/l 4.85 ±  0.95 5.33 ±1.30 0.011*
HDL cholesterol, mmol/l 4.80 (4.29-5.40) 5.32 (4.56-6.36) 0.013*
Triglycerides, mmol/l (median) 1.16 (0.79-1.39) 1.12 (0.82-1.55) 0.504
Data are means ± sd, number (%) or median (interquartile range). HbA1c: glycated hemoglobin, GFR: 
glomerular filtration rate, HDL: high density lipoprotein. Data were compared by paired samples t-test. 
*p<0.05.
Magnetic resonance imaging of the brain
Brain gray and white matter volumes were smaller in T1DM (Table 2). Both the thala-
mus (p<0.001) and the hippocampus (p=0.003) were significantly smaller in T1DM. Of 
the basal ganglia, volumes of the nucleus accumbens (p=0.044), the globus pallidus 
(=0.013), the putamen (p<0.001) and the nucleus caudate (p=0.044) were smaller in 
patients with T1DM compared to healthy volunteers. The amygdala was the only one
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Table 2. Magnetic resonance imaging characteristics of patients with type 1 diabetes mellitus and healthy 
controls
Diabetes mellitus (n=62) Healthy controls (n=62) p-value
Volume, cm3 Volume, cm3
Nucleus accumbens 0.46 ± 0.13 0.50 ± 0.10 0.043* 
Globus pallidus 1.92 ± 0.25 2.02 ±  0.20 0.013* 
Amygdala 1.38 ± 0.23 1.38 ±  0.21 0.984
Putamen 4.77 ± 0.47 5.17 ±  0.57 <0.001* 
Nucleus caudate 3.57 ± 0.41 3.70 ±  0.44 0.044* 
Thalamus 7.53 ± 0.87 7.98 ±  0.77 <0.001* 
Hippocampus 3.96 ± 0.40 4.17 ±  0.41 0.003* 
Whole brain
Gray matter 7.09 ± 0.45×102 7.34 ± 0.43×102 <0.001*
White matter 7.04 ± 0.47×102 7.24 ± 0.46×102 0.014* 
Gray + white matter 14.14 ± 0.72×102 14.57 ± 0.74×102 <0.001*
Values are means ± sd unless otherwise indicated. Volumes are corrected for head size. Gray matter: 
volume of normalized gray matter, White matter: volume of normalized white matter, Gray + white 
matter: volume of white and gray matter. Data were compared by paired samples t-test. *p<0.05.
structure of the gray matter areas explored in this study which did not differ in size be-
tween groups (p=0.984).
After correcting for the potential confounding factors age, gender, GFR, smoking, BMI, 
hypertension, HDL-cholesterol and triglycerides, the volumes of the thalamus (p=0.034), 
hippocampus (p=0.010) and putamen (p=0.002) remained significantly smaller in T1DM 
(Table 3). HbA1c was not associated with volumes of any of the gray matter areas.
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DISCUSSION
The main purpose of the current study was to investigate with VBM technique whether 
the volumes of the hippocampus, thalamus, amygdala and basal ganglia, differed 
between patients with longstanding T1DM and healthy controls. The main finding of 
this study is that T1DM patients showed volume loss of all of these gray matter areas, 
except for the amygdala. Secondly our results show that after correcting for potential 
confounding factors, the thalamus, hippocampus and putamen were still significantly 
smaller in patients with T1DM. 
Previous studies on hippocampal and thalamic volumes in T1DM have been per-
formed (12,14,15,24). However, to our knowledge this is the first study to investigate 
in-depth volume loss in gray matter areas other than the hippocampus and thalamus, in 
T1DM with VBM. Earlier studies on gray matter in T1DM showed equivocal results with 
respect to the hippocampus and thalamus (12,14,15,24). However, three of these studies 
were performed on MR scanners with lower field strengths 1.0T (15) and 1.5T (12,14), as 
compared to our 3.0T MR scanner. In addition two of these studies did not use VBM to 
calculate the hippocampal volumes (14,15). 
In our study the amygdala was the only structure with preserved volume in T1DM pa-
tients which is in contrast to a study performed in patients with type 2 diabetes mellitus 
(25). The amygdala has an important role in the reaction to hypoglycemia (26). Although 
the mechanism behind the differential volume remains unclear, the preservation of the 
volume of the amygdala could be related to its important function in the hypoglycemia 
awareness.
The underlying mechanisms for gray matter changes in T1DM are incompletely un-
derstood. There are several hypotheses on the pathological mechanisms causing these 
brain alterations. Both hyper- and hypoglycemia have been proposed to be involved. 
Hypoglycemic events are associated with less gray matter density (4,12,27). Furthermore 
hyperglycemia, expressed as a higher HbA1c, was suggested to contribute to lower gray-
matter density in the left hippocampus (12), which was not confirmed in our study. In 
addition, accelerated formation and accumulation of advanced glycation end products 
have also been suggested to contribute to brain alterations and brain damage in T1DM 
(13,28,29). It has also been proposed that diabetes mellitus contributes to accelerated 
aging of the brain, which can lead to microvascular abnormalities (5,13). Furthermore, 
prior studies suggest that higher blood pressure or hypertension also negatively affect 
gray matter (30-33). However, in our study, effects of T1DM on specific gray matter 
structures remained significant after correction for hypertension. The intriguing finding 
that T1DM differentially affects specific gray matter areas is challenging but difficult to 
Effects of type 1 diabetes on gray matter volume 65
explain. Potential differences in the susceptibility of the thalamus, hippocampus and 
putamen and other gray matter structures to T1DM related factors may be involved. 
In conclusion using VBM technique, we found differential volume loss of the hip-
pocampus, thalamus and basal ganglia in patients with T1DM, which was independent 
of potential confounding factors. The clinical significance and underlying mechanisms 
remain to be elucidated. 
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Caloric restriction improves 
cardiovascular function in 
advanced type 2 diabetes mellitus
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It is currently unknown whether prolonged caloric restriction improves cardiovascular 
function and reverses myocardial triglyceride (TG) accumulation in obese patients with 
type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). Our objective was 
to study whether caloric restriction improves cardiovascular function and decreases 
myocardial TG accumulation in patients with T2DM and coronary atherosclerosis.
Methods
Twenty-seven overweight or obese T2DM patients with documented CAD, i.e. myocar-
dial infarction or percutaneous coronary intervention and/or coronary artery occlusion 
of >50%, were included. Patients followed a 16-week (very) low calorie diet (V)LCD (450-
1000 kcal/day). A subgroup was observed for 16 weeks without intervention. Cardiovas-
cular function, cardiac ectopic fat accumulation and aortic pulse wave velocity (PWV), a 
marker for vascular stiffness, were assessed with magnetic resonance spectroscopy and 
imaging.
Results
After intervention BMI decreased from 32.2 ± 4.7 (mean ± sd) to 26.8 ± 4.1kg/m², 
p<0.001 and HbA1c from 6.9 ± 0.9 to 5.8 ± 0.5%, p<0.001. Left ventricular ejection frac-
tion increased from 54.8 ± 8.7 to 56.2 ± 7.9%, p=0.016. Myocardial TG decreased from 
1.23 ± 0.60 to 0.82 ± 0.37%, p=0.001. Epicardial and paracardial fat volumes decreased 
from 5.5 ± 1.7 to 4.7 ± 1.7 ml and from 7.8 ± 3.8 to 5.6 ± 3.2 ml respectively, p<0.001. PWV 
decreased from 7.9 ± 1.9 to 7.2 ± 1.1 m/s, p=0.016, reflecting a less stiff aorta.
Conclusion
Prolonged caloric restriction in overweight T2DM patients with CAD improves cardio-
vascular function which is paralleled by decreased ectopic fat accumulation. The results 
of this study are clinically relevant and prove that dietary interventions, superposed on 
optimal pharmacological therapy, are worthwhile strategies, even in advanced T2DM.
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INTRODUCTION
Cardiovascular disease (CVD) is the main cause of death in type 2 diabetes (T2DM) (1,2). 
Patients with T2DM who survived myocardial infarction (MI) are at an even higher risk 
of cardiovascular mortality, despite treatment with antidiabetic, antihypertensive drugs 
and statins (3). The pathogenesis of cardiovascular complications in T2DM is complex 
but a major role is attributed to ectopic accumulation of triglycerides (TG) in organs that 
normally do not store fat, such as the liver and heart. Ectopic fat accumulation is closely 
associated with the generation of toxic intermediates of lipid oxygenation, mitochon-
drial dysfunction and activation of inflammatory pathways which all contribute to organ 
dysfunction (4-8). Cardiac ectopic fat includes myocardial and pericardial fat accumula-
tion. Both are associated with impaired myocardial function (5,9,10) and increased CVD 
risk (11). Ectopic fat can be visualized by magnetic resonance (MR) spectroscopy and 
-imaging (MRI) (5,8,12,13) and can be modulated by dietary interventions in healthy 
subjects (14) as well as in obese subjects (15-18). Prolonged caloric restriction in obese 
patients with T2DM without established coronary atherosclerosis leads to a decrease 
in ectopic fat, including myocardial and pericardial fat and improves myocardial func-
tion (19,20). Because of their increased cardiovascular risk, it is important to establish 
whether T2DM patients with coronary artery disease (CAD) also benefit from prolonged 
caloric restriction. We therefore studied the effects of 16 weeks caloric restriction cardio-
vascular function and ectopic fat accumulation in overweight patients with T2DM and 
established CAD. Additionally, to study the effect of the dietary intervention on vascular 
function, we also assessed aortic pulse wave velocity (PWV), which is an important 
cardiovascular risk indicator (21). 
METHODS
Subjects 
Twenty-seven T2DM patients were included. Patients were recruited from the outpa-
tient clinic of the Leiden University Medical Center and via advertisement. Inclusion 
criteria were T2DM, BMI>25 kg/m² and documented CAD. Established atherosclerosis or 
CAD were defined as a history of myocardial infarction and/or percutaneous coronary 
intervention (PCI) and/or a >50% stenosis in a coronary artery as documented by CT 
angiography. Exclusion criteria were: hepatic disease, glomerular filtration rate <60ml/
min, congenital heart disease and general contraindications to MR scanning. Subjects 
underwent a medical screening including physical examination and blood chemistry 
tests. The study was approved by the local ethics committee and performed in accor-
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dance with the revised Declaration of Helsinki. Written informed consent was obtained 
from all subjects. The study was registered in the Dutch Trial Register (NTR 2897).
Study design
Patients were studied on two days, separated by a 16-week dietary intervention period, 
during which a (very) low calorie diet ((V)LCD) was prescribed. In order to assess the 
variability in study parameters without dietary intervention, 13 of the 27 patients were 
also studied during 16 weeks prior to start of the (V)LCD (baseline observation period). 
Patients were instructed not to alter life style during the study. 
The (V)LCD consisted of Prodimed products (Prodimed®, Prodimed Benelux BV, 
Valkenswaard, The Netherlands) which are low in calories, with a relatively high protein 
content (www.prodimed.nl/producten). All patients started with total meal replacement: 
4-6 sachets a day (400-600 kcal/day) including a warm meal of Prodimed for three weeks, 
supplemented with a limited choice of vegetables. After these 3 weeks caloric intake 
was increased, by replacing a Prodimed at dinnertime by meat or fish. Afterwards, when 
an additional 3% weight loss was achieved, the caloric intake was further expanded with 
one Prodimed being replaced with a normal meal. One week before the last study day, 
the diet was expanded, with a normal breakfast to achieve a caloric intake of 1000 kcal/
day. During the intervention period, weekly visits were performed and blood pressure 
and weight were measured. Blood was drawn monthly to assess safety parameters (liver 
and kidney function). 
Use of sulphonyl urea derivatives was discontinued the day the (V)LCD started and 
insulin therapy was adjusted according to glucose levels. Patients on insulin treatment 
were asked to measure their blood glucose levels 4 times a day throughout the study. 
Anthropometric measurements, blood sampling and MR imaging and spectroscopy 
were performed after ≥5 hours of fasting at each study day. Blood was centrifuged im-
mediately at 4°C and serum was stored at -80°C until analyses.
Magnetic Resonance spectroscopy and Imaging
MR measurements were performed at a 1.5-Tesla MR scanner (Gyroscan ACS-NT15; 
Philips Medical Systems, The Netherlands). 
MR spectroscopy 
MR spectroscopy (1H-MRS) was performed to quantify myocardial and hepatic TG con-
tent. Details on 1H-MRS acquisition and post processing were published before (22,23). 
Shortly, for the heart an 8-ml voxel was positioned in the interventricular septum on 
four-chamber and short-axis images in end-systole. Electrocardiographically (ECG) 
triggering (for myocardial spectra) and respiratory pencil beam navigator were used 
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during acquisition (22). For the liver, voxel sites were matched at all study occasions 
Acquisitions were performed with and without water suppression. jMRUI v2.2 (Leuven, 
Belgium) was used for fitting the spectra. Myocardial and hepatic TG were calculated as 
a percentage of the unsuppressed water signal. 
Delayed enhancement
Delayed enhancement (DCE) MRI for detection of myocardial scar was performed 15 
minutes after injection of gadetorate meglumine, 0.3ml/kg (DOTAREM, Guerbet, USA), 
as described before (24). The optimal inversion time was determined using the Look-
Locker sequence.
Left ventricular dimensions and function
The heart was imaged in short-axis orientation, as previously described (25), using an 
ECG gated breath-hold cine steady-state free-procession sequences to assess systolic 
function. Left ventricular (LV) end-diastolic and end-systolic contours were drawn, us-
ing in-house developed validated MASS®  software (Leiden University Medical Center, 
Leiden, The Netherlands). LV end-diastolic volume (EDV), end-systolic volume (ESV), 
ejection fraction (EF), mass, cardiac output (CO) and stroke volume (SV) were calculated. 
Several function parameters were indexed to body surface area (BSA) (26). We divided LV 
mass by LVEDV to obtain the LV mass/LVEDV ratio (also known as concentricity).
LV diastolic function was studied from transmitral flow rate graphs, assessed from 3D 
three-directional velocity-encoded (VE) MRI with retrospective valve tracking as previ-
ously described (27). From the transmitral flow rate graphs, the following LV diastolic 
function parameters were determined using MASS® software (Leiden University Medical 
Center, Leiden, The Netherlands): maximal flow velocities and peak filling rate in early 
diastole (E) and at atrial contraction (A) and the ratio between peak filling at E and A 
were calculated (E/A ratio). In addition, the downslope after early peak filling rate (E 
deceleration) and the ratio between maximal flow velocity during E and the through-
plane velocity assessed in the myocardial wall Ea (E/Ea), the LV filling pressure, were 
assessed (26,28).
Pericardial fat 
Pericardial fat volume, consisting of epicardial and paracardial fat, was derived from 
fat-selective imaging using SPIR, as described before (29). The heart was imaged using 
a multi shot turbo spin echo sequence in a four-chamber view orientation. Contours 
were drawn around both pericardial fat layers surrounding the ventricles and atria us-
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ing MASS® (Figure 1). The number of pixels were converted to square centimeters and 
multiplied by the slice thickness to obtain volume.
 
Figure 1. This figure shows the quantification of the pericardial fat layer, which can be divided in an 
epicardial (red) and paracardial (green) fat layer.  
Visceral and subcutaneous fat 
Abdominal visceral and subcutaneous fat volumes were quantified at the level of the 
fifth lumbar vertebra, using a turbo spin echo imaging sequence (10). During one 
breath-hold, three consecutive transversal slices of 10mm thickness were scanned. Vis-
ceral and subcutaneous fat areas of each slice were multiplied by the slice thickness to 
acquire a volume and the volumes of all three slices were summed. Volumes of visceral 
and subcutaneous fat accumulation were quantified using MASS®. 
Pulse Wave Velocity
To evaluate the aortic stiffness, aortic PWV was determined, using a previously described 
protocol (21). A scout view of the aorta was obtained. Subsequently, two time-resolved 
velocity-encoded acquisitions perpendicular to the ascending aorta at the level of the 
pulmonary trunk and at the level of the aortic bifurcation were assessed, resulting in 
through-plane flow measurements. PWV was calculated with the formula: Δx/Δt. Δx  is 
the length of the aorta between two measurement sites and Δt  is the time delay be-
tween the arrivals of the foot of the pulse wave at the respective measurements site. The 
distance between the measurement sites was determined manually with MASS®. MASS® 
and FLOW® were used for analyzing the data.
Biochemical Assays
Serum concentrations of glucose, total cholesterol, HDL and TG were measured on a 
Modular P800 analyzer (Roche, The Netherlands) and insulin on an Immulite 2500 
analyzer (Siemens, The Netherlands). HbA1c was measured on a HPLC system (Kordia, 
The Netherlands). FFA concentrations were measured in duplicate by a commercial kit, 
an in vitro enzymatic colorimetric method assay for the quantitative determination of 
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FFAs in serum (Wako Chemicals, Neuss, Germany). hsCRP levels and plasma levels of the 
various cytokines were assessed using precoated 96-well multispot plates from Meso 
Scale Discovery (MSD; Gaithersburg, Maryland, USA), an enzyme linked immunosorbent 
assay (ELISA) based electrochemiluminiscence assay. Plasma CETP was quantified using 
a quantitative assay CETP ELISA kit (ALPCO Diagnostics, Salem, New Hampshire, USA).
Statistical analysis
Statistical analyses were performed with SPSS, version 20.0 (SPSS Inc., Chicago, U.S.A.). 
Within group changes were assessed using paired sample t-test for variables with 
normal distribution. Data are presented as mean ± standard deviation (sd). p<0.05 was 
considered to be statistically significant. 
Based on the previous 16-week VLCD study in obese patients with T2DM without cardio-
vascular complications (19), we performed a sample size calculation. In order to detect 
an improvement of the E/A ratio of 16% with a power of 0.90 and alpha of 0.05 it was 
calculated that 9 patients are needed. In addition, to detect a decrease of myocardial TG 
content with 27%, power of 0.90 and alpha of 0.05, 8 patients are needed. To anticipate 
on patients leaving the study prematurely because of dietary incompliance and insuf-
ficient MR spectra, we aimed to include 30 patients. 
The Dutch Heart Foundation funded this study, but was not involved in study design or 
execution. 
RESULTS
Most patients underwent the dietary intervention without problems. Thirty-two pa-
tients started the (V)LCD, however 3 patients left the study (2 due to intolerance of the 
diet and one because of worsening of Ménière’s disease). Two patients were excluded 
because they did not adhere to the diet.
Characteristics of the study population are shown in Table 1. Mean age of the 
participants was 62.2 ± 6.0 years. Sixteen patients had previously experienced a MI, 24 
underwent PCI and 3 patients had a coronary artery bypass grafting (CABG). One patient 
had >50% occlusion of the coronary arteries on CT without a subsequent intervention 
(i.e. PCI or CABG). There were no differences in age, duration of T2DM or anthropometric 
measurements between patients with and without a MI in medical history. At the start of 
the (V)LCD 12 patients used insulin and all patients were on oral anti-diabetic drugs. All 
patients were on anti-hypertensive treatment, consisting of β-blockers, α-blockers, ACE 
inhibitors, AT II antagonists, nitrates, calcium antagonists, diuretics or a combination of 
the aforementioned medications. During the (V)LCD, 3 patients discontinued insulin 
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treatment and 3 patients discontinued all anti-diabetic drugs. Average weight loss was 
16.5 ± 5.5 kg and BMI reduced from 32.2 ± 4.7 to 26.8 ± 4.1 kg/m2, p<0.001 (Table 1). 
Glycemic control was significantly improved after 16 weeks of (V)LCD, reflected by de-
creased fasting glucose levels, from 7.4 ± 1.7 to 6.3 ± 1.2 mmol/L, p=0.002 and decreased 
HbA1c levels from 6.9 ± 0.9% to 5.8 ± 0.5%, p<0.001. Total cholesterol, HDL-cholesterol 
and plasma TG decreased after the (V)LCD. Plasma free fatty acids (FFA) did not change 
after the (V)LCD nor did interleukin (IL) 6, IL 10 and high sensitive c-reactive protein 
(hsCRP).
Table 1. Clinical and metabolic characteristics
Before (V)LCD After (V)LCD p-value 
Clinical characteristics
Age (years) 62.2 ± 6.0 
Male sex, n (%) 22 (82)
DM type 2 duration (years) 11.0 ± 8.5
BMI (kg/m2) 32.2 ± 4.7 26.8 ± 4.1 <0.001
Patients on insulin, n (%) 12 (44.4) 9 (33.3)
Insulin dose (units/day) 79 ± 36 16 ± 12
Metabolic characteristics
Glucose (mmol/L) 7.4 ± 1.7 6.3 ± 1.2 0.002
HbA1c (%) 6.9 ± 0.9 5.8 ± 0.5 <0.001
TG (mmol/L) 1.80 ± 0.89 1.17 ± 0.43 <0.001
Total cholesterol (mmol/L) 4.18 ± 0.86 3.82 ± 0.67 0.018
HDL-cholesterol (mmol/L) 1.18 ± 0.28 1.32 ±  0.34 0.001
Interleukin 6 (pg/mL) 1.30 ± 1.82 0.81 ± 0.50 0.168
Interleukin 10 (pg/mL) 0.52 ± 0.26 0.51 ± 0.24 0.813
hsCRP (mg/L) 3.82 ± 4.34 2.17 ± 3.03 0.078
Free fatty acids (mmol/L) 0.61 ± 0.25 0.59 ± 0.29 0.836
Data are mean ± sd. HbA1c: glycated hemoglobin, TG: triglycerides, HDL: high density lipoprotein, hsCRP: high 
sensitive c-reactive protein.  
Fat distribution
Delayed enhancement MRI revealed a septal MI in 5 patients, which prohibited myo-
cardial TG measurements in these patients. Therefore we excluded these 5 patients for 
analyses of myocardial TG. Myocardial TG in the other patients decreased from 1.23 ± 
0.60% at baseline to 0.82 ± 0.37% after (V)LCD, p=0.001 (-28%) (Figure 2, upper panel). 
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Figure 2. The upper panel shows changes in the various fat compartments before and after a 16-week 
(very) low calorie diet ((V)LCD). The lower panel shows relative changes in the fat compartments after 
(V)LCD as compared to baseline. TG: triglycerides, *p<0.001.
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There were no differences in myocardial TG in patients with or without MI. Hepatic TG 
content at baseline was 13.2 ± 10.4% and decreased dramatically after (V)LCD to 1.8 
± 1.3%, p<0.001(-80%) (Figure 2, upper panel). Epicardial and paracardial fat volumes 
reduced from 5.5 ± 1.7 to 4.7 ± 1.7 ml, p<0.001 (-15%) and from 7.8 ± 3.8 to 5.6 ± 3.2 ml, 
p<0.001 (-26%) respectively (Figure 2, upper panel). Furthermore, visceral fat volume 
and subcutaneous fat volumes decreased significantly after (V)LCD, respectively from 
577 ± 216 to 279 ± 177 ml and from 1029 ± 447 to 671 ± 390 ml, p<0.001 (-53% and -37% 
respectively) (Figure 2, upper panel, and 3). The relative changes in the above mentioned 
fat compartments are given in Figure 2, lower panel. 
Cardiac dimensions and function
Table 2 shows the changes in cardiac dimensions and function before and after 16 
weeks caloric restriction. Systolic and diastolic blood pressures and heart rate decreased 
after weight loss (Table 2). LV mass decreased significantly, from 114 ± 27 to 104 ± 27 
g, p<0.001 after the (V)LCD and systolic cardiac function improved. Cardiac output (CO) 
decreased significantly. LVEDV and LVSV increased after 16 weeks and LVEF increased.
The E/A ratio increased, however it did not reach statistical significance. E decelera-
tion, another parameter of diastolic function, did not change. The estimated filling pres-
sures remained unchanged after weight loss. 
Pulse wave velocity
The aortic PWV decreased significantly from 7.9 ± 1.9 m/s at baseline to 7.2 ± 1.1 m/s, 
p=0.016, after the (V)LCD. 
Figure 3. Example of a waistfat measurement at the level of the fifth lumbar vertebrae, showing visceral 
and subcutaneous fat accumulation. The left panel shows the effect of the 16-week (V)LCD in one patient 
on these fat accumulations before (left) and after (right) the (V)LCD.
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Baseline observation period
All clinical, biochemical and MR parameters of the subgroup of 13 patients that was 
studied during 16 weeks prior to the start of the (V)LCD, did not change during this 
period (see Supplemental Tables 1 and 2). 
Table 2. Effects of 16 weeks caloric restriction on systolic and diastolic cardiac function
  Before (V)LCD After (V)LCD p-value
Systolic blood pressure (mm Hg) 146 ± 14 129 ± 12 <0.001 
Diastolic blood pressure (mm Hg) 83 ± 10 75 ±  9 0.002
Heart rate (beats/min) 68 ±  12 60 ± 8 0.002
Cardiac dimensions and function
LV mass (g) 114 ± 27 104 ± 27 <0.001
LV mass index (g/m2) 53.4 ± 11.1 52.8 ± 12.3 0.418
EDV (ml) 175 ± 7.3 183 ± 7.6 0.033
EDVI (ml/m2) 81.9 ± 15.1 92.6 ± 16.7 <0.001
ESV (ml) 81 ± 29 82 ± 31 0.481
ESVI (ml/m2) 37.9 ± 13.0 41.4 ± 14.7 <0.001
LV mass/EDV 0.66 ± 0.11 0.57 ± 0.09 <0.001
SV (ml) 94 ± 18 101 ±  17 0.007
SVI (ml/m2) 44.1 ± 7.1 51.1 ± 6.4 <0.001
CO (L/min) 6225 ± 982 5619 ± 1410 0.029
CI (L/min/m2) 2921 ± 390 2846 ± 643 0.571
EF (%) 54.8 ± 8.7 56.2 ± 7.9 0.016
E/A-peak ratio 0.95 ± 0.28 1.08 ± 0.27 0.063
E deceleration (ml/s²x10-³) -2.20 ± 0.96 -1.87 ±  0.53 0.108
E/Ea 8.9 ± 5.0 6.6 ± 4.4 0.076
Data are mean ± sd. LV: left ventricular, EDV: end-diastolic volume, I: indexed for body surface area, ESV: end-
systolic volume, SV: stroke volume, CO: cardiac output, CI: cardiac index, EF: ejection fraction, E: early diastolic 
filling phase, A: diastolic atrial contraction, E/Ea: estimate of LV filling pressure.
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DISCUSSION
The present study was performed to evaluate the effects of 16 weeks caloric restriction 
in overweight patients with T2DM and established coronary atherosclerosis on cardio-
vascular function and ectopic fat accumulation. We found substantial beneficial changes 
in glucoregulation and cardiovascular function. These improvements were paralleled by 
reductions in all fat compartments as well as ectopic fat accumulation in the liver and 
heart. These data show that cardiovascular function and ectopic fat accumulation are 
susceptible to dietary intervention in complicated T2DM, which has important clinical 
implications.  
Fat accumulation
Myocardial TG accumulation is the net result of excessive FFA uptake in relation to FFA 
oxidation. Patients with T2DM have increased myocardial TG content (5), which is associ-
ated with impaired myocardial function (10). Reducing myocardial TG leads to improved 
cardiac function in uncomplicated T2DM patients (19) and according to our study also in 
patients with T2DM and CAD. Although the association between cardiac fat accumula-
tion and cardiac function does not prove a causal relationship, in a previous study we 
demonstrated that inhibiting lipolysis leads to decrease in myocardial TG accumulation 
and improved cardiac function (19). In addition, multiple direct and indirect beneficial 
effects of caloric restriction and weight loss may have added to the results observed, 
such as decreased blood pressure, improved glycemic control, decreased hepatic fat 
accumulation (30) and improved PWV.
In addition to myocardial TG, we found a decrease in pericardial fat. Pericardial fat 
consists of two layers, epicardial fat (located between the myocardium and visceral peri-
cardium) and paracardial fat (located outside the parietal pericardium) which are both 
associated with insulin resistance, T2DM and cardiovascular disease (9,31-33). Therefore, 
the effects as observed in our study in pericardial fat are considered beneficial.
As expected, hepatic TG content and visceral fat decreased dramatically. This is in 
accordance with previous diet intervention studies in patients with T2DM (19,34). 
Cardiac dimensions and function
LV mass and heart rate decreased, which is beneficial, since both are important predic-
tors for cardiovascular disease (35,36). Furthermore, parameters of LV function improved 
even after correction for BSA (19,37,38) which was also observed in uncomplicated 
T2DM (19). The E/Ea ratio, an estimate of LV filling pressure, did not change after the 
diet. The increased LV EDV at similar estimates of LV filling pressure is compatible with 
an improved LV compliance (39). 
Effects of a (V)LCD in advanced type 2 diabetes 81
An interesting finding of the current study is that LVEF increased after the (V)LCD 
(19). In some studies no effect on systolic function was observed (19,40,41). Others 
observed an improved LV systolic function, though based on other parameters than an 
improved LVEF (42-44). However, these studies differed considerably from ours, as not all 
patients had T2DM and/or coronary artery disease (40). In addition, interventions were 
heterogeneous, including exercise (44), other dietary products (19) or bariatric surgery 
(40-43). The follow-up period varied widely, from 3 months up to 3.6 years and except 
for one study (19), all studies used cardiac ultrasound which is considered less accurate 
than MRI (45). The improvement of LVEF in the current study is clinically relevant, since 
LVEF is one of the most important predictors of survival (46). 
Diastolic function did not significantly change after the 16-week (V)LCD in contrast 
to previous studies in uncomplicated T2DM that found significant improvements in E/A 
ratio after prolonged caloric restriction (19,38). 
Pulse wave velocity
PWV is a surrogate marker for arterial stiffness and a powerful independent predictor of 
cardiovascular events (47). Our study revealed a decrease in PWV of 0.7 m/s, indicating 
a less stiff aorta. Given the fact that PWV increases with 0.7m/s per 10 years of aging 
(48) this is a significant improvement. No prior studies have been published on the 
effects of dietary intervention on PWV in complicated T2DM (49-51). As most factors 
that contribute to arterial stiffness improved in our study, including blood pressure (52), 
obesity, insulin resistance and diabetes mellitus (53-55), no single causal mechanism can 
be identified from our data.
Laboratory markers
FFA did not change after the (V)LCD. Serum FFA concentrations are a reflection of di-
etary lipids and lipolysis on the one hand and FFA clearance on the other hand. During 
caloric restriction, both lipolysis and FFA oxygenation increase which can account for a 
net unchanged serum FFA concentration. In addition, the inflammation markers, IL 6, IL 
10 and hsCRP, which were already low at baseline, did not change. Obesity and T2DM 
associated inflammation is concentrated in organs and tissues, like adipose tissue and 
the liver, and may not be reflected in serum concentrations of cytokines. These results 
are in line with a previous study showing no changes in FFA and inflammation markers 
after a 16-week VLCD (56). 
The strength of this study is that it is the first to document the effects of prolonged 
caloric restriction on cardiovascular function and ectopic fat distribution in overweight 
T2DM patients with established CAD. A possible limitation to this study is the relatively 
small sample size. However, power calculation revealed that our study had sufficient 
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power to detect changes in outcome measures. Furthermore in a subgroup, it was es-
tablished that study parameters did not change over time without dietary intervention. 
Since T2DM is associated with increased cardiovascular risk (57) and CVD is the main 
cause of death in patients T2DM (1,2), the results of this study are clinically relevant and 
prove that dietary interventions, superposed on optimal pharmacological therapy, are 
worthwhile strategies, even in advanced complicated T2DM. 
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Supplemental Table 1. Clinical and metabolic characteristics
4 months before (V)LCD before (V)LCD p-value 
Clinical characteristics
Male sex, n (%) 12 (92)
DM type 2 duration (years) 7.8 ± 4.1
BMI (kg/m2) 31.7 ± 3.9 31.9 ± 4.1 0.328
Patients on insulin, n (%) 3 (23) 4 (31)
Insulin dose (units/day) 68 ± 14 70 ±  11
Metabolic characteristics
Glucose (mmol/L) 6.8 ±  1.4 7.4 ± 1.8 0.203
HbA1c (%) 7.2 ± 1.5 6.8 ± 1.1 0.422
TG (mmol/L) 2.01 ± 1.02 2.14 ± 1.00 0.600
Total cholesterol (mmol/L) 4.26 ± 0.76 4.42 ± 0.80 0.404
HDL-cholesterol (mmol/L) 1.15 ± 0.31 1.17 ± 0.30 0.604
Interleukin 6 (pg/mL) 1.19 ± 0.62 0.88 ± 0.48 0.100
Interleukin 10 (pg/mL) 0.46 ± 0.16 0.50 ± 0.21 0.448
hsCRP (mg/L) 3.62 ± 4.03 3.99 ± 4.81 0.807
Free fatty acids (mmol/L) 0.50 ± 0.20 0.54 ± 0.19 0.473
Data are mean ± sd. HbA1c: glycated hemoglobin, TG: triglycerides, HDL: high density lipoprotein, 
hsCRP: high sensitive c-reactive protein.  
Supplemental Table 2. Systolic and diastolic cardiac function
  4 months before (V)LCD Before (V)LCD p-value
Systolic blood pressure (mm Hg) 149 ± 14 143 ± 12 0.212
Diastolic blood pressure (mm Hg) 87 ±  9 84 ± 11 0.129
Heart rate (beats/min) 67 ±  15 63 ± 13 0.276
Cardiac dimensions and function
LV mass (g) 118 ±  27 116 ± 23 0.470
LV mass index (g/m2) 57 ±  12 56 ± 11 0.452
EDV (ml) 178 ±  40 178 ± 40 0.897
EDVI (ml/m2) 85 ±  15 85 ± 17 0.867
ESV (ml) 86 ±  31 86 ± 33 0.919
ESVI (ml/m2) 41 ± 13 41 ± 15 0.994
LV mass/EDV 0.68 ±  0.17 0.67 ± 0.13 0.571
SV (ml) 92 ±  20 93 ± 20 0.695
SVI (ml/m2) 44 ±  8 44 ±  8 0.739
CO (L/min) 5844 ±  834 5762 ± 956 0.701
CI (L/min/m2) 2793 ±  281 2746 ± 355 0.645
EF (%) 52.4 ±  9.2 53.0 ± 10.0 0.443
E/A-peak ratio 0.86 ±  0.27 0.93 ± 0.26 0.304
E deceleration (ml/s²x10-³) -2.10 ±  1.02 -1.92 ±  0.94 0.653
E/Ea 7.2 ±  4.9 6.8 ± 4.4 0.769
Data are mean ± sd. LV: left ventricular, EDV: end-diastolic volume, I: indexed for body surface area, ESV: 
end-systolic volume, SV: stroke volume, CO: cardiac output, CI: cardiac index, EF: ejection fraction, E: 
early diastolic filling phase, A: diastolic atrial contraction, E/Ea: estimate of LV filling pressure. 
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Cardiac ectopic fat depositions are thought to play a role in the pathogenesis of car-
diovascular disease (CVD), the main cause of death in type 2 diabetes (T2DM) patients. 
Diet-induced weight loss results in a decrease in cardiac ectopic fat stores, however if 
this is the same for surgically-induced weight loss is less clear. Therefore, we assessed 
myocardial triglyceride (TG) content, pericardial fat and cardiac function in obese, 
insulin-dependent T2DM patients before and 16 weeks after Roux-en-Y gastric bypass 
(RYGB) surgery.
Methods
Ten obese, insulin-dependent T2DM patients (40% male, age 53.7 ± 8.9 years (mean ± sd)) 
scheduled to undergo RYGB surgery were included. Ectopic fat accumulation and car-
diovascular function and were assessed with magnetic resonance (MR) imaging and 
myocardial TG content with MR spectroscopy before and 16 weeks after RYGB surgery. 
Results
BMI decreased from 41.3 ± 4.3 at baseline to 34.1 ± 2.8 kg/m2 (p<0.001) after 16 weeks. 
Glycemic control improved as well (HbA1c: 7.8 ± 1.1 to 6.8 ± 1.3% (62 ± 12 to 51 ± 14 
mmol/l) (p<0.05)). We did not observe an effect of the RYGB surgery on myocardial TG 
content, cardiac function or pulse wave velocity. There was a greater relative decrease 
in visceral (-35.5 ± 9.6%) as compared to subcutaneous fat volume (-25.0 ± 6.3%) and in 
paracardial (-17.3 ± 17.2%) as compared to epicardial fat volume (-6.4 ± 6.0%). 
Conclusions
This study shows that surgical-induced weight loss leads to a larger decrease in para-
cardial than epicardial fat. Myocardial TG and cardiovascular function did not change. 
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INTRODUCTION
Cardiovascular disease (CVD) is the main cause of death in type 2 diabetes (T2DM) pa-
tients (1). Apart from an increased risk of ischemic heart disease, T2DM is associated with 
non-ischemic heart disease, also referred to as diabetic cardiomyopathy. In the early 
stages this is mainly characterized by diastolic dysfunction (2,3). Several mechanisms 
have been proposed to explain the pathogenesis of diabetic cardiomyopathy, such as 
hyperinsulinemia, insulin resistance, inflammation, deposition of collagen and advanced 
glycation end products, altered calcium handling and lipotoxicity (2,3). 
Lipotoxicity is caused by accumulation of triglycerides (TG) in tissues other than 
adipose tissue, also called ectopic fat deposition. Obesity as well as T2DM are associ-
ated with ectopic fat depositions in liver, skeletal muscle and heart (4). Concerning 
the heart, TG can be stored in the myocardium or in pericardial fat, the adipose tissue 
surrounding the heart. These ectopic fat depots can be visualized non-invasively by 
magnetic resonance imaging (MRI) and magnetic resonance (MR) spectroscopy (3,5-
7). Pericardial fat consists of two distinctive fat depots, epicardial fat and paracardial 
fat (5). An increased pericardial fat volume is associated with insulin resistance and an 
increased cardiovascular risk (8-10). Furthermore, myocardial TG content is increased in 
subjects with impaired glucose tolerance and is associated with diastolic dysfunction 
in T2DM patients (6,11). A previous study showed that a 16-week very low calorie diet 
(VLCD) results in a decrease in myocardial TG content and an improvement in diastolic 
function in obese insulin-dependent T2DM patients (12). Furthermore, in these patients 
a decrease in pericardial fat was seen directly after the diet, but also after 14 months 
follow-up, despite considerable weight regain (13). These data suggest that cardiac 
ectopic fat stores are flexible and can be modulated by weight loss. Indeed, others also 
showed a decrease in cardiac ectopic fat in response to diet-induced weight loss (14,15).
Over 80% of T2DM patients are overweight or obese, and weight loss remains the 
hallmark of their treatment. However, long-term maintenance of weight loss is extremely 
difficult. Bariatric surgery results in sustained weight loss (16). Furthermore, bariatric 
surgery leads to diabetes remission in 70-80% of T2DM patients (17) and is associated 
with a decreased incidence of diabetes (18) and cardiovascular events (19) as well as a 
long-term reduction in overall mortality (20) in obese subjects. It is largely unknown 
whether cardiac ectopic fat depots can also be mobilized by bariatric surgery. In one 
study in obese subjects using MRI a decrease in epicardial fat content was seen 6 months 
after bariatric surgery. However, there was no decrease in myocardial TG content and 
paracardial fat was not assessed (21). In addition, since only 26% of the subjects in this 
study had T2DM, the effects of bariatric surgery on cardiac fat depots in T2DM patients, 
who are at particularly high risk of developing myocardial dysfunction, are currently 
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unknown. We hypothesize that surgically-induced weight loss can lead to mobilization 
of cardiac ectopic fat accumulation in T2DM patients, with a focus on pericardial fat, and 
thereby improve cardiovascular function. Therefore, we assessed pericardial fat, myocar-
dial TG content and cardiac function in obese, insulin-dependent T2DM patients before 
and 4 months after a Roux-en-Y gastric bypass (RYGB) using MRI and MR spectroscopy. 
Furthermore, we studied aortic pulse wave velocity (PWV), which is surrogate marker for 
arterial stiffness and a cardiovascular risk indicator, using MRI.
METHODS 
Patients
Ten morbidly obese subjects with T2DM scheduled to undergo RYGB surgery were 
included in this study. Subjects eligible for surgical treatment were recruited from the 
waiting lists of several Dutch bariatric surgery centers, after referral for a weight loss 
program by their GP or internist. They had been screened previously by a multidisci-
plinary team of the Nederlandse Obesitaskliniek (Dutch Obesity Clinic) to establish if 
they fulfilled the international criteria for bariatric surgery as described by Fried et. al. 
(22): BMI > 35 kg/m2 with co-morbidity (i.e. T2DM), which is expected to improve after 
surgically-induced weight loss, a history of longstanding obesity (>5 years), proven 
failed attempts to lose weight in a conventional way, or initially successful weight loss 
with eventual weight regain. Other inclusion criteria were age between 18-60 years and 
the use of insulin to control T2DM. Exclusion criteria were any significant chronic disease 
except for T2DM, known cardiovascular disease, weight > 150 kg (because of the weight 
restrictions of a standard MRI table) and general contraindications for MRI (for example 
claustrophobia or a pacemaker).
The study was approved by the local ethics committee and performed in accordance 
with the principles of the revised Declaration of Helsinki. Written informed consent was 
obtained from all subjects.
Study design
Patients were studied on 2 occasions. MR studies were performed shortly before and 16 
weeks after the RYGB. The first MRI was planned as close as possible to the planned RYGB 
surgery, however due to scheduling difficulties of the surgery, two patients had a longer 
time interval. An incidental finding at the first MRI, which eventually was proven to be 
a benign cyst in the kidney, prolonged the time interval in a third patient. The median 
time interval between the first MRI and the RYGB was 16 days (interquartile range (IQR) 
62 days). Anthropometric measurements and blood samples were obtained on both 
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study days after ≥ 5 hours of fasting. Fat mass was assessed by bioelectrical impedance 
analysis (BIA; Bodystat® 1500, Bodystat Ltd., Douglas, UK).
MR protocol
All measurements were performed using a 1.5-Tesla whole-body MR scanner (Gyroscan 
ACS-NT15; Philips Medical Systems, Netherlands) in postprandial state (≥ 5 hours after 
the last meal). 
Myocardial and liver triglyceride content
MR spectroscopy (1H-MRS) data were obtained as described before and were used to 
quantify myocardial TG content (23). Briefly, a 8-ml voxel was positioned in the myocar-
dial interventricular septum in end-systole, avoiding contamination from epicardial fat. 
Electrocardiographically (ECG) triggering and respiratory pencil beam navigation were 
used during acquisition. For the liver, at both study occasions, voxel sites were matched, 
avoiding blood vessels and bile ducts. Spectra with water suppression were acquired 
with TE=26ms and TR≥3,000ms. 1,024 data points were collected using a 1,000-Hz 
spectral width and averaged over 128 acquisitions. Spectra without water suppression 
with TR=10s and four averages were obtained without changing other parameters. 
Spectroscopic data were fitted using validated software (jMRUI version 2.2, Leuven, 
Belgium). The TG content was calculated as (amplitude of TG signal/amplitude water 
signal) x 100%. 
Epicardial and paracardial fat quantification
To quantify the pericardial fat volume, the heart was imaged in a four chamber view 
orientation using ECG gated breath-holds with a multi shot turbo spin echo sequence, 
as described before (24). Water was suppressed using Spectral Inversion Recovery 
(SPIR). Imaging parameters were: slice thickness 4mm, scan matrix: 251x256 pixels, 
FA=90°, TE=8.6 ms and TR≥1000 ms. Adipose tissue around the heart was easily identi-
fied because of the water suppression, and contours were drawn around the epicardial 
and paracardial fat surrounding the ventricles and atria using MASS® software (Medis, 
Leiden, the Netherlands). The number of pixels were converted to square centimeters 
and multiplied by the slice thickness to obtain volume. 
Visceral and subcutaneous fat 
Abdominal visceral and subcutaneous fat volumes were imaged using a turbo spin echo 
imaging sequence (11). During one breath-hold, three consecutive transversal slices of 
10mm thickness were scanned at the fifth lumbar vertebrae. Imaging parameters were 
TR=168ms, TE=11ms, FA=90º. Contours were drawn around visceral and subcutaneous 
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abdominal fat depots using Mass®. Visceral and subcutaneous fat areas of each individual 
slice were multiplied by the slice thickness to acquire a volume and the volumes of all 
three slices were summed. 
Left ventricular dimensions and function
The entire heart was imaged in short-axis orientation, using ECG gated breath-hold cine 
steady-state free-precession sequences, as previously described(25). Imaging param-
eters were: repetition time (TR) 3.4ms, echo time (TE) 1.7ms, flip angle (FA) 35º, field 
of view (FOV) 400×320mm, and slice thickness 10mm, no slice gap was used. To assess 
left ventricular (LV) systolic function, epicardial and endocardial contours were manu-
ally drawn in the end-systolic and end-diastolic phases of the short-axis images, using 
validated MASS® software (Medis, Leiden, Netherlands). LV end-diastolic volume (EDV), 
end-systolic volume (ESV), ejection fraction (EF), stroke volume (SV) and end-diastolic 
mass (EDM) were calculated. Volumes and mass were indexed (I) for body surface area 
(BSA).
Furthermore, to assess LV diastolic function, flow across the mitral valve was mea-
sured using an ECG gated gradient-echo sequence with velocity encoding. Scan param-
eters were: TR=9.1ms, TE=1.0ms, FA=20º, slice thickness=8mm, FOV 350x350mm, matrix 
256x256 pixels, velocity encoding = 100 cm/sec. Analysis was performed using FLOW® 
software (Medis, Leiden, Netherlands). Flow velocities in early diastole (E) and at atrial 
contraction (A) were measured and the peak flow ratio was calculated (E/A ratio). In 
addition the peak deceleration gradient of E and LV filling pressures E/Ea were assessed 
(26,27). 
Pulse Wave Velocity
Aortic PWV was determined to assess aortic stiffness, using a previously described 
protocol (28). In short, the aorta was imaged in a double-oblique parasagittal scout 
view. Subsequently, a velocity-encoded image perpendicular to the ascending aorta at 
the level of the pulmonary trunk and at the abdominal descending aorta was assessed. 
This resulted in through-plane flow measurements of the ascending and descending 
aorta. Scan parameters were: TR=5.0ms, TE 3.0ms, flip angle=20º, FOV=300mm, 128×128 
acquisition matrix, slice thickness=8mm, with maximal number of phases reconstructed 
ensuring high (6-10ms) effective temporal resolution. True temporal resolution is de-
fined as 2 times TR=10ms. PWV was calculated using the formula: Δx/Δt, where Δx is the 
aortic path length between two measurement sites and Δt is the time delay between the 
arrivals of the foot of the pulse wave at the respective measurements site. The distance 
between the two measurement sites was manually determined by drawing a poly-line 
in the center of the aorta as defined in a double-oblique parasagittal aortic scout view, 
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using the software package MASS®. Data were analyzed using MASS® and FLOW® (Medis, 
Leiden, Netherlands).
Surgical Intervention
During RYGB, a 25 ml gastric pouch was created and connected to a 100 cm Roux-en-Y 
limb. The Roux limb was connected end-to-side to the jejunum 100 cm distal of the 
ligament of Treitz. 
Assays
Serum concentrations of glucose, total cholesterol, HDL and triglycerides were mea-
sured on a  Modular P800 analyzer (Roche, Netherlands), and serum insulin levels on 
an Immulite 2500 (Siemens, Netherlands). HbA1c was measured on an HPLC system 
(Kordia, Netherlands). 
Statistical analysis
Data are presented as mean ± sd. We used two-tailed paired t-tests to compare the two 
study time points. Nonparametric tests (Wilcoxon signed-rank test for paired samples) 
were performed as appropriate. A p-value of <0.05 was considered statistically sig-
nificant. Statistical analyses were performed using SPSS for Windows version 20.0 (IBM, 
USA).
RESULTS
Clinical and metabolic characteristics
The mean age of the patients was 53.7 ± 8.9 years and mean duration of T2DM was 
13.9 ± 8.2 years. Clinical and metabolic parameters before and after bariatric surgery are 
shown in Table 1. BMI decreased from 41.3 ± 4.3 at baseline to 34.1 ± 2.8 kg/m2 (p<0.001) 
16 weeks after bariatric surgery. After the RYGB, glycemic control was significantly im-
proved, as shown by a decrease in HbA1c from 7.8 ± 1.1 to 6.8 ± 1.3 % (62 ± 12 to 51 ± 14 
mmol/l) (p<0.05). According to the inclusion criteria, all patients used insulin at baseline. 
After 16 weeks the average total daily dose of insulin decreased from 134 ± 66 units 
at baseline to 26 ± 25 units. Two patients were able to discontinue insulin treatment 
completely.
96 Chapter 6
Table 1. Clinical and metabolic characteristics
  Before RYGB   After RYGB p-value
Clinical characteristics (n= 10)
age (years) 53.7 ± 8.9
male sex, n (%) 4 (40)
height (m) 1.72 ± 0.08
weight (kg) 122.4 ± 11.3 101.0 ± 7.7 <0.001
BMI (kg/m2) 41.3 ± 4.3 34.1 ± 2.8 <0.001
systolic BP (mmHg) 143 ± 24 132 ± 12 0.154
diastolic BP (mmHg) 77 ± 11 76 ± 8 0.959
heart rate (bpm) (n= 7) 75 ± 11 63 ± 15 0.031
fat percentage (%) 48.3 ± 6.6 41.3 ± 7.1 <0.001
Metabolic characteristics (n= 9)
HbA1c (%) 7.8 ± 1.1 6.8 ± 1.3 0.028
glucose (mmol/L) 9.8 ± 3.9 7.4 ± 3.0 0.037
triglycerides (mmol/L) 2.5 ± 1.1 1.9 ± 0.7 0.037
total cholesterol (mmol/L) 4.3 ± 0.7 3.6 ± 0.7 0.070
HDL-cholesterol (mmol/L) 0.98 ± 0.36 1.01 ± 0.25 0.594
LDL-cholesterol (mmol/L) (n= 8) 2.1 ± 0.5 1.7 ± 0.7 0.215
CRP (mg/L) (n= 8) 8.24 ± 6.4   6.13 ± 4.6 0.038
Data are presented as mean ± sd. DM: diabetes mellitus, BMI: body mass index, BP: blood pressure. 
MRI and MRS studies
Results from the MR studies are shown in Table 2 and Table 3. Due to technical difficulties 
MRI data are not available for all patients (see tables for details on specific scans).
Fat compartments
Pericardial fat volume decreased 16 weeks after the RYGB. When the two pericardial fat 
compartments (epicardial and paracardial fat) were assessed separately, a significant 
reduction in both fat depots was shown (Table 2). A difference in proportional decreases 
was seen, with a higher relative proportional decrease in paracardial (-17.3 ± 17.2 %) 
as compared to epicardial (-6.4 ± 6.0%) fat volume (Figure 1). Myocardial TG content 
decreased as well, however this did not reach statistical significance. 
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Table 2. Ectopic fat distribution and myocardial and hepatic triglyceride content assessed with MRS and 
MRI before and after RYGB.
  Before RYGB   After RYGB p-value
Visceral fat (ml) 891 ± 210 576 ± 168 <0.001
Subcutaneous fat (ml) (n= 9) 1652 ± 189 1234 ± 141 <0.001
Visceral / subcutaneous ratio (n= 9) 0.54 ± 0.19 0.46 ± 0.17 0.040
Myocardial TG content (%) (n= 9) 1.18 ± 0.44 0.91 ± 0.56 0.192
Hepatic TG content (%) (n= 9) 20.2 ± 12.4 6.6 ± 5.3 0.002
Paracardial fat (ml) (n= 7) 7.5 ± 3.3 6.3 ± 3.4 0.028
Epicardial fat (ml) (n= 7) 6.7 ± 2.3 6.2 ± 2.0 0.047
Pericardial fat (ml) (n= 7) 14.1 ± 4.7 12.5 ± 4.6 0.008
Data are mean ± sd. TG: triglyceride. 
Table 3. Cardiac dimensions and parameters of cardiovascular function assessed with MRI before and 
after RYGB.
  Before RYGB   After RYGB p-value
Cardiac dimensions and basic function (n= 9)
LVEDMI (g/m2) 50.2 ± 8.9 47.7 ± 8.4 0.339
EDVI (ml/m2) 86.2 ± 18.4 93.2 ± 19.4 0.096
ESVI (ml/m2) 35.3 ± 8.8 37.6 ± 11.2 0.186
SVI (ml/m2) 55.6 ± 9.1 50.9 ± 10.4 0.112
CI (ml/min/m2) 3276 ± 498 3030 ± 388 0.085
EF (%) 59.2 ± 3.4 60.2 ± 5.0 0.374
Diastolic cardiac function (n= 9)
E peak filling rate (ml/s) 510 ± 161 492 ± 135 0.110
E acceleration peak (ml/s²x10-³) 7.3 ± 1.9 7.0 ± 2.4 0.542
E deceleration peak (ml/s²x10-³) -4.3 ± 2.0 -4.0 ± 1.5 0.272
A peak filling rate (ml/s) 414 ± 118 410 ± 116 0.848
A acceleration peak (ml/s²x10-³) 7.1 ± 2.4 7.1 ± 1.8 0.984
A deceleration peak (ml/s²x10-³) -8.0 ± 3.1 -8.2 ± 3.4 0.671
E/A-peak ratio 1.26 ± 0.36 1.28 ± 0.51 0.885
E/Ea 8.4 ± 3.2 8.8 ± 2.6 0.801
Pulse wave velocity (n= 7)
PWV total aorta (m/s) 7.5 ± 1.5 6.2 ± 0.8 0.055
Data are mean ± sd. LV: left ventricular, EDM: end-diastolic mass, EDV: end-diastolic volume, ESV: end-
systolic volume, SV: stroke volume, CI: cardiac index, EF: ejection fraction, ESWS: end-systolic wall stress. 
I: indexed for body surface area, E: early diastolic wave, A: atrial diastolic wave, E/Ea: estimated left 
ventricular filling pressure, PWV: pulse wave velocity.
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After the RYGB the visceral and subcutaneous fat volumes were significantly reduced. 
There was a higher relative decrease in visceral as compared to subcutaneous fat volume, 
as reflected by a decrease in the visceral/subcutaneous fat ratio (Table 2 and Figure 1). 
Cardiovascular function
Parameters for cardiac dimensions and systolic and diastolic function are shown in Table 
3. Sixteen weeks after RYGB the parameters of systolic and diastolic cardiac function had 
not changed significantly. However, a trend was seen for a decrease in PVW (baseline: 7.5 
± 1.5; 16 weeks: 6.2 ± 0.8 m/s; p=0.055).
Figure 1. This figure shows the relative changes in epicardial, paracardial, visceral and subcutaneous 
abdominal fat volume. *p<0.05 significant change in fat volume compared to baseline.
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DISCUSSION
This study was performed to assess the effects of bariatric surgery on cardiac ectopic 
fat accumulation in T2DM patients, with a focus on pericardial fat, which has not been 
studied in detail before. We found a substantial reduction in ectopic cardiac fat, after 16 
weeks follow-up. Interestingly, we observed a differential response of the pericardial fat 
layers after RYGB surgery, which has not been shown before. Pericardial fat consists of 
two layers, epicardial fat (located between the myocardium and visceral pericardium) 
and paracardial fat (located outside the parietal pericardium). Epicardial fat is a vis-
ceral fat depot, originating from mesothelial cells, and it is supplied by branches of the 
coronary arteries (5). Epicardial fat is thought to have several beneficial functions, for 
instance serving as a buffer to protect the myocardium from a toxic overload of free fatty 
acids (FFAs) and, on the other hand, supplying FFAs as an immediate energy source for 
the cardiac muscle in times of need. Furthermore, it might protect the coronary arteries 
from torsion (5,29,30). However, increased epicardial fat volume has been associated 
with insulin resistance, T2DM and cardiovascular disease (8-10,31). Studies that assessed 
epicardial fat volume with MRI showed that epicardial fat volume is related to visceral 
fat volume at baseline (32) and decreases after diet-induced weight loss and exercise in 
obese subjects (4). Previous studies with echocardiography revealed that epicardial fat 
thickness decreases after diet-induced weight loss (33). Bariatric surgery also leads to a 
decrease in epicardial fat in obese subjects as measured by echocardiography (14,34) 
and MRI (21). In our study there was a decrease in epicardial fat volume as well; however 
the relative decrease in paracardial fat volume was much higher. The role of paracardial 
fat is currently less clear. Some studies have shown that paracardial fat is a better predic-
tor of cardiovascular risk than epicardial fat (35). Furthermore, a 6-month exercise inter-
vention in T2DM patients led to a decrease in visceral and paracardial, but not epicardial 
fat (24). This study and our findings might suggest that exercise and weight loss in T2DM 
patients have differential effects on paracardial adipose tissue as opposed to epicardial 
adipose tissue. In contrast, a very recent study showed no differences in epicardial nor 
in paracardial fat after bariatric surgery. However, the follow-up duration in that study 
was shorter (mean 80 ± 24 days), as compared to our follow-up, which might explain 
the different results (36). Long-term follow-up of our patient group would be interesting 
to determine whether epicardial fat response is delayed compared with visceral and 
subcutaneous fat.
We also observed that the abdominal fat compartments did not respond equally 
to the surgically-induced weight loss. The observed preferential loss of visceral fat as 
compared to subcutaneous fat confirms findings of earlier studies in obese subjects 
after bariatric surgery (21) and in T2DM patients after a VLCD (13). 
100 Chapter 6
We did not observe a decrease in myocardial TG after RYBG surgery. Gaborit et al. also 
did not show a decrease in myocardial TG content 6 months after bariatric surgery (21). 
It is an interesting finding that previous studies with dietary-induced weight loss inter-
ventions did find decreased myocardial TG in obese subjects with and without T2DM 
(12,15), whereas this is not found in studies on weight loss induced by bariatric surgery. 
It could be suggested that the surgical-induced weight loss has a differential effect on 
myocardial TG as compared to diet induced weight loss. It is, however, unclear what the 
cause of this difference might be. It could be that a major surgery results in a higher 
inflammatory stress response as compared to dietary intervention. However, the CRP 
levels of our patients significantly decreased 4 months after surgery. A rapid decrease in 
markers of a chronic low grade inflammatory state after bariatric surgery has been found 
by others as well (37). In contrast to dietary interventions, bariatric surgery also directly 
induces significant changes in gastro-intestinal hormone secretion (38), which might 
contribute to the differences. The exact mechanism explaining the differences between 
dietary- and surgical-induced weight loss on myocardial TG content therefore warrants 
further investigation.
The high myocardial TG content at baseline in our study is striking. Other studies 
report myocardial TG contents of around 1.0% (12,21), whereas we found a value of 1.18 
± 0.44%. This high baseline value might indicate more severe cardiac lipotoxicity in our 
patient group and concomitant less flexibility of the myocardial TG content. 
After the RYGB, we found a (non-significant) decrease in pulse wave velocity, sug-
gesting an improvement of central arterial stiffness. We did not observe an effect of 
RYGB surgery on cardiac function. The most important parameter for diastolic function, 
the E/A ratio, however, was already within the normal range (> 1.0) at baseline, with a 
mean value of 1.26 ± 0.36. Therefore an improvement in diastolic function might not be 
expected. In a previous study that did find improved diastolic function after weight loss 
using a VLCD, the E/A ratio at baseline was lower as compared to our study (12). In con-
trast, diastolic cardiac function did improve in the study by Gaborit et al. (21) 6 months 
after bariatric surgery, even though a high E/A ratio was present at baseline as well. The 
difference might be explained by the fact that only 26% of the patients in that study had 
T2DM, whereas all of our patients were insulin-dependent T2DM patients. Furthermore, 
in our study only 2 of the 10 patients were able to stop insulin treatment 4 months after 
the bypass surgery. It can therefore not be excluded that continued hyperinsulinemia 
may have influenced cardiac function. 
A limitation of our study is the small sample size. Because of the narrow interior of 
the MRI scanner and the maximum allowable weight of the MRI table many candidates 
for bariatric surgery are not eligible for MR studies. However, our study was successful 
in showing substantial changes of bariatric surgery on ectopic fat accumulation and 
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in particular provided new data on fat distribution in epi- and paracardial fat. Another 
limitation is the relatively short follow-up period, which could be an explanation for the 
fact that we did not find statistically significant differences in cardiovascular function 
parameters between the two time points.
In conclusion, this study shows that weight loss induced by bariatric surgery leads 
to a decrease in abdominal and pericardial fat depots, with a higher relative decrease 
of visceral and paracardial fat volumes. These findings contribute to the existing evi-
dence suggesting tissue-specific changes in body fat distribution after weight loss and 
exercise interventions. However, the decrease in pericardial fat did not lead to improved 
cardiovascular function after the RYGB. 
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Functional and metabolic 
imaging of the cardiovascular 
system in young healthy 
South Asians and Caucasians 
unveils early differences
Different cardiac dimensions and cardiovascular function in young South Asians
Linda D. van Schinkel*, Leontine E.H. Bakker*, 
Jacqueline T. Jonker, Albert de Roos, Hanno Pijl, A. Edo 
Meinders, Ingrid M. Jazet, Johannes W.A. Smit, Hildo J. 
Lamb
*Both authors contributed equally




South Asians have a higher risk of developing cardiovascular disease (CVD) than 
Caucasians. Whether there are already differences in cardiac dimensions and cardiovas-
cular function at a young age between South Asians and Caucasians is unknown. The 
increased CVD risk might relate to alterations in metabolism or ectopic fat deposition. 
Our objective was to assess whether cardiac dimensions and cardiovascular function 
differ between young South Asians and Caucasians and whether there is a differential 
response to a high fat diet.
Methods
Cardiac dimensions and cardiovascular function were assessed using a 1.5T MR scan-
ner in 12 young, healthy male South Asians and 12 matched Caucasians. To elucidate 
if differences in cardiovascular function are related to metabolism, participants were 
subjected to a 5-day high fat high caloric (HFHC) diet.
Results
At baseline South Asians had lower left ventricular mass (p<0.001) and end-diastolic 
volume (p<0.001), indexed for body surface area, than Caucasians. Furthermore, dif-
ferences in cardiac function profile were observed. E acceleration peak (p=0.010) and 
E deceleration peak (p=0.005) were lower in South Asians. Additionally, South Asians 
had lower acceleration (p=0.001) and deceleration peak flows (p<0.001) over the aorta. 
A 5-day HFHC-diet did not increase these differences. Finally, pulse wave velocity at 
baseline was higher in South Asians (p=0.022), which normalized after the diet.
Conclusions
Young, healthy South Asians have smaller cardiac dimensions and a different cardiovas-
cular function profile than Caucasians. A 5-day HFHC-diet did not increase these differ-
ences, suggesting these findings cannot be explained by a different metabolic response 
to dietary fat.
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INTRODUCTION
People of South Asian descent, originating from the Indian subcontinent, represent 
one fifth of the world’s population. South Asians are at an increased risk of developing 
cardiovascular disease (CVD) compared to Caucasians (1). The age-standardized mor-
tality rate from CVD is around 50% higher for South Asians than for Caucasians (2-5). 
Furthermore, the mean age of first acute myocardial infarction is approximately five 
years earlier in South Asians than in Caucasians (6,7). Moreover, CVD in this population is 
more aggressive and has higher mortality rates at younger ages (1-3,7). 
The differences in CVD prevalence and severity between both ethnicities cannot be 
explained by traditional risk factors (4). Since insulin resistance (IR) and type 2 diabetes 
mellitus (T2DM) are highly prevalent in South Asians (8,9) and the mortality risk of CVD 
associated with T2DM is higher in this ethnicity compared to Caucasians (4,10), the in-
creased CVD risk might be related to altered or earlier detrimental metabolic changes as 
reflected by ectopic fat deposition in organs such as the heart, liver and skeletal muscle 
(11). 
Little is known about differences in cardiovascular function between South Asians 
and Caucasians at a relatively young age. In a previous study, in which cardiac function 
was assessed with echocardiography, middle-aged South Asians had attenuated longi-
tudinal left ventricular (LV) function, higher LV filling pressure and a greater degree of 
concentric remodeling compared to Caucasians (12). Whether these findings are related 
to the increased CVD risk, however, remains to be determined.
The aim of the present study was to assess whether differences in cardiac dimensions, 
cardiovascular function, and myocardial triglyceride (TG) content are present between 
young, healthy South Asians and matched Caucasians using Magnetic Resonance (MR) 
Imaging (MRI) and Spectroscopic (MRS) techniques. In addition, we measured abdomi-
nal fat distribution and hepatic TG content. We hypothesize that possible differences 
in cardiovascular function between South Asians and Caucasians can be attributed to 
alterations in energy metabolism, including differential fat distribution in South Asians. 
In a previous study, short-term high fat feeding decreased diastolic function (13). If 
the differences in cardiovascular function and dimensions in South Asians can indeed 
be attributed  to a higher metabolic risk, a high fat high caloric (HFHC) diet may have 
more profound effects on cardiovascular function in this ethnicity then in Caucasians. 




Twelve Dutch South Asian and twelve Dutch Caucasian healthy males matched for 
age (19-25 years) and BMI (<25 kg/m2), with a positive family history for T2DM were 
enrolled. Exclusion criteria were: any significant chronic disease (including T2DM), use 
of medication known to influence glucose and/or lipid metabolism, smoking, recent 
weight change and general contraindications to MR scanning. Subjects were recruited 
via advertisements in newspapers. The study was approved by the local ethics commit-
tee and written informed consent was obtained from all subjects.
Study design
The study consisted of 2 occasions separated by a 5-day HFHC-diet. The HFHC-diet con-
sisted of the subject’s regular diet, supplemented with 375 ml of cream per day (=1275 
kcal/day, 94% fat), yielding to around 3775 kcal/day and 54% of fat. Subjects underwent 
MRI/MRS shortly before the start of the HFHC-diet and at the end of the 5th day of the 
diet. Participants were instructed not to alter lifestyle habits. Anthropometric measure-
ments and blood samples were obtained on both occasions after a 10-hour overnight 
fast. 
MR protocol
All measurements were performed on a 1.5 Tesla MR scanner (Gyroscan ACS-NT15; Phil-
ips Medical Systems, Netherlands) in supine position, and were made in postprandial 
state (four hours after the last meal). 
Left ventricular dimensions and function
Data were analyzed blinded for ethnicity and study occasion. 
The heart was imaged in short-axis orientation, using electrocardiographically gated 
breath-hold cine steady-state free-precession sequences as previously described (14). 
Imaging parameters were: repetition time (TR) 3.4ms, echo time (TE) 1.7ms, flip angle 
(FA) 35º, field of view (FOV) 400×320mm, and slice thickness 10mm, no slice gap was 
used. Epicardial and endocardial LV contours were manually drawn in the end-systolic 
and end-diastolic phases of the short-axis data, using validated MASS® software (Medis, 
Leiden, Netherlands). LV end-diastolic volume (EDV), end-systolic volume (ESV), ejection 
fraction (EF), stroke volume (SV) and end-diastolic mass (EDM) were assessed. We di-
vided LVEDM by LVEDV to obtain the LVEDM/LVEDV ratio (also known as concentricity). 
Volumes and mass were indexed (I) for body surface area (BSA). 
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We calculated LV end-systolic wall stress (LVESWS) with the formula 0.133*systolic 
blood pressure*((3xESV/wall volume)+1) (15).
For assessment of LV diastolic function, transmitral flow was measured, using elec-
trocardiographically gated gradient echo sequence with a velocity sensitivity of 100 
cm/sec (TR 9.1ms, TE 1.0ms, FA 20º, slice thickness 8mm, FOV 350mm2, matrix 256x256 
pixels). Flow velocities in early diastole (E) and at atrial contraction (A) were measured 
and their peak flow ratio was calculated (E/A ratio) using FLOW® software (Medis, Leiden, 
Netherlands). Furthermore, the peak deceleration gradient of E, the E/A peak ratio and 
LV filling pressures E/Ea were determined (15,16). Heart rate was monitored and stored 
during the transmitral flow measurements. 
As a measurement of more subtle changes in systolic function of the heart, aortic 
flow curves were acquired, using electrocardiographically gated gradient echo 
sequence with a velocity sensitivity of 150 cm/sec (TR 5.0ms, TE 1.0ms, FA 20º, slice 
thickness 8mm, FOV 300mm2, matrix 128x128 pixels). Flow velocities in the ascending 
aorta at the level of the pulmonary trunk were measured and calculated using FLOW® 
software (Medis, Leiden, Netherlands). The peak slope of the acceleration (aortic (AO) 
acceleration peak) and deceleration (AO deceleration peak) of the aortic flow curve were 
calculated. Furthermore, AO duration, AO peak filling rate and AO deceleration duration 
were determined (Figure 1).
Pulse Wave Velocity
Aortic pulse wave velocity (PWV) was determined for the evaluation of aortic stiffness, 
using a previously described protocol (17). In short, a scout view of the aorta was per-
formed. Next, a velocity-encoded image perpendicular to the ascending aorta at the 
level of the pulmonary trunk, and at the level of the aortic bifurcation was assessed. This 
resulted in through-plane flow measurements of the ascending and descending aorta. 
Scan parameters were: TR 5.0ms, TE 1.0ms, FA 20º, FOV 300mm, 128×128 acquisition ma-
trix, slice thickness 8mm, with maximal number of phases reconstructed ensuring high 
(6-10ms) effective temporal resolution. True temporal resolution is defined as 2 times TR 
= 10ms. PWV was calculated using the formula: Δx/Δt, where Δx describes the aortic path 
length between two measurement sites and Δt describes the transit time between the 
arrival of the PWV at three respective sites. The distance between the measurement sites 
was manually determined by drawing a poly-line in the center of the aorta as defined 
in a double-oblique parasagittal aortic scout view, using the software package MASS®. 
Data were analyzed using MASS® and FLOW® (Medis, Leiden, Netherlands).
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Figure 1. Panel A and B: Aortic flow curve. Panel C:  Mitral valve flow curve.
Panel A shows how aortic flow parameters are assessed. * is the AO peak flow rate. Acceleration duration 
is the time between the beginning of the flow curve and the peak flow rate. The deceleration duration 
is the time between the peak flow rate and the end of the deceleration period. The acceleration peak 
is the peak slope (dy/dx) of the acceleration phase, the deceleration peak the peak slope (dy/dx) of the 
deceleration phase. Panel B shows an example of flow velocity curve through the ascending aorta. 
The black line represents a typical curve of a South Asian subject, the red line of a Caucasian subject: 
the cardiac contraction is somewhat prolonged in South Asians. Panel C shows an example of the flow 
through the mitral valve, representing diastolic cardiac function. The black line represents a South Asian 
subject, the red line a Caucasian subject. These curves suggest that cardiac relaxation is prolonged in 
South Asians.
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Myocardial and liver triglyceride content
MR spectroscopy (1H-MRS) was used to quantify myocardial and hepatic TG content. De-
tails on 1H-MRS acquisition and post processing were published before (18,19). In short, 
myocardial and hepatic 1H-MR single voxel MR spectroscopic data were acquired using a 
point resolved spectroscopy sequence. For the heart an 8-ml voxel was positioned in the 
interventricular septum on four-chamber and short-axis images in end-systole, avoiding 
contamination from epicardial fat. Electrocardiographically triggering (only for myocar-
dial spectra) and respiratory pencil beam navigator were used during acquisition (18). 
For the liver, voxel sites were matched at both study occasions, avoiding blood vessels 
and bile ducts. Main acquisition parameters for water suppressed spectra were: TE 26ms, 
TR 3000ms, 1,024 data points, spectral bandwidth 1,000-Hz, 128 averages. Acquisitions 
were performed with and without (TE 10000ms, 4 averages) water suppression, with 
myocardial TG expressed as percentage of the unsuppressed water signal. Hepatic 1H-
MRS was performed using the same acquisition parameters, except for 64 averages for 
the suppressed spectrum. Java-based MR user interface software (jMRUI v2.2, Leuven, 
Belgium) was used for fitting of the spectra (19). The TG content was calculated as the 
amplitude of the (TG signal/amplitude of water signal)*100. 
Visceral and subcutaneous fat 
Abdominal visceral and subcutaneous fat volumes were imaged using a turbo spin echo 
imaging sequence (20). During one breath-hold, three consecutive transversal slices 
of 10mm thickness were scanned at level of L5 (TR 168ms, TE 11ms, FA 90º). Volumes 
of visceral and subcutaneous fat depots were quantified using MASS® software (Medis, 
Leiden, Netherlands). Visceral and subcutaneous fat areas of each individual slice were 
multiplied by the slice thickness to acquire a volume and the volumes of all three slices 
were summed. 
Assays
Serum concentrations of glucose, total cholesterol, HDL and triglycerides were mea-
sured on a  Modular P800 analyzer (Roche, Netherlands), and serum insulin levels on 
an Immulite 2500 (Siemens, Netherlands). HbA1c was measured on an HPLC system 
(Kordia, Netherlands). Plasma free fatty acids (FFAs) concentrations were measured by a 
commercial kit (Wako Chemicals, Germany).
Statistical analysis
Data are presented as mean ± SEM or median (interquartile range (IQR)). A mixed model 
was applied to assess mean differences before and after the intervention within and 
between groups, and to assess differences in diet effect. Nonparametric tests (Wilcoxon 
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signed-rank test within group, Mann-Whitney between groups) were performed when 
appropriate. Significance level was set at p<0.05. Statistical analyses were performed 
using SPSS for Windows version 20.0 (IBM, USA).
RESULTS
Clinical and metabolic characteristics
Mean age was 22.1 ± 0.4 years. BSA was lower in South Asians. As expected, BMI did 
not differ between groups (South Asians: 20.9 ± 0.6 kg/m2 vs. Caucasians: 22.2 ± 0.6 kg/
m2 (p=0.11)), but South Asians were shorter and weighed less. After the HFHC-diet a 
very small increase in BMI and weight to a similar extent in both groups was observed. 
Waist circumference did not differ between groups. Blood pressure and heart rate were 
comparable between groups and did not change after the HFHC-diet (Table 1).
HbA1c was higher in South Asians. Fasting glucose, insulin levels and HOMA-B, a 
measure for pancreas function, were similar at baseline, but were significantly higher 
in South Asians after the diet. FFAs were comparable between groups and no diet ef-
fect was found. LDL-cholesterol was slightly higher in South Asians, whereas other lipid 
levels did not differ significantly (Table 1). 
Left ventricular dimensions and function
At baseline all cardiac left ventricular dimensions indexed for BSA, i.e. EDVI, ESVI, SVI, 
CI and EDMI, were lower in South Asians than in Caucasians (Table 2). EF did not differ 
between groups at baseline. In addition, LVESWS and LVEDM/LVEDV were comparable 
(Table 2). 
Flow velocities through the ascending aorta were measured. Typical aortic flow 
curves of a South Asian versus a Caucasian subject are depicted in Figure 1B. The ac-
celeration peak and duration were significantly lower in South Asians. Furthermore, the 
aortic peak flow rate, deceleration peak and duration were significantly lower in South 
Asians. After the HFHC-diet the acceleration peak and deceleration duration over the 
aorta significantly changed in South Asians, but not in Caucasians (Table 2).
Several parameters of diastolic cardiac function differed at baseline between both 
groups: E peak filling rate, E acceleration peak and E deceleration peak were significantly 
lower in South Asians as compared with Caucasians. In addition, the A peak filling rate, 
the A acceleration peak and A deceleration peak were significantly lower in South Asians 
(Table 2). E/A ratio and the estimated filling pressure E/Ea were the same in both groups 
and did not change after the HFHC-diet. Examples of mitral valve flow curves of a South 
Asian versus a Caucasian subject are depicted in Figure 1C.
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Pulse Wave Velocity
The aortic PWV was significantly higher in South Asians than in Caucasians at baseline, 
4.7 ± 0.1 m/s vs. 4.3 ± 0.1 m/s, p=0.022. After the HFHC-diet, PWV decreased significantly 
only in South Asians, and was no longer different from Caucasians.
Fat distribution
Although South Asians tended to have more visceral and subcutaneous adipose tissue, 
differences were not significant between groups (Table 3). Also, the visceral/subcutane-
ous fat ratio did not differ between groups. Furthermore, no diet effect was observed. 
Additionally, there was no significant difference between groups in hepatic and myocar-
Table 1. Clinical and metabolic characteristics
  Caucasians  South Asians
before after before after
Clinical characteristics
age (years) 22.1 ± 0.6 22.2 ± 0.7
height (m) 1.84 ± 0.01 1.74 ± 0.02**
weight (kg) 75.1 ± 1.8 75.6 ± 1.8 63.2 ± 2.3** 63.7 ± 2.3† **
BSA (m2) 1.97 ± 0.02 1.98 ± 0.02 1.76 ± 0.04** 1.76 ± 0.04† **
BMI (kg/m2) 22.2 ± 0.6 22.4 ± 0.6 20.9 ± 0.6 21.0 ± 0.6†
waist (cm) 81 ± 2 82 ± 2 79 ± 2 80 ± 3
systolic BP (mmHg) 135 ± 3 133 ± 3 129 ± 3 129 ± 3
diastolic BP (mmHg) 79 ± 3 80 ± 2 76.8 ± 2.3 76 ± 2
heart rate (bpm) 65 ± 2 64 ± 2 61 ± 2 66 ± 3
Metabolic characteristics
HbA1c (%) 5.02 ± 0.06 5.24 ± 0.05*
HbA1c (mmol/mol) 31.2 ± 0.5 33.8 ± 0.6*
glucose (mmol/L) 5.09 ± 0.09 5.22 ± 0.07 5.26 ± 0.09 5.53 ± 0.08†† *
insulin (pmol/L) 16 (24) 30 (37) 30 (26) 52 (31)†† ** §§
HOMA-B% 52 ± 11 55 ± 10 65 ± 14 90 ± 11†† * §
free fatty acids (mmol/L) 0.46 ± 0.05 0.43 ± 0.04 0.51 ± 0.04 0.54 ± 0.05
triglycerides (mmol/L) 0.79 (0.26) 0.75 (0.67) 1.01 (0.65) 1.12 (0.77)
total cholesterol (mmol/L) 3.10 (1.80) 4.34 (2.21)
HDL-cholesterol (mmol/L) 1.05 (0.35) 1.02 (0.38)
LDL-cholesterol (mmol/L) 1.84 (0.91) 2.77 (1.69)*
total cholesterol/HDL ratio 3.00 (0.80) 4.05 (2.48)
Data are presented as mean ± SEM or median (IQR). BSA: body surface area, BMI: body mass index, BP: 
blood pressure.  † p<0.05, †† p<0.05 within groups. * p<0.05, ** p<0.005 between groups. § p<0.05, §§ 
p<0.005 diet effect between groups.
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Table 2. Cardiac dimensions and parameters of cardiovascular function assessed with MRI
  Caucasians  South Asians
before after  before after
Cardiac dimensions and basic function
LVEDMI (g/m2) 62.2 ± 1.2 62.0 ±  1.5 50.7 ± 1.4** 50.0 ± 1.3**
EDVI (ml/m2) 102.2 ± 3.0 102.7 ± 2.8 83.3 ± 3.4** 81.5 ± 2.9**
ESVI (ml/m2) 42.8 ± 2.1 42.3 ± 2.4 33.9 ± 2.0* 33.1 ± 1.7**
SVI (ml/m2) 59.4 ± 2.2 60.4 ± 1.3 49.3 ± 2.1** 48.3 ± 1.7**
CI (ml/min/m2) 3845 ± 256 3834 ± 159 2994 ± 96** 3161 ± 159*
EF (%) 58.2 ± 1.5 5901 ± 1.4 59.4 ± 1.4 59.4 ±  1.1
LVESWS (kN/m2) 56.3 ± 1.4 55.4 ± 2.1 53.0 ± 1.8 52.4 ± 1.2
LVEDM/EDV (g/ml) 0.61 ± 0.02 0.61 ± 0.02 0.62  ± 0.02 0.62 ± 0.02
Systolic cardiac function
AO peak filling rate (ml/s) 538 ± 17 549 ± 18 404 ± 17** 429 ± 14**
AO acceleration peak (ml/s²x10-³) 13.1 ± 0.5 13.6 ± 0.7 10.6 ± 0.4** 12.6 ± 0.5†
AO acceleration duration (ms) 101 ± 3 99 ± 4 91 ± 2* 88 ± 3*
AO deceleration peak (ml/s²x10-³) -5.9 ± 0.3 -5.9 ± 0.4 -3.7 ± 0.2** -3.9 ± 0.2**
AO deceleration duration (ms) 227 ± 6 231 ± 4 252 ± 4** 240 ± 5† §
AO duration (ms) 328 ± 6 330 ± 5 343 ± 5 328 ± 6†
Diastolic cardiac function
E peak filling rate (ml/s) 570 ± 20 571 ± 13 431 ± 18** 447 ± 14**
E acceleration peak (ml/s²x10-³) 7.5 ± 0.5 7.3 ± 0.4 5.9 ± 0.3** 6.4 ± 0.3
E deceleration peak  (ml/s²x10-³) -5.0 ±  0.3 -4.9 ± 0.4 -3.8 ±  0.2* -4.1 ± 0.2
A peak filling rate (ml/s) 262 ± 10 266 ± 13 201 ± 9** 205 ± 10**
A acceleration peak (ml/s²x10-³) 4.4 ± 0.3 4.8 ± 0.4 3.3 ± 0.2* 3.7 ± 0.3*
A deceleration peak (ml/s²x10-³) -4.6 ±  0.3 -4.7 ±  0.3 -3.7 ±  0.3* -4.2 ±  0.5
E/A-peak ratio 2.2 ± 0.1 2.2 ± 0.1 2.2 ± 0.1 2.2 ± 0.1
E/Ea 8.8 ± 1.0 8.6 ± 0.6 11.0 ± 1.3 10.4 ± 1.1
Pulse wave velocity
PWV total aorta (m/s) 4.3 ± 0.1 4.4 ± 0.1 4.7 ± 0.1* 4.4 ± 0.1†
Data are mean ± SEM. LV: left ventricular, EDM: end-diastolic mass, EDV: end-diastolic volume, ESV: 
end-systolic volume,  SV: stroke volume, CI: cardiac index, EF: ejection fraction, ESWS: end-systolic wall 
stress. I, indexed for body surface area, AO: Aortic, E: early diastolic wave, A: atrial diastolic wave, E/Ea: 
estimated left ventricular filling pressure, PWV: pulse wave velocity. † p<0.05 within groups. * p<0.05, ** 
p<0.005 between groups. § p<0.05 diet effect between groups.
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dial TG content at baseline (Table 3). After the HFHC-diet hepatic TG content increased 
in both groups, whereas myocardial TG content did not change.
Table 3. Waist fat distribution and myocardial and hepatic triglyceride content
  Caucasians South Asians
  before after before after
Visceral fat (ml) 104 ± 14 111 ± 12 120 ± 19 125 ± 18
Subcutaneous fat (ml) 348 ±  54 363 ± 59 442 ± 61 432 ± 54
Visceral / subcutaneous ratio 0.33 ±  0.04 0.36 ± 0.05 0.28 ± 0.03 0.29 ± 0.03
Total fat (ml) 453 ±  65 474 ± 70 563 ± 76 558 ± 71
Myocardial TG content (%) 0.34 ±  0.06 0.32 ± 0.03 0.33 ± 0.04 0.34 ± 0.08
Hepatic TG content (%) 1.7 ± 0.4 4.5 ± 0.8†† 1.3 ± 0.4 3.0 ± 0.5††
Data are mean ± SEM. TG: triglyceride. †† p<0.005 within groups.
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DISCUSSION
South Asians have a higher risk of developing CVD than Caucasians (1). The cause of 
these differences between both ethnicities is still unknown. This study showed that 
young, healthy South Asians have smaller cardiac dimensions compared to age- and 
BMI-matched Caucasians, even after correction for BSA. Furthermore, diastolic cardiac 
function in South Asians is different. In addition, although the EF, a gross parameter of 
systolic function, was similar between both groups, more subtle parameters of systolic 
function were different. A 5-day HFHC-diet did not increase these differences. Finally, 
South Asians had a higher aortic PWV on baseline.
Cardiac dimensions
Little is known about differences in cardiac dimensions and cardiovascular function at 
a young age between South Asians and Caucasians. Previous studies showed smaller 
left heart volumes, i.e. LVEDV, LVESV, and LV mass in South Asians, which is in line with 
our results (12,21). However, these studies were performed in older subjects (mean age 
~50yr) using echocardiography, while in the current study young adults (mean age ~22yr) 
were included and MRI was used. One might suggest that the smaller cardiac dimensions 
observed in South Asians are a consequence of their overall smaller body size. However, 
adjustment for different parameters of body size such as BMI, BSA and lean body mass did 
not attenuate the observed differences in the present and other studies. 
Left ventricular function
Besides smaller cardiac dimensions, we found a different diastolic and systolic functional 
profile between both ethnicities. Although the traditional parameters of diastolic func-
tion (E/A) and systolic function (EF) did not differ between both groups, more sensitive 
parameters were significantly different. E and A peak filling rate, and E and A acceleration 
peak were lower and E and A deceleration peak were higher in South Asians, suggesting 
that cardiac relaxation is prolonged in South Asians compared to Caucasians. The E/
Ea ratio, an estimation of LV filling pressure, was the same for both ethnicities, which 
is expected in two groups with comparable blood pressures. In concordance with the 
present study, Chahal et al. also found that E/A ratio did not differ between South Asians 
and Caucasians (12). However, in contrast to the present study, they did find a higher E/
Ea ratio in South Asians. This discrepancy could be due to differences in age of subjects 
and/or to different methods of cardiac assessment between the studies. In this study 
we assessed flow through the aorta ascendens at the level of the pulmonary trunk. This 
showed a flow profile difference between groups (Figure 1B). The difference is similar to 
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what we observed in the diastolic flow profile as described above: the cardiac contrac-
tion is somewhat prolonged in South Asians (Figure 1C). 
LVESWS, which is considered to be an important determinant of cardiac function 
and myocardial oxygen demand, did not differ between South Asians and Caucasians. 
This finding indicates that no pressure overload was present in either of the groups, 
which is compatible with the normal LV mass in both groups. Additionally, LVEDM/EDV, 
a measure for concentricity, was the same between both groups, suggesting there was 
no difference in LV concentric remodeling either.
HFHC-diet
With respect to the increased risk of CVD, an important notion is that IR and T2DM are 
also highly prevalent in South Asians (8,9). Moreover, South Asians develop T2DM at a 
younger age and lower BMI compared to Caucasians (22,23), suggesting South Asians 
are metabolically at a higher risk. The increased risk of CVD might be related to the 
metabolic changes that occur with IR. Therefore, we hypothesized that metabolic dif-
ferences and altered fat depositions between South Asians and Caucasians might be 
responsible for the higher risk of CVD in South Asians. In this study, South Asians were 
already more insulin resistant at baseline compared to Caucasians, as reflected by a 
similar glucose but higher insulin curve and area under the curve measured by an OGTT 
(data not shown). Since people with IR are known to have abnormal cardiac relaxation 
(24), the prolonged cardiac relaxation observed in South Asians in this study might be 
due to their underlying IR. 
To test whether possible differences in cardiovascular function between South Asians 
and Caucasians can be attributed to alterations in energy metabolism the effect of a 5-day 
HFHC-diet, inducing fat overload, on cardiovascular function was assessed. Previous stud-
ies showed that short-term dietary interventions can induce changes in cardiac function 
(13,25). A short-term HFHC-diet, consisting of 800 ml cream per day, in 15 Caucasian 
healthy males (age 25.0 ± 6.6yr), already decreased diastolic function after 3 days (13). 
Therefore, we expected that if metabolic variations were the cause of differences in cardio-
vascular function, these differences would become more pronounced after a HFHC-diet. 
However, although both insulin levels and HOMA-B% increased significantly only in 
South Asians, indicating they were even more insulin resistant, cardiovascular function 
did not deteriorate after the diet. Therefore, we did not find support for our hypothesis. It 
might be that the observed differences in cardiovascular function are innate and that these 
findings are simply representative of differing normal reference values in these two ethnic 
groups. Whether these findings are related to increased CVD risk in South Asians is unclear. 
After the HFHC-diet hepatic TG content significantly increased in both groups, 
indicating good dietary compliance of the volunteers. In contrast to accumulation of 
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hepatic TG content, myocardial TGs did not increase after the diet in both groups. A 
possible explanation is that the liver acts as a buffer for excessive postprandial flux of 
FFAs and TGs resulting in no net change in myocardial TG content. This is in line with 
results of the above mentioned study in Caucasian males who received a 3-day HFHC-
diet (13). However, in contrast to other studies, which observed higher hepatic TG in 
(young) healthy South Asians compared to Caucasians (26,27), in the present study no 
differences were found between groups before and after the diet. Surprisingly, we did 
not find a significant difference in abdominal fat distribution between groups either, 
although South Asians tended to have more visceral and subcutaneous fat mass. Other 
studies did find significantly more abdominal fat mass in South Asians compared to 
Caucasians (27-29), though not all studies reached significance (30). These differences 
in (ectopic) fat distribution might be attributed to the relatively young age and low BMI 
of subjects in the present study compared to other studies. Possibly, the differences in 
body fat distribution become stronger with increasing age. Other explanations might be 
that we included only males, or that the group sizes were too small to reach significance. 
Vascular function
PWV is a surrogate marker for arterial stiffness and is a powerful independent predictor 
of cardiovascular events (31). The aortic PWV in this study was significantly higher in 
South Asians at baseline, indicating a stiffer aorta. Previous studies in older subjects also 
reported a higher PWV in South Asians than in Caucasians (32,33). After the HFHC-diet the 
PWV decreased significantly in South Asians, but not in Caucasians. This difference in diet 
effect might be explained by the significant increase in insulin levels after the diet occur-
ring only in South Asians. Insulin is known to acutely act as a vasodilator via stimulation of 
the vasculature to produce endothelial-derived vasodilator nitric oxide (34,35). In contrast, 
long-term increased insulin levels, as present in IR and T2DM, can contribute to increased 
arterial wall thickness by direct and indirect trophic effects on smooth muscle cells (36).
In conclusion, already at a young age, South Asians have smaller cardiac dimensions 
and different diastolic and systolic cardiac function profiles as compared to Caucasians. 
To our knowledge, these differences in cardiac dimensions and function between 
healthy, lean South Asians and Caucasians of young age have not been described before. 
Additionally, South Asians have higher aortic PWV, indicating increased arterial stiffness. 
Whether these differences contribute to the higher incidence of CVD in South Asians, 
however, remains to be determined. A 5-day HFHC-diet did not increase the observed 
functional cardiovascular differences between both groups, suggesting that these find-
ings cannot be explained by a different metabolic response to dietary fat consumption 
between both ethnicities at young age.
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ABSTRACT
South Asians develop type 2 diabetes (T2DM) at a younger age and lower BMI compared 
to Caucasians. The underlying cause is still poorly understood but might result from 
an innate inability to adapt to the Westernized diet. This study aimed to compare the 
metabolic adaptation to a high-fat-high-calorie (HFHC) diet between both ethnicities. 
Twelve healthy young lean male South Asians and 12 matched Caucasians underwent 
a 2-step hyperinsulinemic-euglycemic clamp with skeletal muscle biopsies and indirect 
calorimetry before and after a 5-day HFHC-diet. Hepatic triglyceride content (HTG) and 
abdominal fat distribution were assessed using MRI/S. At baseline, South Asians had 
higher insulin clamp levels than Caucasians, indicating reduced insulin clearance rate. 
Despite the higher insulin levels, endogenous glucose production was comparable be-
tween groups, suggesting lower hepatic insulin sensitivity in South Asians. Furthermore, 
a 5-day HFHC-diet decreased insulin-stimulated (non-oxidative) glucose disposal rate 
only in South Asians. In skeletal muscle no significant differences were found between 
groups in insulin/mTOR-signaling, metabolic gene expression and mitochondrial 
respiratory-chain content. Furthermore, no differences in (mobilization of ) HTG and 
abdominal fat were detected. We conclude that HFHC-feeding rapidly induces insulin 
resistance only in South Asians. Thus, distinct adaptation to “Western” food may partly 
explain their propensity to develop T2DM.
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INTRODUCTION 
The incidence of type 2 diabetes (T2DM) is increasing rapidly worldwide, especially in 
people of South Asian descent (1). South Asians originate from the Indian subcontinent 
and represent one fifth of the world’s population. Both native and migrant South Asians 
are at high risk of developing T2DM compared to Caucasians (2-4). Not only is the preva-
lence of T2DM four to six times higher, it also occurs at a younger age and lower BMI 
(4-6). Moreover, the risk of cardiovascular and renal complications is higher (7-10). The 
underlying cause of this excess risk is still incompletely understood, and only few in-
depth studies have been conducted to investigate the pathogenesis of T2DM in South 
Asians (11,12). 
The observation that South Asians have high hepatic and intramyocellular lipid con-
tent compared to people of Caucasian descent (13,14) might suggest that South Asians 
have an impaired mitochondrial fatty acid beta-oxidation in either skeletal muscle and/
or adipose tissue, resulting in ectopic fat deposition in peripheral tissues, eventually 
leading to insulin resistance (IR) and other metabolic dysfunctions (15). South Asians 
may therefore be less capable to handle the Western-type high fat (HF)-diet as com-
pared to Caucasians. 
Interesting in this context are recent findings on the nutrient and energy-sensing 
mammalian target of rapamycin (mTOR)-pathway. The mTOR-pathway regulates cell 
growth according to cellular energy status and nutrient availability (16). Activated mTOR 
complex 1 (mTORC1) controls key cellular processes, e.g. it inhibits insulin signaling (17) 
and plays a crucial role in the regulation of oxidative metabolism and mitochondrial 
biogenesis (18-21). Importantly, mTORC1 also appears to promote lipid synthesis and 
storage, while inhibiting processes leading to lipid consumption (22). Indeed, there is 
growing evidence that mTORC1 suppresses fatty acid beta-oxidation (21,23,24). There-
fore, we hypothesize that differences in mTOR activity between the two ethnicities may 
underlie or contribute to the increased risk of T2DM in South Asians.
The aim of this study was to investigate whether the metabolic adaptation to a 5-day 
high fat high calorie (HFHC) diet is different between young healthy lean South Asian 
males and matched Caucasians. In particular, we were interested whether differences 
in the activity of mTOR in skeletal muscle exist between the two ethnicities, both at 
baseline and in response to the HFHC-diet. Furthermore, hepatic and peripheral insulin 
sensitivity, substrate oxidation, abdominal fat distribution and skeletal muscle insulin 




Twelve Dutch South Asian and twelve Dutch Caucasian, lean (BMI < 25 kg/m2) and healthy 
males, aged 19-25 years with a positive family history of T2DM were enrolled via local ad-
vertisements. Subjects underwent a medical screening including their medical history, a 
physical examination, blood chemistry tests and an oral glucose tolerance test to exclude 
individuals with T2DM according to the American Diabetes Association  2010 criteria. 
Other exclusion criteria were rigorous exercise, smoking and recent body weight change. 
The study was approved by the Medical Ethical Committee of the Leiden University Medi-
cal Center and performed in accordance with the principles of the revised Declaration of 
Helsinki. All volunteers gave written informed consent before participation.
Study design
Subjects were studied before and after a 5-day HFHC-diet, consisting of the subject’s 
regular diet supplemented with 375 ml of cream per day (=1275 kcal/day, 94% fat). 
At the end of the first study day, subjects received 15 125ml cups of cream. They were 
instructed to continue their regular diet and, on top of that, to consume three cups of 
cream per day, directly following a meal in order to make sure they could adhere to 
their regular dietary habits. In addition, they kept a food diary before and during the 
HFHC-diet to estimate normal dietary intake, to maximize compliance with the diet, and 
to check for compliance and compensation behavior. Diaries were entered and analyzed 
using a specialized internet application (http://www.dieetinzicht.nl, Dutch). Compliance 
was measured by asking to bring leftover cups, asking, analyzing the food diaries and 
laboratory parameters. Subjects were instructed not to alter life style habits, and not to 
perform physical activity in the last 48 hours before the study days. Magnetic resonance 
(MR) studies were performed shortly before and on the fifth day of the HFHC-diet. Meta-
bolic studies were performed one day before and one day after the diet.
MR studies
Abdominal fat depots were quantified with turbo spin echo MR-imaging using a 1.5 Tesla 
whole body MR scanner (Gyroscan ACS-NT15; Philips, The Netherlands) four hours after 
the last meal (25). During one breath hold, three transverse images were obtained at the 
level of L5. Volumes of visceral and subcutaneous fat depots were quantified using MASS 
analytical software (Medis, The Netherlands). The number of pixels were converted to cm2 
and multiplied by the slice thickness (10mm). Hepatic triglyceride content (HTG) was as-
sessed by proton MR-spectroscopy (1H-MRS) (26). A spectrum without water suppression, 
four averages, as internal standard was obtained, and 64 averages were collected with 
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water suppression. The spectra were fitted using Java-base MR user interface software 
(jMRUI version 2.2) (26). The percentage of hepatic triglyceride signals was calculated as: 
(signal amplitude hepatic triglycerides / signal amplitude water) x 100.
Metabolic studies
Anthropometric measurements, a 2-step hyperinsulinemic-euglycemic clamp with stable 
isotopes and indirect calorimetry were performed after an overnight fast. In addition, 
skeletal muscle biopsies were obtained. Fat and lean body mass (LBM) were assessed by 
bioelectrical impedance analysis (BIA; Bodystat® 1500, Bodystat Ltd., Douglas, UK).
Hyperinsulinemic-euglycemic clamp 
A 6-h 2-step hyperinsulinemic-euglycemic clamp was performed as described previ-
ously (27). In short, a primed constant infusion of glucose tracer ([6,6-2H2]-glucose; 0.22 
μmol/kg/min) was used to determine rates of glucose appearance (Ra) and disposal 
(Rd). At t=120 min (step 1) and t=240 min (step 2), a primed constant infusion of insulin 
(step 1: 10 mU/m2/min, step 2: 40 mU/m2/min) was started and glucose-20% enriched 
with 3% [6,6-2H2]-glucose was infused at a variable rate to maintain glucose level at 5.0 
mmol/L. In basal state (t=0 min), at the end of the non-insulin stimulated period (t=95-
115 min) and at the end of each step (t=210-240 min and t=330-360 min), blood samples 
were taken for determination of glucose, insulin, C-peptide, free fatty acids (FFAs), and 
[6,6-2H2]-glucose specific activity. 
Indirect calorimetry 
Indirect calorimetry was performed with a ventilated hood (Oxycon Pro™, CareFusion, 
Germany) in basal condition and during both steps of the clamp. 
Skeletal muscle biopsies 
Muscle biopsies from the m. vastus lateralis (~75-100 mg) were collected in basal and 
hyperinsulinemic condition (at 30 minutes of step 2) under localized anesthesia, using 
a modified Bergström needle (28). Muscle samples were divided into two parts, snap-
frozen in liquid nitrogen and stored at -80°C until further analysis.
Calculations 
Glucose Ra and Rd were calculated as the tracer infusion rate divided by the tracer-to-
tracee ratio (29). Endogenous glucose production (EGP) was calculated as the difference 
between the rates of Ra and glucose infusion. Rd and EGP were adjusted for kilograms 
LBM. The metabolic clearance rate of insulin (MCRi) was computed according to Elahi et 
al. (30). Resting energy expenditure (REE), respiratory quotient (RQ) and substrate oxida-
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tion rates were determined as described by Simonson and DeFronzo (31). Non-oxidative 
glucose disposal (NOGD) was calculated by subtracting the glucose oxidation rate from 
Rd. The hepatic insulin resistance index (HIR) was calculated as the product of non-insulin 
stimulated EGP and fasting serum insulin concentration (32). Glucose metabolic clear-
ance rate (MCRg) was calculated as the rate of disappearance of glucose (Rd) divided by 
the serum glucose concentration (average of steady-state measurements) (33).
Laboratory analysis
Fasting serum glucose and triglycerides were measured on a Modular P800 analyzer 
(Roche, The Netherlands), serum insulin and C-peptide levels on an Immulite 2500 (Sie-
mens, The Netherlands), HbA1c on an HPLC machine Primus Ultra 2 (Kordia, The Neth-
erlands), and plasma FFAs were determined by a colorimetric method (Wako Chemicals, 
Germany). Arterialized whole blood glucose levels during the clamp were measured 
by glucose dehydrogenase-NAD technique (Precision Xtra Blood Glucose Monitoring 
System, Abbott USA). [6,6-2H2]-glucose enrichment was measured in a single analytical 
run using gas chromatography-mass spectrometry as described previously (34).
DNA/RNA isolation and real-time RT-PCR 
Total RNA was isolated from skeletal muscle biopsies (~25-30 mg) using the phenol-
chloroform extraction method (Tripure RNA Isolation reagent, Roche, Germany), 
treated with a DNAse kit according to the manufacturer instruction (TURBO DNAse, Life 
Technologies, The Netherlands), and quantified by NanoDrop. First-strand cDNA were 
synthesized from 1 µg total RNA using a Superscript first strand synthesis kit (Invitro-
gen, The Netherlands). Real-time PCR assays were performed using specific primers 
sets (sequences provided on request) and SYBR Green on a StepOne Plus Real-time 
PCR system (Applied Biosystems, USA). mRNA expression was normalized to ribosomal 
protein S18 (Rps18) and expressed as arbitrary units. Genomic DNA was extracted using 
the Qiagen Tissue and Blood Kit (Qiagen, Germany) and concentrations were measured 
spectrophotometrically (GeneQuant, GE Healthcare, Germany). Mitochondrial (mtDNA) 
and nuclear (nDNA) DNA copy numbers were quantified as described before (35) and 
the mtDNA-to-nDNA-ratio was used as an index of mitochondrial density. A complete 
overview of all analyzed genes can be found in Supplemental Table 1.
Western Blot 
Skeletal muscle biopsies (~30-45mg) were homogenized by Ultra-Turrax (22.000 rpm; 
2x5sec) in a 6:1 (v/w) ratio of ice-cold buffer containing: 50mM HEPES (pH 7.6), 50mM NaF, 
50mM KCl, 5mM NaPPi, 1mM EDTA, 1mM EGTA, 5mM β-GP, 1mM Na3VO4, 1mM DTT, 1% 
NP40 and protease inhibitors cocktail (Complete, Roche, The Netherlands). Western blots 
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were performed using phospho-specific (Ser473-PKB, phospho-Akt substrate, Ser2448-
mTOR, and Thr389-S6K from Cell Signaling; Thr246-PRAS40 from Biosource) or total 
primary antibodies (Tubulin, Akt1+2, Akt substrate of 160kDa, mTOR and S6K from Cell 
Signaling; PRAS40 from Biosource; MitoProfile OXPHOS from AbCam; IRβ from Santa Cruz) 
(36). Blots were quantified by densitometric analysis using Image J software (NIH USA).
Table 1. Clinical characteristics, body composition, and fasting plasma and serum levels before and after a 
5-day HFHC-diet in healthy, young South Asian males and matched Caucasians.
  Caucasians  South Asians
  before after  before after
Clinical characteristics
age (years) 22.1 ± 0.6 22.2 ± 0.7
length (m) 1.84 ± 0.01 1.74 ± 0.02**
weight (kg) 75.1 ± 1.8 75.6 ± 1.8 63.2 ± 2.3** 63.7 ± 2.3† **
BMI (kg/m2) 22.2 ± 0.6 22.4 ± 0.6 20.9 ± 0.6 21.0 ± 0.6† 
waist (cm) 81.3 ± 2.2 82.0 ± 2.3 78.9 ± 2.2 79.5 ± 2.6
Body composition
fat mass (%) 11.3 ±  0.9 11.3 ± 0.8 15.1 ±  0.9* 14.7 ± 0.8*
visceral fat (ml) 104 ± 14 111 ± 12 120 ± 19 125 ± 18
subcutaneous fat (ml) 348 ± 54 363 ± 59 442 ± 61 432 ± 54
hepatic TG content (%) 1.7 ± 0.4 4.5 ± 0.8†† 1.3 ± 0.4 3.0 ± 0.5††
Fasting plasma and serum levels
HbA1c (%) 5.0 ± 0.1 5.2 ± 0.1*
HbA1c (mmol/mol) 31.2 ± 0.5 33.8 ± 0.6*
glucose (mmol/L) 5.1 ± 0.1 5.2 ± 0.1 5.3 ± 0.1 5.5 ± 0.1†† *
insulin (pmol/L) 34 (32) 49 (46) 49 (29) 73 (34)†† ** ‡‡
C-peptide (nmol/L) 0.47 (0.15) 0.57 (0.28)† 0.48 (0.11) 0.61 (0.18)††
FFA (g/L) 0.131 ±  0.01 0.121 ± 0.01 0.144 ± 0.01 0.151 ± 0.01
TG (mmol/L) 0.79 (0.26) 0.75 (0.67) 1.01 (0.65) 1.12 (0.77)
Data are presented as mean ± SEM or median (IQR). BMI: body mass index, TG: triglyceride, FFA: free 
fatty acid. † p<0.05, †† p<0.005 within group vs. before diet. * p<0.05, ** p<0.005 vs. Caucasians. ‡ 
p<0.05, ‡‡ p<0.005 diet effect vs. Caucasians.
Statistical analysis
Data are presented as mean ± SEM when normally distributed or as median (IQR) when 
not normally distributed. A mixed effects model was applied to assess mean differ-
ences before and after the intervention within and between groups, and to determine 
differences in diet effect. Groups and intervention were modeled as fixed effects and 
the subject specific deviances from the group mean were modeled as random effects. 
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Nonparametric tests (Wilcoxon signed-rank test within group, Mann-Whitney between 
groups) were performed when appropriate. Significance level was set at p<0.05. Statisti-
cal analyses were performed using SPSS for Windows version 20.0 (IBM, USA).
RESULTS 
Clinical characteristics
BMI did not differ between groups (South Asians: 20.9 ± 0.6 vs. Caucasians (C): 22.2 ± 0.6 
kg/m2, p=0.11), but South Asian subjects were significantly shorter and lighter (Table 
1). The percentage of fat mass was significantly higher in South Asians on both study 
days, and, consequently, the percentage of LBM was lower. Waist circumference did not 
differ between groups. Fasting glucose and insulin levels were similar at baseline, but 
were significantly higher in South Asians after the HFHC-diet. Fasting C-peptide levels 
increased significantly to a similar degree in both groups. HbA1c was higher in South 
Asians, as was LDL-cholesterol (2.77 (1.69) vs. 1.84 (0.91) mmol/L, p=0.03).
Diet and exercise
The physical activity level was comparable between both ethnicities (Supplemental Table 
2). The South Asian diet consisted of fewer calories per day (South Asians: 2170 ± 102 
vs. Caucasians: 2593 ± 100 kcal, p=0.008), but corrected for bodyweight the amount of 
calories was similar (South Asians: 34 ± 2 vs. Caucasians: 35 ± 1 kcal/day/kg, p=0.91). Both 
ethnicities ate the same percentage of fat (~30%), carbohydrates (~50%) and proteins 
(~16%). Both groups complied well with the diet. Mean daily calorie intake was ~55% 
higher compared to their normal diet, and ~54% of energy was derived from fat (Supple-
mental Table 2).
Fat distribution
No differences were found between groups for visceral and subcutaneous fat volumes 
both at baseline and after the HFHC-diet. Furthermore, no diet effect was observed. HTG 
increased significantly after the diet in both groups, but no differences between groups 
were observed (Table 1).
Endogenous glucose production and rate of glucose disposal
During the hyperinsulinemic-euglycemic clamp glucose concentrations were similar 
within and between groups for both steps (Table 2). Clamp insulin levels were signifi-
cantly higher in South Asians compared to Caucasians before and after the HFHC-diet; 
no diet effect was observed. The MCRi was significantly lower in South Asians on both 
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study days. EGP in basal and insulin-stimulated conditions was similar for both groups, 
despite higher insulin levels in insulin-stimulated conditions in South Asians. Further-
Table 2. Metabolic parameters of a 2-step hyperinsulinemic-euglycemic clamp with stable isotopes 
before and after a 5-day HFHC-diet in healthy, young South Asian males and matched Caucasians.
  Caucasians South Asians
  before after before after
Basal steady state
average glucose (mmol/L) 5.1 ±  0.1 5.1 ± 0.1 5.2 ±  0.1 5.4 ±  0.1†
average insulin (pmol/L) 41 (26) 41 (27) 49 (36) 68 (45)† *
EGP = Rd (μmol/kgLBM/min) 16.3 ±  0.4 17.0 ±  0.3 17.5 ±  0.5 17.5 ±  0.4
HIR (μmol*pmol/kgLBM/min/L) 562 (600) 760 (778) 763 (512) 1269 (520)†† ** ‡
MCRg (ml/kgLBM/min) 3.2 ±  0.1 3.3 ±  0.1 3.4 ±  0.1 3.3 ±  0.1
Step 1
average glucose (mmol/L) 5.1 ±  0.1 5.2 ± 0.1 5.0 ±  0.1 5.2 ±  0.1
average insulin (pmol/L) 83 ±  12 89 ± 11 116 ±  6** 126 ±  11**
average C-peptide (nmol/L) 0.26 (0.13) 0.27 (0.13) 0.22 (0.14) 0.29 (0.15)†
EGP (μmol/kgLBM/min) 12.6 ±  0.5 13.4 ±  0.4 12.8 ±  0.4 12.8 ±  0.4
suppression EGP (%) -22.6 ±  1.8 -21.6 ±  1.6 -26.8 ±  1.3 -27.2 ±  1.0
Rd (μmol/kgLBM/min) 15.3 ±  0.8 17.4 ±  1.2 16.2 ±  0.9 15.3 ±  1.1
MCRg (ml/kgLBM/min) 3.0 ±  0.2 3.4 ±  0.2 3.2 ±  0.2 3.0 ±  0.2
Step 2
average glucose (mmol/L) 4.8 ±  0.1 4.8 ±  0.1 4.6 ±  0.1 4.6 ±  0.1
average insulin (pmol/L) 276 ±  19 285 ±  19 396 ± 15** 386 ±  21**
average C-peptide (nmol/L) 0.07 (0.12) 0.07 (0.09) 0.06 (0.12) 0.08 (0.08)†
EGP (μmol/kgLBM/min) 10.0 ±  0.7 1.2 ±  0.5 9.7 ±  0.7 9.6 ±  0.5
suppression EGP (%) -38.9 ±  3.5 -39.8 ±  2.7 -43.9 ±  3.0 -45.7 ±  2.3
Rd (μmol/kgLBM/min) 41.7 ±  2.9 41.0 ±  2.8 48.7 ± 2.9** 39.0 ±  2.1†† ‡‡
Rd / insulin (μmol*L/kgLBM/min/mU) 1.14 ±  0.13 1.07 ±  0.12 0.87 ±  0.07 0.72 ±  0.05† *
MCRi (ml/m2/min) 1076 (397) 1054 (270) 735 (70)** 771 (164)† ** ‡
MCRg (ml/kgLBM/min) 8.8 ±  0.7 8.7 ±  0.6 10.7 ± 0.8** 8.6 ±  0.5†† ‡‡
Data are presented as mean ± SEM or median (IQR). Due to hypoglycemia in the last part of step 2 of the 
clamp, two South Asian subjects on occasion 1 and one Caucasian subject on occasion 2 were excluded 
in the analysis of step 2. EGP: endogenous glucose production, Rd: rate of glucose disposal, HIR: hepatic 
insulin resistance, MCRg: metabolic clearance rate of glucose, MCRi: metabolic clearance rate of insulin. 
† p<0.05, †† p < 0.005 within group vs. before diet. * p<0.05, ** p<0.005 vs. Caucasians. ‡ p<0.05, ‡‡ 
p<0.005 diet effect vs. Caucasians.
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more, no diet effect was observed. However, the calculated HIR index was higher in 
South Asians compared to Caucasians (p=0.065 before diet, p=0.002 after diet), and 
showed a significant increase after the diet only in South Asians (p diet effect = 0.008). 
Suppression of EGP by insulin was comparable between groups and was around 24% in 
step 1 and 42% in step 2. Insulin-stimulated Rd in step 1 was similar for both groups on 
both occasions. In step 2 Rd was higher in South Asians compared to Caucasians before 
the diet (South Asians: 48.7 ± 2.9 vs. Caucasians: 41.7 ± 2.9 μmol/kgLBM/min; p=0.003). 
However, when corrected for insulin level, this difference disappeared and was almost 
reversed (p=0.052). After the diet Rd decreased significantly in South Asians despite 
similar insulin levels, whereas no diet effect was found in Caucasians (South Asians: 39.0 
± 2.1 μmol/kgLBM/min (p<0.001) vs. Caucasians: 41.0 ± 2.8 μmol/kgLBM/min (p=0.78); p 
diet effect = 0.002).
Glucose and lipid oxidation rates
REE, corrected for LBM, RQ, substrate oxidation rates and NOGD in basal condition and 
step 1 of the clamp were comparable for both groups before and after the HFHC-diet 
(Table 3). In step 2, however, glucose oxidation increased significantly in South Asians, 
whereas no diet effect was observed in Caucasians. Interestingly, NOGD in step 2 was 
significantly higher in South Asians compared to Caucasians at baseline (p<0.001), but 
decreased significantly after the HFHC-diet only in South Asians (South Asians: 34.4 ± 4.0 
vs. 19.3 ± 2.0 μmol/kgLBM/min (p<0.001), Caucasians: 24.1 ± 2.1 vs. 23.8 ± 1.6 μmol/kgLBM/
min (p=0.87); p diet effect < 0.001).
Skeletal muscle signaling
The protein expression and phosphorylation state of key molecules involved in the 
insulin and mTOR signaling pathways were determined in basal condition and during 
the hyperinsulinemic-euglycemic clamp in skeletal muscle (Figure 1). A trend for a 
reduced IRβ expression was observed in South Asians. During hyperinsulinemia, the 
phosphorylation state of key proteins involved in the insulin/mTOR pathway (PKB, 
AS160, PRAS40, mTOR and S6K1) was significantly increased when compared to basal, 
as expected (Figure 1). No obvious differences were observed between groups what-
ever the conditions. 
Skeletal muscle metabolic gene expression
The skeletal muscle expression of key metabolic genes involved in the regulation of 
glucose and fatty acid metabolism was determined (Supplemental Table 1).
At baseline, no significant differences between groups were observed in the tran-
script levels of all analyzed genes. The HFHC-diet induced significant downregulation of 
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Figure 1. Insulin and mTOR signaling in skeletal muscle from healthy, young South Asian males and 
matched Caucasians before (black bars) and after (white bars) a 5-day HFHC-diet. The protein expression of 
A. IRβ, B. Ser473-PKB, C. PKB, D. phospho-AS160, E. AS160, F. Thr246-PRAS40, G. PRAS40, H. Ser2448-mTOR, 
I. mTOR, J. Thr389-S6K, and K. S6K, were assessed by Western Blot. The phosphorylation state in basal and 
hyperinsulinemic (step 2) conditions (B, D, F, H, J), or the protein expression in basal conditions (A, C, E, G, I, K) 
are shown. Representative blots for one subject per group are shown. Results are normalized to Caucasian 
subjects (before diet, basal condition) and expressed as mean ± SEM. Due to a small amount of tissue two 
Caucasian subjects were excluded for Western Blot analysis. † p<0.05 within group vs. before diet. § p<0.05, 
§§ p<0.005 within groups vs. basal condition. * p<0.05 vs. Caucasians. IRβ, insulin receptor isoform β. PKB, 
protein kinase B. AS160, Akt substrate of 160 kDa. PRAS40, Proline rich Akt substrate of 40 kDa. mTOR, 
mammalian target of rapamycin. S6K1, ribosomal protein S6 kinase β1. 
134 Chapter 8
SLC2A4, GSK3A, GYS1, AGL, PPP1R3A, PDK2, ACACA, PPARA and PPARD mRNA expres-
sion in Caucasian subjects, with a comparable response in South Asians. Only PKM2 was 
differentially affected in South Asians in response to the HFHC-diet.
Skeletal muscle mitochondrial respiratory-chain content
The protein expression of several mitochondrial respiratory chain complex subunits was 
determined (Figure 2A). Although at baseline no differences were observed between groups, 
the expression of respiratory chain complex 1 and 2 was significantly increased after the 
HFHC-diet only in Caucasians (Figure 2B). However, the complex 2-on-complex 1 ratio, as a 
measure of change in fat vs. glucose oxidation, was not significantly different between both 
ethnicities (Figure 2C). The mtDNA-on-nDNA-ratio was significantly lower in South Asians 
compared to Caucasians, but was not affected in response to the diet (Figure 2D). Of note, the 
mRNA expression of key genes involved in mitochondrial biogenesis and tricarboxylic acid 
cycle was not different between groups, whatever the conditions (Supplemental Table 1).
Table 3. Parameters for indirect calorimetry before and after a 5-day HFHC-diet in healthy, young South 
Asian males and matched Caucasians.
  Caucasians  South Asians
  before after  before after
Basal
REE (kcal/day) 1469 ±  50 1523 ± 38 1220 ± 31** 1224 ± 22**
REE (kcal/day/kgLBM) 22.4 ±  0.7 22.7 ± 0.5 23.0 ±  0.9 22.8 ± 0.9
RQ 0.88 ±  0.01 0.87 ± 0.01 0.87 ± 0.02 0.89 ± 0.02
glucose oxidation 14.3 ±  1.0 13.6 ± 1.1 13.9 ± 1.3 14.7 ± 1.5
lipid oxidation 2.4 ±  0.3 2.7 ± 0.3 2.7 ± 0.4 2.4 ± 0.5
NOGD 2.3 ±  0.7 3.7 ± 0.8 4.2 ± 1.2 3.5 ± 1.4
Step 1
RQ 0.90 ±  0.02 0.91 ± 0.02 0.88 ± 0.02 0.90 ± 0.03
glucose oxidation 16.2 ±  1.6 16.4 ±  1.6 14.3 ± 1.7 14.8 ± 1.5
lipid oxidation 2.2 ±  0.5 1.9 ± 0.4 2.6 ± 0.5 2.3 ± 0.5
NOGD 1.8 ±  0.9 2.8 ± 0.9 3.1 ± 1.2 2.5 ± 1.2
Step 2
RQ 0.92 ±  0.02 0.93 ± 0.02 0.88 ± 0.02 0.95 ± 0.02†
glucose oxidation 17.7 ±  1.5 18.2 ± 1.8 14.4 ± 1.2 19.2 ± 1.5†
lipid oxidation 1.8 ±  0.4 1.6 ± 0.4 2.5 ± 0.4 1.4 ± 0.4
NOGD 24.1 ±  2.1 23.8 ± 1.6 34.4 ± 4.0** 19.3 ± 2.0†† ‡‡
Data are presented as mean ± SEM. Units are in μmol/kgLBM/min. REE: resting energy expenditure, RQ: 
respiratory quotient, NOGD: non-oxidative glucose disposal rate. † p<0.05, †† p<0.005 within group vs. 
before diet. **p<0.005 vs. Caucasians. ‡‡ p<0.005 diet effect vs. Caucasians. 
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Figure 2. Protein expression of mitochondrial respiratory-chain subunits in skeletal muscle from healthy, 
young South Asian (striped bars) males and matched Caucasians (closed bars) before (black bars) and 
after (white bars) a 5-day HFHC-diet. A. Representative blots for one subject per group. B. The expression 
of various mitochondrial-respiratory chain subunits (CI: NDUFB8, CII: SDHB, CIII: UQCRC2, CIV: MTCO1, CV: 
ATP5A) were assessed by Western Blot in basal condition. C. The respiratory-chain complex 2-on-complex 
1 ratios were calculated. D. The mtDNA on nDNA ratio as assessed by qPCR in basal condition (n=7/12 
(Caucasian/South Asian)). Results are normalized to Caucasian subjects (before diet) and expressed as 
mean ± SEM. Due to a small amount of tissue two Caucasian subjects were excluded for Western Blot 




This is the first study in South Asians in which a 2-step hyperinsulinemic-euglycemic 
clamp with stable isotopes was performed to measure peripheral and hepatic insulin 
sensitivity, and the first one in this ethnicity which assessed the effect of HF-feeding 
on both insulin sensitivity and skeletal muscle insulin and mTOR signaling. Strikingly, 
a 5-day HFHC-diet was already sufficient to impair insulin-stimulated (non-oxidative) 
glucose disposal in South Asians, while such an effect was not observed in Caucasians.
Baseline comparisons
In contrast to other studies, waist fat distribution and HTG did not significantly differ be-
tween both ethnicities (13,14,37,38). In addition, we did not find higher fasting serum in-
sulin levels (14,37-41), nor lower peripheral insulin sensitivity in South Asians compared 
to Caucasians at baseline in both basal and insulin-stimulated conditions (12,38,40-42). 
Instead, South Asians seemed to have even higher insulin-stimulated peripheral insulin 
sensitivity. However, insulin levels during the clamp were higher in South Asians on both 
study days, which is in line with other studies (40-42). After correction for insulin levels, 
the difference in Rd between groups disappeared and was almost reversed. The higher 
insulin levels were presumably due to a lower MCRi in South Asians, which has been 
shown before (40). The lower MCRi together with the higher HIR index in South Asians 
indicates lower hepatic insulin sensitivity both at baseline and after the diet.
The difference in above-mentioned findings compared to literature might be ex-
plained by the relatively young age, low BMI and sex (no females were included) of our 
subjects, geographical differences as reflected by dietary and/or other acculturation 
changes, and/or the small sample size (despite power calculation beforehand).
Response to a 5-day HFHC-diet
The mean daily calorie intake during the HFHC-diet was ~55% higher compared to their 
normal diet, and both groups reached ~54% of energy derived from fat compared to 
~30% of their normal daily energy intake. HTG increased significantly after the diet in 
both groups, indicating good compliance to the diet, and consistent with a previous 
study in which young, healthy Caucasian males were subjected to a 3-day HF-diet 
(26). In contrast, fasting glucose and insulin levels increased significantly only in South 
Asians. No effect of the diet on basal EGP or on the capacity of insulin to suppress EGP 
was observed in either group, although the HIR index, which corrects EGP for insulin 
level (32), was significantly increased in South Asians only. Strikingly, insulin-stimulated 
Rd was significantly impaired after the diet in South Asians, whereas no diet effect was 
observed in Caucasians. 
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The response to a HF-diet on (skeletal muscle) insulin sensitivity in people of Cauca-
sian descent is variable in the literature, depending on the percentage of fat and carbo-
hydrates, duration of the diet, amount of calories (eucaloric or hypercaloric), effect on 
bodyweight, and method used to assess insulin sensitivity. In general, HF-diets of several 
hours up to 3 days induce whole-body IR (43,44), whereas after HF-diets of several days 
up to 3 weeks usually no effect is seen on insulin sensitivity (45-48). This difference in 
effect on insulin sensitivity might be attributed to a greater intramuscular lipid storage 
and/or use after several days, compensating for the increase in FFA availability induced 
by the HF-diet (47).
The impairment in insulin-stimulated Rd after the diet in South Asians appears to 
be due to a decrease in NOGD, suggesting a defect in glycogen storage. Impaired 
non-oxidative glucose disposal is the main defect observed in patients with T2DM (49). 
Interestingly, at baseline insulin-stimulated NOGD was significantly higher in South 
Asians compared to Caucasians, but this was possibly due to the higher insulin levels 
in South Asians. Because of the impairment in NOGD in South Asians after the diet, we 
also analyzed proteins (Supplemental Figure 1) and genes involved in glycolysis and 
glycogen synthesis. However, no obvious differences were found between groups. 
The mRNA expression of GYS was significantly reduced in both groups after the diet 
(Supplemental Table 1). Of note, in contrast to what was observed in South Asians in 
the present study, in several short-term HF-diet studies in Caucasians an increase in 
NOGD and a decrease in glucose oxidation was observed (45,47,48,50), accompanied by 
an increase in skeletal muscle mRNA level of pyruvate dehydrogenase kinase 4 (PDK4) 
and a corresponding decrease in pyruvate dehydrogenase enzyme complex (PDH) in 
basal and insulin-stimulated conditions (44,47,48). In the present study, PDK4 was not 
affected by the diet, and PDH was reduced only in South Asians (Supplemental Table 
1). Therefore, it would have been interesting to determine skeletal muscle glycogen 
content. Further research is required to clarify the pathophysiological relevance of these 
apparent paradoxical findings in glycogen metabolism in South Asians.
The nutrient-sensing mTOR-pathway is mostly known for its regulating role in cel-
lular proliferation and growth but it was also recently shown to be involved in key 
metabolic processes (16). Therefore, it constitutes an interesting and relevant pathway 
to be investigated in the context of increased IR together with increased ectopic fat 
deposition in South Asians vs. Caucasians. Interestingly, mTORC1 appears to have nega-
tive effects on insulin signaling (17). There are various mechanisms through which this 
negative feedback loop of mTORC1 on insulin signaling is initiated. When activated by 
mTORC1, downstream target S6K1 can suppress IRS-1 via direct phosphorylation of IRS1 
on multiple serine residues, and via transcription repression of IRS1 gene expression. 
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Additionally, mTORC1 directly interacts with IRS1 via raptor and phosphorylates IRS1 
at Ser636/639. Furthermore, several biochemical and genetic studies have shown that 
mTORC1 plays a crucial role in the regulation of oxidative metabolism and mitochon-
drial biogenesis (18-21) as well as in lipid metabolism (22). In particular, mTORC1 seems 
to suppress FA beta-oxidation (21,23,24). Therefore, we hypothesized that differences in 
mTOR activity between the two ethnicities might underlie or contribute to the increased 
risk of IR and T2DM in South Asians. However, we did not find obvious differences in 
the mTOR-pathway between or within groups, neither at baseline nor after a 5-day 
HFHC-diet. Additionally, apart from a small difference in diet effect on respiratory chain 
complex subunits 1 and 2, we did not observe relevant differences in diet effect on skel-
etal muscle insulin signaling, mitochondrial density and expression of genes involved 
in oxidative phosphorylation and mitochondrial biogenesis that could explain the 
diet-induced impairment in insulin-stimulated Rd in South Asians, which is in line with 
a previous study in which young, healthy Caucasian males were subjected to a 5-day 
HFHC-diet (46). The fact that we did not find obvious differences between groups might 
be explained by the relatively good health of our subjects and/or the small sample size. 
Of note, to confirm our findings on mitochondrial function other mitochondrial markers, 
such as ex vivo determination of activities of mitochondrial respiratory-chain complexes 
and citrate synthase activity should be measured in future studies.
Only two other studies have been performed before in South Asians in which skeletal 
muscle biopsies were obtained to assess insulin signaling and/or mitochondrial func-
tion, and none assessed the mTOR-pathway. Nair et al found no impairment in mito-
chondrial function in healthy, middle-aged South Asians, even despite the finding that 
they were more insulin resistant than matched Caucasians (12). Correspondingly, Hall 
and colleagues reported that healthy, young, lean South Asian males did not exhibit 
lower expression of skeletal muscle oxidative and lipid metabolism genes compared to 
matched white Caucasians, and that mtDNA-to-nDNA-ratio, an index of mitochondrial 
content, did not significantly differ between groups, although a trend for a lower ratio 
in South Asians was observed (11). Thus, both studies concluded that mitochondrial 
dysfunction did not account for the observed IR in South Asians, which is in line with our 
present findings concerning the effect of a HFHC-diet. Additionally, Hall’s study showed 
that South Asians had reduced skeletal muscle protein expression of key insulin signal-
ing proteins in the fasted state (11). In that study, insulin sensitivity, as measured from 
the Matsuda insulin sensitivity index, was however significantly lower in South Asians. 
Thus, these subjects might have been more insulin resistant, explaining the reduced 
expression of insulin signaling proteins as compared to our study. Other possibilities 
for the different findings on insulin signaling are the larger group size in the study of 
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Hall, and/or geographical differences as reflected by dietary and/or other acculturation 
changes.
Finally, we cannot exclude the possibility that white adipose tissue (WAT) might have 
contributed to the diet-induced impairment in insulin-stimulated Rd in South Asians. 
Indeed, about 10-20% of whole-body glucose uptake occurs in WAT, which corresponds 
to the observed reduction in Rd in South Asians (mean percentage decrease: 20 ± 5%). 
In conclusion, we showed that a 5-day HFHC-diet is already sufficient to affect insulin-
stimulated (non-oxidative) glucose disposal in healthy, young, lean South Asian males, 
whereas no diet effect was found in age- and BMI-matched Caucasians, suggesting that 
the propensity of South Asians to develop T2DM may be partly explained by the way 
they adapt to HF western food. The mTOR-pathway does not seem to be involved, at 
least in skeletal muscle. These findings might provide new leads for further investigation 
aimed to elucidate the pathogenesis of IR and T2DM in South Asians.
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Supplemental Table 2. Activity level, normal dietary intake and intake during a 5-day HFHC-diet of 
healthy, young South Asian males and matched Caucasians.
  Caucasians  South Asians
Activity level
exercise (min/week) 150 (203) 125 (210)
exercise (category) 2.5 (4) 2.5 (4)
activity factor 1.375 (0.22) 1.375 (0.26)
Normal diet
total kcal per day 2593 ± 100 2170 ± 102 *
kcal per day per kg 34.6 ± 1.2 34.3 ± 2.0
fat (kcal/day) 835 ± 63 674 ± 60
carbohydrates (kcal/day) 1217 ± 47 1079 ± 48
protein (kcal/day) 404 ± 19 363 ± 35
fat (%) 31.6 ± 1.6 29.8 ± 1.9
carbohydrates (%) 47.6 ± 1.6 51.6 ± 2.1
protein (%) 15.8 ± 0.7 16.5 ± 1.0
Intake during a 5-day HFHC-diet
total kcal per day 3824 ± 177 3453 ± 149
kcal per day per kg 51.1 ± 2.5 54.5 ± 2.9
fat (kcal/day) 2041 ± 92 1839 ± 62
carbohydrates (kcal/day) 1220 ± 81 1128 ± 65
protein (kcal/day) 439 ±  27 434 ± 31
fat (%) 54.0 ± 1.2 53.9 ± 1.2
carbohydrates (%) 31.6 ± 1.3 32.4 ± 0.9
protein (%) 11.4 ±  0.3 12.4 ± 0.6
Data are presented as mean ± SEM or median (IQR), n=12-11. Exercise categories: 0 = 0 minutes, 1 = 1-60 
minutes, 2 = 61-120 minutes, 3 = 121-180 minutes, 4 = 181-240 minutes, 5 = 241-300 minutes. Activity 
factor according to the Harris-Benedict principle.
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Supplemental Figure 1. Phosphorylation state of glycogen synthase kinase 3 and protein expression 
and phosphorylation state of glycogen synthase in skeletal muscle from healthy, young South Asian 
males and matched Caucasians before (black bars) and after (white bars) a 5-day HFHC-diet. The 
protein expression of A. Ser21/9-GSK3, B. Ser641-GS, and C. GS were assessed by Western Blot. The 
phosphorylation state in basal and hyperinsulinemic (step 2) conditions (A, B), or the protein expression in 
basal conditions (C) are shown. Results are normalized to Caucasian subjects (before diet, basal condition) 
and expressed as mean ± SEM. Due to a small amount of tissue two Caucasian subjects were excluded 
for Western Blot analysis. § p<0.05, §§ p<0.005 within groups vs. basal condition. GS: glycogen synthase. 
GSK3: glycogen synthase kinase 3. 
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Cardiovascular function in 
middle-aged overweight 
South Asians compared with 
Caucasians: response to short-
term caloric restriction
Different cardiac dimensions and cardiovascular function in middle-aged South Asians
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South Asians have a higher risk of developing cardiovascular disease than Caucasians. 
The underlying cause is unknown, but might be related to higher cardiac susceptibility 
to metabolic disorders. Short-term caloric restriction (CR) can be used as a metabolic 
stress test to study cardiac flexibility. The objective was to assess whether metabolic and 
functional cardiovascular flexibility to CR differs between South Asians and Caucasians.
Methods
Cardiovascular function and myocardial triglycerides (TG) were assessed using a 1.5T 
MRI/S-scanner in 12 middle-aged overweight male South Asians and 12 matched Cau-
casians before and after an 8-day very low calorie diet (VLCD). 
Results
At baseline South Asians were more insulin resistant than Caucasians. Cardiac dimen-
sions were smaller, despite correction for body surface area, and PWV in the distal aorta 
was higher in South Asians. Systolic and diastolic function, myocardial TG and pericardial 
fat did not differ between groups. After the VLCD body weight reduced on average with 
4.0 ± 0.2 kg. Myocardial TG increased in both ethnicities with 69 ± 18%, and diastolic 
function decreased. Pericardial fat and PWV in the proximal and total aorta were re-
duced in Caucasians only. 
Conclusion
At baseline middle-aged overweight South Asians were more insulin resistant than Cau-
casians. Cardiac dimensions were smaller and PWV was higher in South Asians. After an 
8-day VLCD, myocardial TG increased and diastolic function decreased to a similar extent 
in both groups, indicating comparable myocardial metabolic and functional flexibility 
in response to short-term CR. However, paracardial fat and PWV showed a differential 
effect in response to the VLCD, with a more favorable response in Caucasians. 
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INTRODUCTION
People of South Asian descent are at an increased risk of developing cardiovascular 
disease (CVD) compared to Caucasians. The age-standardized mortality rate from CVD 
is approximately 50% higher for South Asians (1-4). Furthermore, CVD in South Asians 
is more aggressive and has higher mortality rates at younger ages (1,2,5,6). The mean 
age of first acute myocardial infarction is around five years earlier than in Caucasians 
(6,7).
Traditional risk factors, such as smoking, hypertension and cholesterol levels, do not 
seem to account for the excess risk for CVD in South Asians (3,8). Major contributing fac-
tors to the high prevalence of CVD in South Asians are insulin resistance (IR) and type 2 
diabetes mellitus (T2DM), which are also highly prevalent in this ethnicity. Mortality risk 
of CVD associated with T2DM is higher in South Asians compared to Caucasians (3,9), 
which might suggest that South Asians have a higher cardiac susceptibility to metabolic 
disorders. Since South Asians represent one fifth of the world’s population, the increased 
risk for CVD and T2DM in this ethnicity poses a major burden on the health care system. 
Therefore, gaining more insight in the interrelationship between metabolic disorders 
and cardiac function in people of South Asians descent is of great importance.
We have shown previously that short-term caloric restriction (CR) can be used as a 
metabolic stress test to induce a short-term physiological increase of plasma free fatty 
acid (FFA) levels, which enables us to study the flexibility of myocardial triglyceride (TG) 
content and cardiac function, as assessed by magnetic resonance (MR) techniques (10-
13). Surprisingly, so far no studies have been published on the effect of CR on cardiovas-
cular function in South Asians.
Given the high risk of CVD in South Asians, we hypothesize that cardiovascular 
function in middle-aged overweight South Asians is impaired compared to Caucasians. 
Furthermore, we hypothesize that the metabolic and functional cardiovascular flex-
ibility in response to CR is compromised in people of South Asians descent. Therefore, 
we subjected middle-aged, overweight South Asians and age-, sex- and BMI-matched 
Caucasians to an 8-day very low calorie diet (VLCD) and studied cardiac function and 
myocardial TG content using MR techniques. In addition, we studied aortic pulse wave 




Twelve Dutch South Asians and twelve Dutch Caucasian males, aged 40-50 year, with 
a positive family history for T2DM were enrolled. Subjects were overweight (BMI 25-30 
kg/m2) and had a waist circumference of >90 cm (South Asians) or >94 cm (Caucasians). 
Subjects were recruited via local advertisements, and underwent a medical screening 
including a physical examination, blood chemistry tests and an oral glucose tolerance 
test (OGTT) to exclude T2DM. Other exclusion criteria were: CVD, any significant chronic 
disease, use of medication known to influence glucose and/or lipid metabolism, smok-
ing, recent weight change, and general contraindications to MR scanning. The study 
was approved by the local ethics committee and performed in accordance with the 
principles of the revised Declaration of Helsinki. Subjects gave written informed consent 
prior to participation.
Study design
Participants were studied on 2 study days separated by an 8-day VLCD. The VLCD con-
sisted of three sachets of Modifast® (Nutrition & Santé Benelux, Breda, The Netherlands) 
per day (~450 kcal/day; ~50 g protein, 50-60 g carbohydrates, ~7 g lipids and ~15 g 
dietary fibers). MR studies were performed shortly before the start and at the end of the 
8th day of the diet. Subjects were instructed not to alter life style habits. Anthropometric 
measurements and blood samples were obtained on both study days after a 10-hour 
overnight fast.
MR protocol
All measurements were performed using a 1.5-Tesla whole-body MR scanner (Gyroscan 
ACS-NT15; Philips Medical Systems, The Netherlands) in postprandial state (four hours 
after the last meal). 
Myocardial triglyceride content
MR spectroscopy (1H-MRS) was used to quantify myocardial TG content. Details on 
1H-MRS acquisition and post processing were published before (14,15). In summary, a 
8-ml voxel was placed in the interventricular septum on four-chamber and short-axis 
images at end-systole. Electrocardiographic (ECG) triggering (for myocardial spectra) 
and respiratory pencil beam navigator were used during acquisition (14). Acquisitions 
were performed with and without water suppression, with myocardial TG expressed as 
percentage of the unsuppressed water signal. 
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Pericardial fat quantification
As described before (16), to quantify the pericardial fat volume, the heart was imaged 
using electrocardiographically gated breath-holds with a multi shot turbo spin echo 
sequence in a four-chamber view orientation. Water was suppressed using Spectral 
Inversion Recovery (SPIR). Contours were drawn around both pericardial fat layers sur-
rounding the ventricles and atria using MASS® software (Medis, Leiden, The Netherlands) 
(Figure 1). The number of pixels were converted to square centimeters and multiplied by 
the slice thickness to obtain volume. 
Left ventricular dimensions and function
Data were analyzed blinded for ethnicity and study occasion. As previously described, 
the entire heart was imaged in short-axis orientation, using ECG gated breath-hold cine 
steady-state free-precession sequences (17). Left ventricular (LV) epicardial and endo-
cardial contours were manually drawn in the end-systolic and end-diastolic phases of 
the short-axis images, using validated MASS® software. LV end-diastolic volume (EDV), 
end-systolic volume (ESV), ejection fraction (EF), stroke volume (SV) and end-diastolic 
mass (EDM) were calculated. 
Furthermore, an ECG gated gradient-echo sequence with velocity encoding (100 cm/
sec) was performed to measure transmitral blood, for the determination of LV diastolic 
function. Analysis was performed by using FLOW® software (Medis, Leiden, The Nether-
lands). The early filling phase (E) and the atrial contraction (A) were analyzed and their 
peak flow ratio was calculated (E/A ratio). Additionally, the peak deceleration gradient 
of E and LV filling pressures (E/Ea) were assessed (18,19). Heart rate was monitored and 
stored during the transmitral flow measurements. 
Figure 1. Quantification of the pericardial fat layer. This figure shows the quantification of the pericardial 
fat layer, which can be divided in an epicardial (red) and paracardial (green) fat layer.  
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Pulse Wave Velocity
To evaluate the aortic stiffness, aortic PWV was determined, using a previously described 
protocol (20). Shortly, a scout view of the aorta was performed. Subsequently, a velocity-
encoded image perpendicular to the ascending aorta at the level of the pulmonary 
trunk, at the level of the aorta crossing the diaphragm and at the level of the aortic 
bifurcation was assessed (Figure 2). This resulted in through-plane flow measurements 
of the ascending and descending aorta. PWV was calculated using the formula: Δx/Δt, 
where Δx is the aortic path length between two measurement sites and Δt is the time 
delay between the arrivals of the foot of the pulse wave at the respective measurements 
site. The distance between the measurement sites was determined manually using 
MASS®. Data were analyzed using MASS® and FLOW®.





























3PWV aortic arch (m/s) PWV distal descending aorta (m/s)
PWV proximal descending aorta (m/s)
Figure 2. Aortic PWV determination with MRI. The left panel shows a double-oblique parasagittal image 
of the aorta. The colored lines represent the acquisition planes for velocity-encoded MRI which are 
positioned perpendicular to the aorta. 1 is the path length of the aortic arch, 2 of the proximal descending 
aorta and 3 of the distal descending aorta, determined along the centerline of the aorta. The right panel 
shows the velocity-time curves for the four different measurement sites in the aorta. 
Assays
Serum concentrations of glucose, total cholesterol, HDL and TG were measured on 
a Modular P800 analyzer (Roche, The Netherlands), and serum insulin levels on an Immu-
lite 2500 (Siemens, The Netherlands). HbA1c was measured on an HPLC system (Kordia, 
The Netherlands). Plasma FFAs were measured by a commercial kit (Wako Chemicals, 
Germany).
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Statistical analysis
Data are presented as mean ± SEM or median (interquartile range (IQR)). A mixed ef-
fects model was applied to assess mean differences within and between groups, and to 
determine differences in diet effect. Groups and intervention were modeled as fixed ef-
fects and the subject specific deviances from the group mean were modeled as random 
effects. Nonparametric tests were performed when appropriate. Significance level was 
set at p<0.05 (two-sided). Statistical analyses were performed using SPSS for Windows 
version 20.0 (IBM, USA).
RESULTS
Clinical and metabolic characteristics
Baseline 
Mean age was 44.6 ± 0.8 year. Body surface area (BSA) was significantly lower in South 
Asians compared to Caucasians. However, BMI (28.3 ± 0.3 kg/m2), waist and hip circumfer-
ence and percentage of fat mass were comparable between groups. The same was true 
for blood pressure and heart rate. Both ethnicities had similar fasting glucose levels, but 
HbA1c and insulin levels (both fasting and during OGTT) were higher in South Asians. 
Fasting FFAs, TGs and cholesterol levels did not significantly differ between groups, 
except LDL-cholesterol, which was higher in South Asians (Table 1).
Effect of VLCD 
Anthropometric measurements were significantly reduced after the diet in both groups. 
The mean reduction in body weight for both groups was 4.0 ± 0.2 kg, of which approxi-
mately 50% was fat mass. BMI decreased on average with 1.28 ± 0.07 kg/m2. Systolic 
and diastolic blood pressure were reduced in both ethnicities. The heart rate was not 
affected. In both groups, fasting glucose, insulin and TG levels decreased significantly, 
while FFAs increased in response to the VLCD (Table 1). 
Myocardial TG content
Baseline 
No differences in myocardial TG content were found between both groups at baseline 
(Table 2).
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Effect of VLCD 
Myocardial TG content increased in both ethnicities, although in Caucasians this did not 
reach significance (p=0.067). The percentage of myocardial TG increase, however, was 
comparable between groups (69 ± 18%, p=0.868) (Table 2 and Figure 3).
Pericardial fat distribution
Baseline 
There were no differences in pericardial, epicardial or paracardial fat volumes between 
groups at baseline (Table 2).
Effect of VLCD 
The pericardial and paracardial fat volumes decreased significantly in Caucasians in re-
sponse to the VLCD (p=0.003 and p=0.050, respectively), whereas no significant changes 
occurred in South Asians (Table 2).
Left ventricular dimensions and function
Baseline 
Despite correction for BSA EDV, ESV and SV were significantly lower in South Asians. 
EF was on average 61 ± 4%, and was comparable between ethnicities (p=0.808). There 
were no significant differences in diastolic cardiac function, as reflected in the E/A ratio 
(p=0.168) and the E/Ea ratio (p=0.088) (Table 3).
Effect of VLCD 
LV mass, indexed for BSA, decreased slightly in both groups after the diet. EDV reduced 
in Caucasians, however no significant change occurred in South Asians. The cardiac 
index reduced equally in both ethnicities. The E/A ratio reduced significantly in Cau-
casians, whereas no significant diet effect was observed in South Asians. In contrast, 
the VLCD did not induce significant changes in the E/Ea ratio in Caucasians, while in 
South Asians E/Ea decreased significantly. The early peak filling rate (EPFR) and early 




PWV in the distal segment of the aorta was significantly higher in South Asians com-
pared to Caucasians. Furthermore, PWV in the total aorta tended to be higher in South 
Asians, however this did not reach statistical significance (p=0.068) (Table 3).
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Table 1. Clinical and metabolic characteristics
  Caucasians South Asians
Baseline VLCD Baseline VLCD
Clinical characteristics
age (years) 44.3 ± 1.1 44.9 ± 0.9
height (m) 1.81 ± 0.02 1.75 ± 0.01**
weight (kg) 92.6 ± 2.5 88.2 ± 2.5†† 86.7 ± 1.4 83.2 ± 1.6†† ‡
BSA (m2) 2.14 ± 0.04 2.09 ± 0.04†† 2.02 ± 0.02* 1.99 ± 0.02††*‡
BMI (kg/m2) 28.1 ± 0.5 26.8 ± 0.5†† 28.4 ± 0.4 27.3 ± 0.4††
waist (cm) 103 ± 2 100 ± 2†† 99 ± 2 97 ± 1††
hip (cm) 102 ± 1 100 ± 1 99 ± 2 97 ± 1†
WHR 1.01 ± 0.01 0.99 ± 0.01† 1.02 ± 0.01 1.01 ± 0.01
fat mass (%) 23.1 ± 0.6 21.8 ± 0.6†† 23.8 ± 0.6 23.0 ± 0.6††
systolic BP (mmHg) 130 ± 3 118 ± 2†† 136 ± 3 124 ± 3††
diastolic BP (mmHg) 85 ± 3 77 ± 3†† 90 ± 4 85 ± 3††
heart rate (bpm) 64 ± 3 61 ± 2 70 ± 3 65 ± 3
Metabolic characteristics
free fatty acids (mmol/L) 0.53 ± 0.03 1.36 ± 0.13†† 0.58 ± 0.04 0.85 ± 0.06†**‡‡
triglycerides (mmol/L) 1.29 (2.48) 0.89 (0.18) †† 1.78 (2.91) 0.91 (0.25)††
total cholesterol (mmol/L) 4.93 ± 0.16 5.05 ± 0.27
HDL-cholesterol (mmol/L) 0.92 ± 0.05 0.84 ± 0.07
LDL-cholesterol (mmol/L) 3.11 ± 0.16 3.13 ± 0.23
total cholesterol/HDL ratio 5.53 ± 0.33 6.61 ± 0.78
HbA1c (mmol/mol) 33.0 (6) 36.5 (1)*
glucose (mmol/L) 5.33 ± 0.20 4.45 ± 0.22†† 5.30 ± 0.11 4.51 ± 0.14††
insulin (mU/L) 6.0 (3.0) 1.7 (3.7)†† 8.5 (2.5)** 2.3 (4.7)††
Oral glucose tolerance test
2 hour insulin (mU/L) 31 (29) 77 (76)*
glucose AUC (mmol/L) 959 ± 32 1027 ± 58
insulin AUC (mU/L) 4477 ± 586 8790 ± 711**
Data are presented as mean ± SEM or median (IQR). VLCD: very low calorie diet, BSA: body surface area, 
BMI: body mass index, WHR: waist hip ratio, BP: blood pressure, AUC: area under the curve. 
 † p<0.05, †† p<0.005 within group vs. before diet. * p<0.05, ** p<0.005 vs. Caucasians. ‡ p<0.05, ‡‡ p<0.005 
diet effect vs. Caucasians.
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Effect of VLCD 
After the VLCD, PWV in the proximal descending part of the aorta and PWV of the total 
aorta were significantly reduced in Caucasians. In contrast, no diet effect on PWV in any 
of the segments of the aorta was observed in South Asians (Table 3).
Table 2. Pericardial fat distribution and myocardial triglyceride content assessed with MRI and MRS before 
and after an 8-day VLCD
  Caucasians South Asians
  Baseline VLCD Baseline VLCD
Epicardial fat (ml) 3.1 (1.8) 3.6 (1.4) 3.3 (1.4) 3.0 (1.0)
Paracardial fat (ml) 4.8 (3.7) 3.7 (3.0)†† 3.5 (2.1) 2.7 (2.6)‡
Pericardial fat (ml) 7.6 (4.0) 6.6 (3.5)† 6.7 (3.0) 6.0 (4.0)
Myocardial TG content (%) 0.56 ± 0.08 0.74 ± 0.08 0.59 ± 0.08 0.98 ± 0.13††
Data are mean ± SEM or median (IQR). VLCD: very low calorie diet, TG: triglyceride. † p<0.05, †† p<0.005 
within group vs. before diet. * p<0.05, ** p<0.005 vs. Caucasians. ‡ p<0.05, ‡‡ p<0.005 diet effect vs. 
Caucasians.
Figure 3: Myocardial spectra. Example of typical myocardial spectra of one subject before and after an 
8-day VLCD.
Different cardiac dimensions and cardiovascular function in middle-aged South Asians 159
Table 3. Cardiac dimensions and parameters of cardiovascular function assessed with MRI before and 
after an 8-day VLCD
  Caucasians South Asians
Baseline VLCD Baseline VLCD
Cardiac dimensions and basic function
LVEDMI (g/m2) 51 ±  2 48 ± 2†† 52 ± 1 50 ± 1†
EDVI (ml/m2) 87 ±  3 83 ± 2† 74 ±  3** 72 ±  3*
ESVI (ml/m2) 34 ±  1 32 ± 1 29 ±  1* 27 ±  1*
SVI (ml/m2) 5 ±  2 51 ± 2 46 ±  2* 45 ±  2*
CI (ml/min/m2) 3366 ±  104 3074 ± 84† 3204 ± 175* 2916 ± 74†*
EF (%) 61 ±  2 62 ± 1 62 ±  1 63 ±  1
Diastolic cardiac function
E peak filling rate (ml/s) 549 ±  28 477 ± 26†† 493 ±  26 445 ±  22†
E acceleration peak (ml/s²x10-³) 8.4 ±  0.6 7.0 ± 0.5†† 7.5 ±  0.5 6.4 ±  0.3
E deceleration peak  (ml/s²x10-³) -4.7 ±  0.3 -3.7 ± 0.2†† -4.9 ±  0.3 -4.1 ± 0.3†
E deceleration mean  (ml/s²x10-³) -3.2 ±  0.2 -2.5 ± 0.2†† -3.4 ±  0.3 -2.8 ± 0.3†
A peak filling rate (ml/s) 392 ±  18 364 ± 20 365 ±  17 360 ±  10
E/A-peak ratio 1.43 ± 0.10 1.34 ± 0.09† 1.37 ±  0.08 1.24 ± 0.07
E/Ea 9.4 ±  0.7 8.3 ± 1.0 9.8 ±  0.8 7.2 ± 0.8†
Pulse wave velocity
PWV aortic arch (m/s) 5.6 (0.9) 5.3 (1.1) 5.7 (1.3) 5.7 (0.9)
PWV proximal aorta (m/s) 6.7 (2.4) 5.2 (1.4)† 7.2 (3.7) 7.1 (2.6)**
PWV distal aorta (m/s) 5.0 (0.5) 4.9 (1.7) 5.5 (1.2)* 5.2 (1.0)
PWV total aorta (m/s) 5.5 (1.0) 5.2 (0.4)† 6.1 (0.9) 5.8 (0.9)*
Data are mean ± SEM or median (IQR). VLCD: very low calorie diet, LV: left ventricular, EDM: end- diastolic 
mass, EDV: end-diastolic volume, ESV: end-systolic volume, SV: stroke volume, CI: cardiac index, EF: 
ejection fraction, ESWS: end-systolic wall stress, I: indexed for body surface area, E: early diastolic wave, 
A: atrial diastolic wave, E/Ea: estimated left ventricular filling pressure, PWV: pulse wave velocity. † 
p<0.05, †† p<0.005 within group vs. before diet. * p<0.05, ** p<0.005 vs. Caucasians. ‡ p<0.05, ‡‡ 
p<0.005 diet effect vs. Caucasians.
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DISCUSSION
South Asians have a higher risk of developing CVD than Caucasians. Additionally, the 
risk of cardiac complications in subjects with IR and T2DM is higher in this population, 
indicating they are metabolically more at risk. Previous studies in healthy subjects and 
obese patients with T2DM with and without CVD of Caucasian descent demonstrated 
metabolic and functional flexibility of the heart in response to both short- and long-
term CR. To date, however, it was unknown if CR in South Asians has comparable effects. 
This study showed that an 8-day VLCD increased myocardial TG content and decreased 
diastolic function to a similar degree in middle-age overweight South Asians as com-
pared to age-, sex- and BMI-matched but less insulin resistant Caucasians, indicating 
comparable flexibility of the heart. Paracardial fat volume and PWV, however, showed a 
differential effect in response to CR in favor of Caucasians.
Myocardial TG content
At baseline, South Asians were more insulin resistant, indicated by higher insulin levels 
(both in fasted condition and during OGTT) (Table 1). Studies in animals and humans 
have demonstrated that increased myocardial TG content in IR is associated with im-
paired myocardial function (21-23). Paradoxically, however, the increase in myocardial 
TG observed after a short-term VLCD is a sign of preserved metabolic flexibility of the 
heart. Given the high risk on CVD and T2DM in South Asians, we hypothesized, therefore, 
that the flexibility of the heart to adjust myocardial TG content in response to CR was 
diminished in South Asians compared to Caucasians. Surprisingly, however, an 8-day 
VLCD increased myocardial TG similarly in both groups. Thus, South Asians showed a 
similar physiological flexibility of myocardial lipid metabolism as Caucasians. 
Previous short-term VLCD studies have shown that the increase in myocardial TG is 
the net result of increased uptake of FFAs in cardiomyocytes in relation to oxidative FFA 
requirements. This increased uptake is due to an increased release of FFAs from the adi-
pose tissue into the circulation, which is caused by increased lipolysis of TG in adipose 
tissue in response to CR (11,13). Indeed, in the present study FFAs were significantly 
increased after the diet in both ethnicities, and waist fat was significantly reduced (data 
not shown), indicating increased lipolysis in the adipose tissue. 
Pericardial fat
Pericardial fat, the layer of fat surrounding the heart, can be divided in an epicardial and 
paracardial layer. Both fat layers are metabolically different. Whereas epicardial fat has 
been shown to be a source of several inflammatory mediators, paracardial fat seems to 
have a greater importance in mechanical restriction, which exerts an unfavorable effect 
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on the coronary vasculature (24). In the present study, pericardial fat distribution was 
similar between groups at baseline. However, pericardial fat decreased significantly in 
Caucasians in response to the dietary intervention, mainly due to a reduction in the 
paracardial fat layer, whereas in South Asians no significant diet effect was observed. 
Since the paracardial fat layer has been found to be a predictor of CVD, the decrease in 
this specific fat compartment in Caucasians probably conveys reduced cardiovascular 
risk (25).
Cardiac dimensions and function
Cardiac dimensions were smaller in South Asians compared to Caucasians, despite 
correction for BSA. This is in line with other studies, which showed smaller left heart 
volumes in middle-aged South Asians (26,27), using echocardiography. In a recent study 
in healthy young adults, we showed that these smaller cardiac dimensions are already 
present at a young age (28). No major effects of the diet on cardiac dimensions were 
observed.
Cardiac systolic function, reflected as the LV ejection fraction, was normal (~62%) 
and comparable in both groups. Systolic function was not affected by the diet, which is 
in line with previous VLCD studies (11,13,29).
Diastolic cardiac function, reflected as the E/A ratio, decreased after the diet as ex-
pected from previous studies (11,13,30). The reduction, however, was only significant 
in Caucasians. This difference in diet effect might be attributed to a decrease in filling 
pressure (E/Ea ratio) in South Asians. In addition, other parameters for diastolic function 
did decrease in both groups. The decrease in diastolic function can probably be ex-
plained by changes in elastic properties of the LV. In animal models, TG accumulation in 
cardiomyocytes is directly related to impaired cardiac function via complex mechanisms 
involving fatty acid derivatives (21). An alternative explanation may be that changes 
in plasma FFAs, induced by CR, change the calcium homeostasis in the myocardium, 
thereby influencing LV diastolic function (31).
Pulse wave velocity
The PWV is a powerful independent predictor of cardiovascular events (32). In the pres-
ent study, PWV in the distal aorta was significantly higher in South Asians compared to 
Caucasians at baseline, indicating a stiffer aorta. This is in line with other studies that 
showed a higher PWV in middle-aged South Asians compared to Caucasians (33,34). In 
addition, we have shown recently that PWV is already higher in healthy young South 
Asians (28). It is known that IR and T2DM compromise aortic elastic function. Although 
the precise underlying mechanisms remain unclear, it is known that long-term increased 
insulin levels can contribute to increased arterial wall thickness, and thereby to increased 
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arterial stiffening, by direct and indirect trophic effects on smooth muscle cells (35). In 
the present study, South Asians were more insulin resistant than Caucasian subjects – as 
reflected in higher insulin levels (both fasting and during OGTT) – which might explain 
the higher PWV observed in South Asians. 
The PWV responded differentially to an 8-day VLCD, consisting of a reduction in 
proximal and total PWV in Caucasians, whereas no diet effect was observed in South 
Asians, suggesting that large arteries are less flexible in South Asians in response to 
CR. This might be due to the, probably long-term existing, higher IR observed in South 
Asians which may have induced irreversible changes in the arterial wall according to the 
aforementioned mechanism.
A strength of this study is that for the first time the response to a VLCD on cardiovas-
cular function was assessed in South Asians. Furthermore, this is, to our knowledge, the 
first study measuring myocardial and pericardial TG content in people of South Asians 
descent, which is in our opinion very relevant given their high risk on CVD. A possible 
limitation is the relatively small sample size, which might limit generalization potential. 
However, subjects were their own controls, which increases power to detect relevant 
differences.
In conclusion, this study proves that myocardial TG stores in middle-aged overweight 
and insulin resistant South Asians are as flexible and amenable to therapeutic interven-
tion by CR as age-, sex- and BMI-matched but less insulin resistant Caucasians. However, 
paracardial fat volume and PWV showed a differential effect in response to an 8-day 
VLCD in favor of Caucasians. 
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After treatment with cisplatin-based chemotherapy for testicular cancer (TC), patients 
have higher prevalence of cardiovascular complications after long-term follow up. 
Little is known about acute cardiovascular effects of cisplatin-based chemotherapy. The 
aim of this study was to explore acute effects of chemotherapy on cardiac function in 
patients treated for TC. 
Methods
Fourteen TC patients (age 34.6 ± 12.3 years) were studied before and 3 months after 
start with cisplatin-based chemotherapy. Cardiac function was assessed with magnetic 
resonance imaging. Fasting glucose and insulin levels were measured and insulin sensi-
tivity, reflected by the Quicki index, was calculated. 
Results
Left ventricular (LV) end-diastolic volume and LV stroke volume significantly decreased 
from 192 ± 27 ml to 175 ± 26 ml (p<0.05) and 109 ± 18 ml to 95 ± 16 ml (p<0.05) respec-
tively. The ratio of early and atrial filling velocities across the mitral valve, a parameter of 
diastolic heart function, decreased after chemotherapy from 1.87 ± 0.43 to 1.64 ± 0.45 
(p<0.01). Metabolic parameters were unfavorably changed, reflected by a decreased 
Quicki index, which reduced from 0.39 ± 0.05 to 0.36 ± 0.05 (p<0.05). 
Conclusion
Chemotherapy for TC induces acute alterations in diastolic heart function, paralleled by 
unfavorable metabolic changes. Therefore, early after chemotherapy, metabolic treat-
ment may be indicated to possibly reduce long-term cardiovascular complications.
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INTRODUCTION
Testicular cancer (TC) is the most frequent form of cancer in young men. The prognosis 
of TC is good, with high cure rates since the introduction of treatment with cisplatin-
based chemotherapy (1,2). Because of the increasing number of survivors with a long life 
expectancy, understanding and prevention of short-term and long-term cardiovascular 
effects of chemotoxicity is very important.
Treatment of TC with cisplatin, bleomycin and etoposide (BEP) combination chemo-
therapy is associated with acute vascular toxicity and subacute changes in cardiac func-
tion (3,4), as well as with long-term cardiovascular disease (5,6). Previous studies showed 
that cisplatin and bleomycin induce alterations in endothelial function and endothelial 
damage in vitro (7,8). These findings suggest direct toxic effects of chemotherapy on 
the cardiovascular system. Little is known about acute effects of cisplatin-based che-
motherapy on cardiac function. More insight in the pathophysiology of the direct toxic 
effect of cisplatin-based chemotherapy on cardiac function and vessel wall is relevant 
to possibly prevent long-term cardiovascular disease. One previous study reported sub-
acute deterioration of diastolic function, assessed with echocardiography 10 months 
after cisplatin-based chemotherapy (3). 
Indirect effects of chemotherapy also seem to play a role in the increased risk of 
cardiovascular complications. For example, early after treatment with cisplatin-based 
chemotherapy changes in serum lipids have been described (9). Additionally, higher 
incidences of hypercholesterolemia, hypertension, microalbuminuria, obesity, elevated 
insulin-glucose ratio, and thereby metabolic syndrome have been reported at least 3 
years after chemotherapy (6,10,11). The acute effects of chemotherapy, defined as ef-
fects occurring 3 months after start of chemotherapy, on these risk factors are largely 
unknown. The aforementioned indirect risk factors are all independently associated 
with a higher risk of cardiovascular disease and may contribute to the overall increased 
risk of cardiovascular complications after treatment with cisplatin-based chemotherapy. 
The increased risk of cardiovascular disease in cured TC patients after cisplatin-based 
chemotherapy is probably a combination of direct and indirect effects of chemotherapy 
(10,12). Early changes in cardiac function and risk factors may have prognostic value 
for long-term development of cardiovascular complications (13). Magnetic resonance 
(MR) imaging is a highly reproducible imaging modality to assess cardiac function. 
Furthermore, myocardial triglyceride (TG) content can be measured with proton (1H)MR 
spectroscopy (14). Additionally, abdominal visceral and subcutaneous fat volume can be 
accurately assessed with MRI (15). Therefore, the purpose of this study was to investigate 
acute changes in cardiac function and myocardial TG, in relation to body fat distribution 
168 Chapter 10
and metabolic parameters 3 months after start with chemotherapy for TC, assessed with 
MR techniques.
METHODS
This study was approved by the local medical ethics committee and all subjects gave 
written informed consent. Metastatic TC patients, scheduled for first-line curative 
cisplatin-based combination chemotherapy in the Leiden University Medical Center 
were included between 2007-2009. Exclusion criteria were co-morbidities, including 
cardiovascular disease and diabetes mellitus.
Patients received three or four cycles of standard BEP-chemotherapy repeated every 
3 weeks. Each cycle consisted of intravenously administered etoposide (100mg/m2 over 
1 hr, days 1-5), cisplatin (20mg/m2 over 4 hr, days 1-5), and bleomycin (30 IUSP over 
30min) at days 2, 8, and 15. According to Dutch oncological guidelines, TC patients with 
good prognosis were treated with three cycles of BEP and patients with intermediate 
prognosis were treated with four cycles BEP. One patient, in addition received paclitaxel 
(175mg/m2) on day 1 of each of his 4 chemotherapy cycles as part of a randomized 
phase III study comparing paclitaxel-BEP and standard BEP in patients with intermedi-
ate prognosis TC. All patients were orchidectomized before adjuvant chemotherapeutic 
treatment.
BMI was determined at baseline and after chemotherapy. Fasting serum glucose, 
insulin, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) 
and triglycerides were determined. Insulin resistance was assessed with the quantita-
tive insulin sensitivity index (Quicki index), which is calculated using the formula: 1 / 
(log(fasting insulin µU/mL) + log(fasting glucose mg/dL)) (16). Renal function defined as 
estimated glomerular filtration rate was calculated with the Modification of Diet in Renal 
Disease (MDRD) equation: 186 * (serum creatinine µmol/L / 88,4)-1.154 x (age)-0.203.
Patients underwent MRI before start and shortly after the last chemotherapy cycle, 
which was approximately three months after start of chemotherapy. 
Blood pressure and heart rate were measured during MRI using a semiautomated 
sphygmomanometer (Dinamap, Critikon, Tampa, Fla, USA).
We have included part of a studygroup from a previous study, describing metabolic 
changes and MRI assessment of hepatic triglyceride content, aortic pulse wave velocity 
and abdominal fat mass in TC patients undergoing curative chemotherapy at 3 and 9 
months after start of chemotherapy (submitted).
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MRI protocol
Left and right ventricular function
Cardiac imaging was performed using a 1.5 Tesla whole-body MRI scanner (Gyroscan 
ACS-NT15; Philips Medical Systems, Best, The Netherlands) after a night fast. The heart 
was imaged in short-axis orientation, using electrocardiographically gated breath-hold 
cine steady-state free-precession sequences as previously described (17). Imaging 
parameters were: repetition time (TR) 3.4ms, echo time (TE) 1.7ms, flip angle (FA) 35º, 
field of view (FOV) 400×320mm, slice thickness 10mm, no slice gap was used. To assess 
LV and RV systolic function, endocardial contours were manually drawn, using MASS® 
software (Medis, Leiden, the Netherlands). LV and RV ejection fraction (EF), stroke 
volume (SV), end-diastolic volume (EDV) and end-systolic volume (ESV) were assessed. 
Epicardial contours of the LV were drawn to calculate LV end-diastolic mass (LVED mass).
To assess LV and RV diastolic function, flow across mitral and tricuspid valve was 
measured using an electrocardiographically gated gradient echo sequence with ve-
locity-encoding. Scan parameters: TR=9.1ms, TE=1.0ms, FA=20º, slice thickness=8mm, 
FOV=350mm2 and matrix=256x256 pixels. Flow velocities in early diastole (E) and at 
atrial contraction (A) were measured and peak flow ratio was calculated (E/A ratio) using 
FLOW® software (Medis, Leiden, the Netherlands). The downslope of the early filling 
phase (E deceleration peak) and LV filling pressures (E/Ea) were calculated (18,19)
Myocardial triglyceride content
Myocardial 1H-MR spectra were obtained as described before (14). A voxel was positioned 
in the myocardial interventricular septum in end-systole. ECG triggering and respiratory 
pencil beam navigator were used during acquisition. Spectra with water suppression 
were acquired with TE=26ms and TR≥3,000ms. 1,024 data points were collected using 
a 1,000-Hz spectral width and averaged over 128 acquisitions. Spectra without water 
suppression with TR=10s and four averages were obtained without changing other 
parameters. Spectroscopic data were fitted using validated software (jMRUI version 2.2, 
Leuven, Belgium) (20). Myocardial TG content was calculated as (amplitude of TG signal/
amplitude water signal) x 100%. 
Pericardial fat
Pericardial fat was quantified as described previously using electrocardiographically 
gated breath-holds with balanced turbo-field echo MR sequence (21). Imaging param-
eters: TR=3.2ms, TE=1.60ms, FA=50°, slice thickness=10mm, FOV=400mm2. The four-
chamber view was analyzed, with the plane of respiratory mitral and tricuspid valves 
as margins. To quantify periventricular fat volume, contours around pericardial fat were 
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drawn manually at end-systole and multiplied by the thickness of the slice. We used 
MASS® for postprocessing. 
Visceral and subcutaneous fat
Visceral and subcutaneous fat volumes were imaged using a turbo spin echo imaging 
sequence (15). During one breath-hold, three consecutive transversal slices of 10mm 
thickness were scanned at the fifth lumbar vertebrae. Imaging parameters: TR=168ms, 
TE=11ms and FA=90º. Contours were drawn around visceral and subcutaneous abdominal 
fat depots using MASS®. Visceral and subcutaneous fat areas of each slice were multiplied 
by the slice thickness to acquire a volume, the volumes of all three slices were summed. 
Statistical Analysis
Statistical analyses were performed using SPSS 17.0 (SPSS Inc.Chicago, Illinois, USA). We 
used two-tailed paired t-tests to compare the two study timepoints, since all data were 
normally distributed. To determine which significantly changed parameters influenced 
the differences of the other cardiac parameters, univariate regression analyses were per-
formed. In these regression analyses the delta of the significantly changed parameter 
(the difference of the parameter before and after chemotherapy) was the independent 
variable and the delta of the cardiac parameter of interest was the dependent vari-
able. In case of a significant influence the corrected difference between baseline and 
follow-up was extracted from the regression analysis. A p-value of <0.05 was considered 
statistically significant. Data are expressed as mean ± standard deviation (sd).
RESULTS
Forty consecutive patients were asked to participate. Twenty-one patients could not 
participate, based on logistic reasons (n=5), refusal or non-eligibility (n=16). These pa-
tients had unwillingness to undergo frequent blood drawings during chemotherapy or 
MRI. Nineteen patients underwent baseline MRI. Five patients missed the follow-up MRI 
due to treatment-related sickness (n=2), study withdrawal (n=2) and treatment-related 
death (n=1). Accordingly, 14 patients were included in data analysis of the present study. 
Three HDL-concentration and 1 insulin-concentration were missing. 
Table 1 shows the tumor characteristics and staging. Table 2 shows the patient 
characteristics at baseline and after chemotherapy. Average age was 35 ± 12 years. 
Average time between the two MRI scans was 2.6 ± 0.5 months. Time between the last 
day of chemotherapy and the MRI after chemotherapy was 18 ± 18 days. Weight, BMI 
and blood pressure did not change during follow-up. Heart rate increased significantly 
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from 64 ± 9 beats/minute to 76 ± 15 bpats/minute (p=0.007). Laboratory parameters at 
baseline and at follow-up are described in Table 2. The Quicki index decreased, from 0.39 
± 0.05 to 0.36 ± 0.05 (p=0.018), reflecting greater insulin resistance. 
Left and right ventricular function
Due to technical difficulties two diastolic LV and RV scans and one systolic RV were missing.
LV EDV and SV significantly decreased, respectively from 192 ± 27 ml to 175 ± 26 
ml (p=0.012) and from 109 ± 18 ml to 95 ±  16 ml (p=0.025) (Table 3). Although LV EDV 
and SV were significantly influenced by the increased heart rate, the difference between 




Combined tumor 8 (57.1)
TNM Tumor Staging; n (%)
Stage II (para-aortic lymph node metastasis) 7 (50)
Stage III (distant metastasis) 7 (50)
Table 2. Patient characteristics at baseline and after chemotherapy
Baseline After chemotherapy 
Systolic blood pressure (mmHg) 123 ± 17 118 ± 11
Diastolic blood pressure (mmHg) 73 ± 11 70 ± 12
Heart rate (beats per minute) 64 ± 9 76 ± 15†
Weight (kg) 83.3 ± 15.5 84.5 ± 18.5
Body Mass Index (kg/m²) 24.4 ± 4.0 24.7 ± 4.6
Cholesterol (mmol/l) 4.7 ± 1.3 5.5 ± 1.5†
Estimated GFR (MDRD), ml/min 102 ± 16 113 ± 18†
HDL (mmol/l) 1.30 ± 0.31 1.36 ± 0.25
LDL (mmol/l) 3.12 ± 1.15 3.74 ± 1.41*
Triglycerides (mmol/l) 1.16 ± 0.60 1.64 ± 1.11
Fasting glucose (mmol/l) 5.1 ± 0.5 5.2 ± 0.6
Insulin (mU/l) 6.2 ± 5.0 9.8 ± 6.8
Quicki index 0.39 ± 0.05 0.36 ± 0.05*
*p<0.05, †p<0.01. Data are mean ± standard deviation.
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baseline and follow-up remained significant after correction for heart rate. The other 
systolic LV parameters did not change after chemotherapy (Table 3). 
LV E/A ratio decreased significantly after chemotherapy from 1.87 ± 0.43 to 1.64 ± 
0.45 (p=0.009). In addition, the atrial peak filling rate increased significantly after chemo-
therapy. The LV E/A ratio and the atrial peak filling rate were not significantly influenced 
by the increased heart rate, thus correction for heart rate was not required. Other LV 
diastolic function parameters did not change after chemotherapy. 




EDV (ml) 192 ± 27 175 ± 126*
ESV (ml) 84 ± 16 80 ±  14
SV (ml) 109 ± 18 95 ±  16*
CO (ml/min) 6816 ± 1112 7050 ± 1160
EF (%) 56.6 ± 5.3 54.3 ± 5.1
Diastolic function
E peak filling rate (ml/s) 657 ± 119 662 ± 122
E deceleration (ml/s²x10-³) 6.3 ± 2.2 6.0 ± 1.7
A peak filling rate (ml/s) 362 ± 78 425 ±  111*
E/A-peak ratio 1.87 ± 0.43 1.64 ± 0.45†
E/Ea 6.8 ± 2.0 6.8 ± 2.0
Right ventricle
Systolic function
EDV (ml) 210 ± 32 196 ± 38*
ESV (ml) 105 ± 29 103 ± 25
SV (ml) 105 ± 14 93 ± 16*
CO (ml/min) 6595 ± 927 6976 ± 851
EF (%) 49.9 ± 6.7 47.9 ± 4.6
Diastolic function
E peak filling rate (ml/s) 415 ± 55 406 ± 60
E deceleration (ml/s²x10-³) 3.7 ± 1.9 3.0 ± 1.2
A peak filling rate (ml/s) 311 ± 57 325 ± 100
E/A-peak ratio 1.37 ± 0.25 1.32 ± 0.31
SV: stroke volume, ED: end-diastolic, ES: end-systolic, CO: cardiac output, EF: ejection fraction, E: early 
diastolic wave, A: atrial diastolic wave, E/Ea: estimated left ventricular filling pressure. *p<0.05, †p<0.01. 
Data are mean ± standard deviation.
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Right ventricular EDV and SV decreased significantly, from 210 ± 32 ml to 196 ± 32 ml 
and from 105 ± 14 (p=0.011) to 93 ± 16 ml (p=0.038) respectively. Both parameters were 
influenced by the increased heart rate. After correction for heart rate the difference be-
tween baseline and follow-up remained statistically significant. All other RV parameters, 
systolic or diastolic, remained unchanged after chemotherapy (Table 3). 
Fat distribution
Myocardial triglyceride content
Baseline and follow-up data from eight myocardial 1H-MR spectra were present. Myocar-
dial triglyceride content did not significantly change after chemotherapy. At baseline TG 
content was 0.69 ± 0.41%, after chemotherapy 0.74 ± 0.35% (p=0.742). 
Pericardial fat
Pericardial fat volume did not change significantly after chemotherapy, 27.0 ± 3.9 ml at 
baseline and 28.1 ± 5.5 ml early after chemo (p=0.343).
Visceral and subcutaneous fat
One waist fat MRI scan was missing. Visceral fat volume increased significantly from 186 
± 125 ml to 227 ± 162 ml (p=0.039), whereas subcutaneous fat volume did not change. 




The main finding of this study is that LV diastolic function is decreased 3 months after 
start of cisplatin-based chemotherapy for TC. Decreased diastolic function was accom-
panied by an unfavorable change in metabolic profile as measured by increased serum 
LDL and total cholesterol and decreased insulin sensitivity. Additionally, visceral fat vol-
ume and visceral/subcutaneous fat ratio increased. Several studies reported increased 
cardiovascular risk factors, increased incidence of cardiovascular disease and diminished 
cardiac function as long-term complications years after treatment with cisplatin-based 
chemotherapy (5,6,13,22,23). Only few studies report on the (sub-)acute cardiovascular 
effects of cisplatin-based chemotherapy (3,8,24). To the best of our knowledge we are 
the first to investigate the acute effects of chemotherapy on cardiac function. Altena 
et al showed deterioration of diastolic heart function assessed with echocardiography 
approximately 10 months after chemotherapy (3). In contrast, we assessed cardiac func-
tion immediately after completion of chemotherapy. 
In the present study the LV E/A ratio decreased, reflecting deterioration in diastolic 
LV function. Since the E/A ratio is load dependent and thus influenced by the filling 
status of the patient, an estimation of LV filling pressure was determined (E/Ea) (18), 
which did not change after chemotherapy. Therefore, the decreased E/A ratio after 
chemotherapy presumably reflects disturbed intrinsic relaxation of the LV, rather than 
change in LV filling pressure. A previous study showed progressive deterioration of 
diastolic heart function, 10 months and 6.9 years after cisplatin-based chemotherapy 
(13). Therefore, acute changes in diastolic function observed in the present study might 
be of prognostic clinical significance. Long-term follow-up data of our patient group 
would be interesting to have some information of the predictive value of these early 
cardiac changes. LV ejection fraction (LVEF), an important parameter of systolic function, 
did not change. Change in LV diastolic function with preserved LVEF after treatment 
with cisplatin-based chemotherapy is in line with previous studies (3,13,23). It is known 
that diastolic dysfunction precedes a decline in systolic function and can be regarded as 
an important prognostic marker of ongoing disease (25,26). For future studies it would 
be interesting to combine echocardiography with cardiac MRI, since previous studies 
suggest that early impairment of systolic function may also be detected using strain 
echocardiography and that it could be predictive of subsequent reduction in LVEF (27). 
Furthermore, in further studies biomarkers such as N-terminal pro-brain natriuretic pep-
tide and troponin I could be determined, because determination of these biomarkers 
may be useful in evaluation of early cardiac toxicity (27). 
Cisplatin can directly injure cardiomyocytes through oxidative stress and mitochon-
drial damage (28). Additionally, cisplatin and bleomycin cause decreased endothelial cell 
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survival and induce apoptosis of endothelial cells in vitro (8). These endothelial changes 
may promote inflammation and atherosclerosis, which can contribute to chemothera-
py-induced vascular toxicity. In addition, endothelial cells at the endocardium play an 
obligatory role in maintaining cardiac function (29). Cisplatin-based chemotherapy may 
also indirectly lead to cardiovascular disease, via increased prevalence of cardiovascular 
risk factors (10,22). Increased prevalence of cardiovascular risk factors, such as dyslipid-
emia, central obesity and insulin resistance, can lead to accelerated atherosclerosis (12). 
In this study the follow-up time is presumably too short for these indirect effects of che-
motherapy to contribute to impaired cardiac function. We could not establish a direct 
relationship between cardiac function and metabolic profile. However, already 3 months 
after start of chemotherapy, we identify a shift to an unfavorable metabolic profile: vis-
ceral fat volume, visceral/subcutaneous fat ratio, LDL-cholesterol and total cholesterol 
were increased and insulin sensitivity decreased. Visceral fat is more deleterious than 
subcutaneous fat and is associated with the metabolic syndrome and cardiovascular 
disease (10,30,31). The metabolic syndrome consists of a cluster of risk factors: dyslipid-
emia, hypertension, central obesity and insulin resistance. This syndrome is associated 
with a long-term increased risk for atherosclerotic disease (10,32), with cardiovascular 
disease as one of the major complications. Via insulin resistance and the concomitant 
increased release of adipokines such as resistin, the metabolic syndrome is associated 
with endothelial dysfunction (33). High C-reactive protein (CRP) levels are associated 
with the metabolic syndrome and endothelial dysfunction (34). In this study we did 
not measure CRP levels unfortunately, but in subsequent studies these levels should be 
measured. A recent study showed that the metabolic syndrome is more prevalent and 
develops at earlier age in TC survivors, treated with cisplatin-based chemotherapy (35). 
Visceral adipose tissue contributes to insulin resistance (30), which is associated with 
decreased cardiac function (25,36,37), even in absence of diabetes mellitus (38,39). In 
the metabolic syndrome, insulin resistance and (visceral) adiposity is correlated with 
myocardial TG accumulation, which might negatively influence cardiac function (40,41). 
In this study we did not find a difference between myocardial TG content before and 
after chemotherapy. The number of measurements of myocardial TG (n=8) content is 
probably too small to draw firm conclusions regarding myocardial TG changes early af-
ter chemotherapy. Another explanation could be that the follow-up period is too short, 
so the oxidative capacity of the myocardium is still sufficient, preventing storage of TG 
in the myocardium.
Diastolic cardiac function progressively deteriorates in TC survivors treated with 
cisplatin-based chemotherapy (13). Subclinical changes in cardiac diastolic function 
may therefore precede late clinical dysfunction. If these early changes are predictive for 
later abnormalities in cardiac function, such changes may be used to monitor patients 
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more specifically. Furthermore, patients treated with cisplatin-based chemotherapy are 
at increased risk of developing an unfavorable cardiovascular-risk profile, which can 
contribute to development of long-term cardiac failure. Accordingly, early detection 
of risk factors for cardiovascular disease is important, as treatment of the unfavorable 
metabolic changes with lifestyle intervention or medication can contribute to an im-
proved long-term prognosis in patients treated with cisplatin-based chemotherapy. 
In conclusion, treatment with cisplatin-based chemotherapy for TC induces acute 
alterations in diastolic cardiac function, paralleled by unfavorable metabolic changes. 
Although the predictive significance of the diastolic cardiac changes for long-term 
cardiovascular morbidity is not clear at present, it seems plausible that they may even-
tually lead to overt cardiovascular disease. As the detrimental metabolic changes can 
contribute to the development of cardiovascular disease, these risk factors should be 
monitored and treated if necessary. 
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Magnetic Resonance Imaging (MRI) of the vessel wall enables determination of 
luminal area, vessel wall thickness, and atherosclerotic plaque characteristics. 
For clinical application, high spatial resolution, deriving from optimal signal-to-noise-
ratio (SNR) and contrast-to-noise-ratio (CNR) is paramount. Vessel wall MRI is expected 
to benefit from higher magnetic field strength. Therefore, the purposes of the present 
study were to develop an ultrahigh field 7T MRI hardware and protocols for vessel wall 
imaging of the carotid artery and to compare quantitative parameters of vessel wall 
morphology and image quality between 3T and 7T MRI.
Methods
18 volunteers (11 males, 7 females, mean age 29 ± 7 yrs) underwent MRI-examinations 
at 7T (using a custom built surface transmit/receive coil of 15 cm diameter) and at 3T 
(using a commercial phased-array coil with two flexible oval elements,14 x 17 cm each). 
MRI of the left common carotid artery vessel wall was performed at 7T with identical 
in-plane resolution as that of 3T MRI (0.46 x 0.46 mm2) providing transverse T1- and 
T2-weighted images. Blinded analysis of morphologic measurements (luminal area and 
vessel wall area), SNR for vessel wall (SNRVW), and the CNR between the lumen and the 
vessel wall (CNR) were compared between 7T and 3T.
Results
Morphologic carotid vessel wall measurements were comparable between 7T and 3T for 
both T1-weighted images (luminal area: intraclass correlation [ICC]: 0.81 and  vessel wall 
area: ICC: 0.84) and T2-weighted images (luminal area: ICC: 0.97 and vessel wall area: ICC: 
0.92). At 7T, SNRVW and CNR were significantly higher as compared to 3T MRI for both T1- 
(p<0.001) and T2-weighted images (p<0.05), with gain factors ranging from 1.3 to 3.6. 
Conclusions
Ultrahigh field 7T MR carotid vessel wall imaging is feasible. 7T MRI of the common 
carotid artery has comparable accuracy for determining luminal area and vessel wall 
area and has improved SNRVW and CNR as compared to 3T MRI. Therefore, ultrahigh field 
7T vessel wall MRI may enable more detailed assessment of plaque morphology.
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INTRODUCTION
Atherosclerosis and its thrombotic complications are the major cause of morbid-
ity and mortality in industrialized countries (1). Early detection of atherosclerosis by 
a non-invasive imaging tool may permit optimized risk stratification, prevention and 
early treatment initiation in patients with various degrees of atherosclerotic disease (2). 
Magnetic resonance imaging (MRI) has emerged as a promising imaging modality for 
studying atherosclerotic disease in humans in vivo (2).
For clinical application, high spatial resolution, deriving from optimal signal-to-
noise-ratio (SNR) and contrast-to-noise-ratio (CNR) is paramount. A new generation of 
ultrahigh field MR scanners operating at 7T has recently become available for clinical 
research (3-6). In many applications ultrahigh field MRI provides higher SNR and CNR, 
which can be used to increase spatial resolution (3,7-9). Therefore, it is expected that MR 
imaging of the carotid vessel wall may potentially benefit from higher magnetic field 
strength.
At present only limited data are available on the feasibility of 7T carotid artery MRI 
(10). To our knowledge, no comparative studies between 3T and 7T imaging of the ca-
rotid artery that investigate vessel morphology measurements (luminal area and vessel 
wall area) and quantification of image quality (SNR and CNR) have been performed..
Therefore, the purposes of the present study were to develop an ultrahigh field 7T 
MRI protocol for vessel wall imaging of the carotid artery and to compare quantitative 
parameters of vessel wall morphology and image quality between 3T and 7T MRI.
METHODS
Patient population and study protocol
Subjects
18 volunteers (11 males, 7 females, mean age 29 ± 7 yrs) were included. None of these 
volunteers had a previous history of cardiovascular disease. Approval from the local 
Medical Ethical Committee was obtained and all volunteers gave written informed 
consent.
General MRI protocol
Subjects underwent MRI examinations of the left carotid artery consecutively on 3T and 
7T MR systems. Scanning was performed using commercial 3T and 7T scanners (Achieva, 
Philips, Best, The Netherlands). The MR systems were equipped with a commercial vec-
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tor ECG module. The electrodes of the vector were placed on the anterior chest wall, 
with two electrodes (lead 1 [L1], L2) in the sternum and one electrode (L3) vertical to L1 
and L2, just below the sternum. In addition one electrode (L4) was placed horizontal to 
L2, on the left thorax in the mid axillary line (5). All subjects were positioned head first 
and in the supine position in the scanner.
Similar protocols were employed at both MR field strengths: After acquisition of a 
three-dimensional (3D) time-of-flight (TOF) sequence to localize the vessel bifurcation, 
sagittal and coronal 2D survey scans of the left carotid artery were acquired. The multi-
contrast carotid vessel wall protocol was planned on these images and consisted of a 
T1 fast gradient echo (FGE) sequence, a T2 turbo spin echo (TSE) sequence and a 3D 
TOF sequence. The scan parameters for the multi-contrast protocol at 3T and 7T field 
strength are given in the next section and an overview is provided in Table 1. The main 
difference between the T1-weighted protocols at 7T and 3T is that 7T black blood (BB) 
preparation was performed using local saturation slabs saturating the inflowing venous 
and arterial blood. In contrast, at 3T BB preparation was performed by a global inversion 
followed by a slice-selective 10 mm thick re-inversion using the body coil. The difference 
in BB preparation between 7T and 3T is due to the absence of a body coil at 7T MR system 
and limited RF coverage of the transmit/receive (T/R) coil at 7T. For the T2-weighted TSE 
protocols no BB prepulse was used. For the TOF images a saturation slab superior to the 
imaging stack was placed at 3T, which was not the case at 7T.













3T 7T 3T 7T 3T 7T
Acquisition sequence FGE FGE TSE TSE FFE FFE
Acquisition mode 2D 2D 2D 2D 3D 3D
Echo time (ms) 3.5 3.7 50 50 3.30 3.6
Repetition time (ms) 12.4 13 2 heartbeats 2 heartbeats 26.20 15
Excitation flip angle (degrees) 45 45 90 90 20 20
FOV (mm) 140 x 140 140 x 140 140 x 140 140 x 140 140 x 140 140 x 140
Resolution (mm2) 0.46 x 0.46 0.46 x 0.46 0.46 x 0.46 0.46 x 0.46 0.46 x 0.46 0.46 x 0.46
Slice thickness/gap (mm) 2; 0.7 2; 0.7 2; 0.7 2; 0.7 2; 0.7 2; 0.7
3T: 3 Tesla magnetic field strengt, 7T: 7 Tesla magnetic field strength, FGE: fast gradient echo, TSE: turbo 
spin echo, FOV: field of view.
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3T MRI acquisition
RF coil
A standard Philips SENSE-flex-M surface coil with two flexible elements of 14×17cm was 
positioned around the neck, as previously described (11). An example of coil positioning 
at 3T and 7T is provided in Figure 1.
Figure 1. A: Standard Philips SENSE-flex-M surface coil (14 x 17 cm) used for the 3T MR acquisition is 
shown. B: Custom-built local surface transmit/receive coil of 15-cm diameter used for the 7T acquisition is 
shown. C: Coil positioning and scanning set-up at 3T MRI. D: Coil positioning and scanning set-up at 7T. 
Survey
The 3T protocol has been previously described (11). In short, two survey scans in sagittal 
and coronal direction were planned on a 3D TOF sequence scout scan.
Multicontrast 3T protocol
Subsequently the multi-contrast 3T protocol, including three sequences were planned 
on the two surveys scans, perpendicular to the course of the common carotid artery in 
both views. Nine contiguous transverse slices of 2-mm thickness, with identical in-plane 
resolution (0.46×0.46mm2), were positioned with the middle of the stack (slice number 
5) at the level of the carotid bifurcation of the left carotid artery. The scan parameters 
were:
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1: 2D BB T1-weighted fast gradient echo (FGE) sequence (scan parameters; field-of-
view (FOV) 140 x 140 mm, 2.0 mm slice thickness, repetition time (TR): 12.41 ms / echo 
time (TE): 3.54 ms / flip angle (FA): 45º, acquired pixel size 0.46 x 0.46 x 2 mm3 , scan 
duration per slice = 1.3 minutes at a typical heart rate of 65 beats per minutes, ECG 
triggering at end-diastole), with up to second order shimming.
2: 2D BB T2-weighted turbo spin echo (TSE) sequence (scan parameters; FOV 140 x 
140 mm, 2.0 mm slice thickness, TR / TE / FA: 2 heartbeats/ 50 ms / 90º, acquired pixel 
size 0.46 x 0.46 x 2 mm3, scan duration per slice = 1.5 minutes at a typical heart rate of 65 
beats per minutes, ECG triggering at end-diastole), using linear shimming.
All BB images were obtained with spectral presaturation inversion recovery (SPIR) fat 
suppression.
3: 3D TOF sequence (scan parameters; FOV: 300 x 300 mm, 2.0 mm slice thickness, TR 
/ TE / FA: 26.20 ms / 3.3 ms/ 20º, acquired pixel size 0.46 x 0.46 x 2 mm3, scan duration per 
slice = 0.4 minutes, acquired without ECG triggering), using linear shimming.
7T MRI acquisition
RF Coil
A 15-cm diameter local surface T/R surface coil was locally developed. The coil was 
segmented into six sections by series connected non-magnetic capacitors (American 
Technical Ceramics). The coil was positioned at the left side of the neck. A cushion was 
used to fix the position of the neck (Figure 1).
Survey Scans
Three FGE sequence survey scans were performed to facilitate planning of the carotid 
vessel wall protocol. A 2D TOF sequence was acquired with the following parameters, 
voxel size = 1 x 1.2 x 5 mm3 and a FOV= 300 x300 mm2, 20 transverse slices, TR/ TE/ FA= 
7.7 ms / 3.7 ms / 20°, during free breathing and without using ECG triggering. The scan 
covered 10 cm of the left carotid artery in 38 seconds scan duration. The second survey 
was planned by defining three points in the center of the common, internal and external 
carotid arteries, which resulted in an oblique sagittal view of the carotid bifurcation. The 
third survey was planned in an oblique sagittal plane. The survey scans were acquired 
using a single slice ECG triggered FGE following parameters: voxel size = 0.46 x 0.47 x 
2.5 mm3, FOV = 140 x 140 mm2, TR /TE / FA = 12 ms / 3.6 ms / 20°, resulting in an average 
scan duration of 56 seconds each.
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Multi Contrast 7T protocol
Subsequently the multi-contrast 7T protocol, including three sequences were planned 
on the two surveys scans, perpendicular to the course of the common carotid artery in 
both views. To ensure registration between 7T and 3T scans, the 7T images, consisting of 
five contiguous transverse slices of 2-mm thickness, with identical in-plane resolution as 
3T (0.46×0.46mm2), were positioned with the top-slice at the level of the carotid bifurca-
tion of the left carotid artery. Acquisition of slices continued in the proximal (caudal) 
direction covering 1.0 cm of the left common carotid artery.
A localized tip angle calibration was performed as a preparation step before the 
actual sequences to calibrate the tip angle in the target region (12), and linear shimming 
was performed in the same region. The scan parameters were:
1: 2D BB T1-weighted FGE sequence (scan parameters: FOV = 140 x 140 mm2, TR / 
TE / FA = 13 ms / 3.7 ms / 45°, scan duration per slice = 1.25 minutes at a typical heart 
rate of 65 beats per minutes). Three saturation slabs (35 mm thickness), consisting of 
pairs of manufacturer provided adiabatic RF pulses, were used (two were placed inferior, 
and one superior and performed interleaved) to suppress flowing blood after which 
8 excitations were performed, with linear profile encoding. The slices were measured 
sequentially and the saturation slabs followed each slice to obtain optimal blood sup-
pression. Acquisitions were triggered to end diastole.
2: 2D BB T2-weighted fat suppressed TSE sequence (scan parameters: FOV = 140 x140 
mm2, TR / TE / FA = 2 heartbeats / 50 ms / 90°, TSE factor = 8, scan duration per slice 
= 1.2 minutes at a typical heart rate of 65 beats per minutes). Cardiac triggering was 
performed at end diastole. Fat suppression was performed using a spectrally selective 
adiabatic inversion pulse to improve the homogeneity of the suppression.
3: 3D TOF sequence (scan parameters: FOV = 140 x 140 mm2, TR / TE / FA = 15 ms / 3.6 
ms / 20°, scan duration per slice = 0.3 minutes, acquired without ECG triggering).
MR analysis
The cross-sectional images of the three sequences for the 3T and 7T scans were matched 
using the bifurcation of the carotid artery as a marker. The 3T and 7T analysis of morpho-
logic measurements and measurements of image quality was performed on one slice of 
the left common carotid artery (4 mm proximal (caudal) to the carotid bifurcation) using 
Vessel MASS software (Leiden University Medical Center, Leiden, the Netherlands) (13).
Morphological measurements were performed by one observer for each individual 
sequence (T1- and T2 sequence for luminal area and vessel wall area; TOF sequence for 
luminal area) for 3T and 7T images (Figure 2). To test intra-observer reproducibility, each 
scan was analyzed twice by one experienced observer (Observer 1, two years of expe-
rience in cardiac MRI). To test inter-observer reproducibility, the scans were analyzed 
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by a second observer (Observer 2, one year experience of cardiac MRI) and data were 
















Figure 2. Example of multi-contrast black-blood images (T1- and T2-weighted) and time-of-flight image 
(TOF) of the left carotid artery obtained on 3T and 7T scanners with identical spatial resolution. A and 
B: T1-weighted, C and D: T2-weighted, E and F: TOF. Asterisks are provided on the transverse slices to 
indicate vessel lumen. 3T: 3-T magnetic field strength, 7T: 7-T magnetic field strength, JV: jugular vein, T1: 
T1-weighted images, T2: T2-weighted images.
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Measurements of image quality (SNR vessel wall (SNRVW) and CNR lumen/wall) were 
performed by one observer (Observer 1) for the T1- and T2 sequences. In addition, 
the SNRVW and CNR were compared between 3T and 7T taking into account the non-
gaussian distribution of the signal close to zero (4). SNR was calculated as SNR= S/σ (14). 
S is the true signal intensity corrected for the noise contribution and is obtained by the 
measured signal (Sm) and the measured background signal (Sn): S = (Sm
2 – Sn
2)1/2. The true 
standard deviation of the noise (σ) depends on the number of receivers. For 7T, when a 
single single receiver is used the measured standard deviation needs to be divided by 
0.655 (11) to obtain σ. Although at 3T two receiver coils were used, the elements are 
spaced sufficiently apart (left and right side of the neck) such that coupling between 
the two is negligible. An identical correction factor was therefore applied to the data 
acquired at 3T and 7T.
CNR was calculated as the difference between vessel wall and lumen SNR: CNR= 
SNR vessel - SNR lumen. Signal intensity from the background noise was sampled by 
a manually drawn region of interest in the corner of each image, devoid of signal and 
artifact. Mean signal intensity ± standard deviation of the vessel wall area and lumi-
nal area were provided by Vessel MASS software (Leiden University Medical Center, 
Leiden, the Netherlands).
Statistical analysis
The correlation between morphologic measurements obtained at 3T and 7T MRI was 
tested with intraclass correlation (ICC) for absolute agreement. ICCs close to 1.0 indi-
cate good agreement between two measurements. The mean differences between 
repeated measurements against the mean value of repeated scans were described by 
Bland-Altman plots (15). For the morphological measurements, both intra-observer 
and inter-observer mean relative errors (MREs) were calculated. For this calculation, 
the absolute difference between two measurements was calculated per volunteer and 
divided by the first measurement, to yield the relative error. Consecutively, the MRE was 
then calculated.
SNRVW and CNR values are expressed as median (interquartile range). Data from 
the different measurements were compared using the Wilcoxon signed ranks test 
for non-parametric paired observations. A p-value <0.05 was considered statistically 
significant.
All statistical analyses were performed using SPSS v. 18.0 (SPSS, Chicago, IL).
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RESULTS
All 18 volunteers underwent successful MRI scanning at the 3T and 7T MR system.
Lumen and vessel wall
Figure 2 illustrates example carotid artery imaging of the left common carotid artery 
from a healthy volunteer at 3T and 7T.
The agreement between 3T and 7T images was calculated using the ICCs. An overview 
of the calculated ICCs and MRE (%) for the luminal area and vessel wall area is provided 
in Table 2. Morphologic carotid vessel wall measurements were comparable between 7T 
and 3T for both T1-weighted images (luminal area: ICC: 0.81, vessel wall area: ICC: 0.84), 
T2-weighted images (luminal area: ICC: 0.97, vessel wall area: ICC: 0.92) and TOF images 
(luminal area: ICC: 0.97).
ln differences, for lumen and vessel wall area between 3T and 7T measurements are 
presented (Bland Altman plots) in Figure 3 for both the T1- and T2-weighted images and 
TOF images. No dependence of the difference vs. the mean was observed.
Furthermore, both intra-observer and inter-observer reproducibility (including ICCs 
and MRE) for lumen- and vessel wall measurements for both the 3T and the 7T acquisi-
tions was calculated (Table 3). No trend for differences was observed for the intra- and 
inter-observer reproducibility between the field strengths.
Table 2. Results of comparison of morphological measurements at matched location between 3T and 7T








T1 luminal area 33.16 (6.5) 31.07 (5.88) 5.8 0.85 (0.65; 0.94)
T1 vessel wall area 17.83 (3.32) 17.17 (3.71) 3.8 0.85 (0.64; 0.94)
T2 luminal area 33.11 (10.15) 33.28 (8.98) 1.8 0.97 (0.91; 0.99)
T2 vessel wall area 16.36 (4.58) 16.62 (4.1) 2.8 0.91 (0.78; 0.97)
TOF luminal area 34.91 (8.39) 34.54 (9.42) 1.5 0.97 (0.91; 0.99)
3T: 3 Tesla magnetic field strength, 7T: 7 Tesla magnetic field strength, T1: T1-weighted images, T2: T2-
weighted images, TOF: time-of-flight, MRE: mean relative error, ICC: intraclass correlation coefficient. 
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Figure 3. Agreement of morphological measurements between 3T and 7T. Bland-Altman plots for luminal 
area and vessel wall area, acquired at 3T and 7T, presented for T1-and T2-weighted images and TOF. 
A and B: T1-weighted, C and D :T2-weighted, E: TOF. 3T: 3 Tesla magnetic field strength, 7T: 7 Tesla 
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SNR and CNR
Measurements of SNRVW and CNR of the left carotid artery at 3T and 7T are presented 
in Figure 4. At 7T carotid vessel wall imaging provided a significant increase in SNRVW 
and CNR for both the T1- (p<0.001) and T2-weighted images (p<0.05). The median gain 
factor for 7T T1-weighted images was 3.6 for SNRVW and 2.8 for CNR. For T2-weighted 
images the median gain factor was 1.4 for SNRVW and 1.3 for CNR. Examples (n=10) of 
T1-weighted images and T2-weighted images obtained at 7T are provided in Figure 5
Figure 4. Comparison of image quality between 3T and 7T. Individual measurements of signal-to-noise 
ratio of the carotid vessel wall (SNRVW) and contrast to noise ratio (CNR) for T1-weighted and T2-weighted 
images 3T and 7T are provided. A and B: T1-weighted, C and D: T2-weighted. Individual median gain factor 
(interquartile range) is provided. SNRVW signal-to-noise-ratio for vessel wall, CNR: contrast-to-noise-ratio, 
3T: 3 Tesla magnetic field strength, 7T: 7 Tesla magnetic field strength.
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DISCUSSION
The present study, directly compares 3T and 7T carotid vessel wall imaging in healthy 
volunteers and demonstrates that in vivo carotid vessel wall imaging, with multi contrast 
protocol is technically feasible at ultrahigh field 7T MR equipped with a custom-built RF 
transmit and receive surface coil. Furthermore, this is the first study comparing mor-
phological measurements and measurements of image quality in a quantitative setting. 
The main findings of the study are: i) 7T BB common carotid vessel wall imaging, at a 
predefined position in the common carotid artery relative to the flow divider, is feasible 
using local saturation slabs, ii) morphologic carotid vessel wall measurements (luminal 
area and vessel wall area) and intra- and inter-observer reproducibility are comparable 
between 3T and 7T, iii) ultrahigh field 7T MRI carotid vessel wall imaging improves SNRVW 
and CNR compared to 3T.
Our study highlights the potential of 7T carotid MR imaging for assessment of carotid 
luminal area and vessel wall area, since accurate delineation of the carotid artery vessel 
T1
T2
A B C D E
D G H I J
A B C D E
D G H I J
Figure 5. Examples of T1-weighted images and T2-weighted images obtained at 7T. A to J, ten examples 
of T1-weighted images and the corresponding T2-weighted images. T1, T1-weighted images; T2, T2-
weighted images.
Carotid vessel wall imaging: 3T versus 7T 195
wall structure is crucial to detect carotid atherosclerosis and atherosclerotic changes of 
the vessel wall over time.
A recent study showed initial in vivo results of imaging of the carotid arteries at 7T in 
three volunteers (10). Estimation of luminal narrowing was performed with high-resolu-
tion magnetic resonance angiography images, with a non-contrast 3D FLASH sequence. 
In addition, proton density and T2-weighted TSE images were used for the analysis of 
the carotid vessel wall (10).
The feasibility of carotid vessel wall imaging at 7T is further confirmed by the present 
study in a larger population, and our data show that the feasibility of analysis of the 
vessel wall also extends to T1-weighted images obtained at 7T.
The present study also provided a comparison of the morphologic measurements 
at 3T versus 7T. In comparison with previous studies on vessel morphology, the agree-
ment on interscan- and inter-observer reproducibility is in the same magnitude as that 
observed at 3T (11,16).
Carotid vessel wall MRI at 7T is of significant interest because it may provide higher 
SNRVW and CNR (3). As a consequence spatial resolution can be improved (8). These 
advances hold potential for more detailed assessment of carotid atherosclerotic plaque 
morphology (17). The present study provides a direct quantitative comparison for SNRVW 
and CNR at 3T and 7T. SNRVW and CNR values at 3T were in the same magnitude as previ-
ously shown by Underhill et al, comparing carotid vessel wall imaging at 1.5T and 3T 
(18). At ultrahigh field strength (7T), improved SNRVW and CNR were observed in our 
study, both for the T1-weighted gradient echo (p<0.001) and for the T2-weighted TSE 
images (p<0.005). T1-weighted images are the cornerstone for identification of carotid 
plaque composition and therefore, the significant gains in image quality with median 
gain factors of 3.6 and 2.8 for SNRVW and CNR respectively, may increase applications to 
improved carotid vessel wall imaging at ultrahigh field strength (19,20).
The improved SNRVW and CNR suggest that 7T MRI is a potential technique to assess 
carotid atherosclerosis in more detail. The vessel wall area is thought to be a surrogate 
marker for atherosclerotic disease and detailed assessment of carotid atherosclerosis 
and plaque morphology permits the assessment of disease burden (21-23) and iden-
tification of vulnerable patients who are at risk of future vascular events (22). A more 
detailed assessment of atherosclerosis may also permit an increased identification of 
changes in the carotid artery vessel wall structure over time and can be used to monitor 
progression of the disease or to monitor intervention (2).
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The following limitations need to be acknowledged. Our study focused on the tech-
nical feasibility of 7T carotid vessel wall imaging of the common carotid artery in a popu-
lation of healthy volunteers, without occlusive plaques or reduced flow. Whether carotid 
vessel wall imaging at 7T MR systems will lead to a better identification of atherosclerosis 
cannot be concluded from the present study and therefore further study is warranted. 
In addition, 7T imaging of the internal and external carotid artery distal to the carotid 
bifurcation was not performed. Therefore, the results of the present study (including the 
observed improvement in image quality at 7T) only relate to one slice of the common 
carotid artery. Further evaluation of the feasibility of carotid vessel wall imaging should 
involve more challenging populations, i.e. patients with extensive carotid plaques, a 
longer trajectory of the carotid artery, bilateral carotid artery imaging and the develop-
ment of dedicated coils at 7T. Indeed, carotid imaging is expected to benefit (in terms 
of penetration depth and image quality) from using more sophisticated transmit array 
coils as is shown in other applications at high field as well (3,6,10). Kraff et al. showed 
that, when using a multi-element T/R coil at 7T it is possible to image both carotid arter-
ies at the same time; however there are still image inhomogeneities present (10). In the 
current study, even though the coverage of the local T/R coil was limited, sufficient RF 
penetration was obtained for adequate visualization of one of the carotid arteries. The 
RF field was sufficiently homogeneous that, with the proper sequence and hardware 
modification, it was possible to achieve the most relevant image contrasts for carotid 
artery imaging (black blood T1-weighted and T2-weigthed images and TOF images). 
Furthermore, although the design of our 7T feasibility study involved a comparison of 
3T and 7T acquisitions under identical conditions, in the future, the parameters of 7T 
imaging sequences need to be optimized for time efficiency.
In conclusion, this study shows our initial experience and feasibility of ultrahigh field 
7T MR carotid vessel wall imaging. Morphologic carotid vessel wall measurements 
were comparable between 7T and 3T. The 7T MR of the common carotid artery showed 
improved SNRVW and CNR compared with 3T MRI. Therefore, ultrahigh field 7T vessel 
wall MRI may permit a more detailed assessment of carotid atherosclerosis and plaque 
morphology.
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The purposes of this study were to test coronary stent safety at 7T cardiovascular 
magnetic resonance (CMR) by determining displacement and heating for cobalt alloy 
stents. Furthermore, to assess initial clinical feasibility of 7T CMR in healthy volunteers 
and patients with cardiovascular disease in the format of a multiple-case presentation. 
Methods
Coronary stents (Cobalt Alloy) ranging from 5-85.8 mm in length were tested for safety 
by measuring magnetically induced displacement and radiofrequency induced heating 
according to standardized American Society for Testing and Material test methods. 
CMR was performed at 7T with various custom-built transmit/receive coils and imag-
ing sequences for evaluation of coronary magnetic resonance angiography, vessel wall 
imaging, systolic and diastolic heart function and myocardial delayed enhancement.
Results
The 7T magnetic field did not induce a force greater than that of gravity on the stents 
and the maximum temperature rise was below 1°C. Preliminary results in the format 
of a multiple-case presentation demonstrated clinical feasibility of 7T CMR in healthy 
volunteers and patients with cardiovascular disease.
Conclusion
7T CMR is safe to perform in patients with cobalt alloy coronary stents (5-85.8 mm in 
length) and clinical CMR at 7T is feasible. Technical challenges have to be overcome 
before routine clinical application becomes possible.
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INTRODUCTION
Cardiovascular magnetic resonance (CMR) is considered the gold standard modality 
for clinical assessment of cardiovascular anatomy, function and myocardial viability (1). 
CMR might benefit from a higher magnetic field strength, because the increased signal 
to noise ratio (SNR) allows higher spatial resolution imaging. This is especially important 
for coronary magnetic resonance angiography (MRA) and vessel wall imaging.
Promising CMR results have been reported in comparative studies using 3T versus 
1.5T (2-5) and 7T versus 3T (6). However, the increased field strength produces a series 
of technical challenges for CMR (2,7). CMR requires robust compensation for heart mo-
tion, breathing motion and field inhomogeneity. Another challenge is acquisition of a 
reliable electrocardiogram (ECG) (8). Snyder et al. showed initial feasibility for CMR at 7T 
(9), with a subsequent study deriving quantitative assessment of functional parameters 
in healthy volunteers (10). To our knowledge, there is only limited data available on the 
feasibility of CMR in patients with cardiovascular disease at 7T. For example, despite re-
cent progress in obtaining human coronary MR images (8) and carotid artery MR images 
(11) at 7T, specific work on vessel wall imaging at 7T is scarce.
Before clinical CMR at 7T can be performed, coronary stent safety has to be determined. 
The static magnetic field of the MR system exerts a force during patient positioning on fer-
romagnetic objects, possibly causing displacement of, for example, coronary artery stents. 
Furthermore, medical implants can potentially interact with the rapidly changing RF field, 
thereby inducing unwanted currents and heating of surrounding tissue. 
Therefore, the first purpose of the present study was to test coronary stent safety 
at 7T MR by determining displacement and heating for cobalt alloy stents ranging in 
length from 5 to 85.8 mm in a worst case scenario. The second purpose was to assess 
initial clinical feasibility of 7T CMR in healthy volunteers and patients with cardiovascular 
disease in the format of a multiple-case presentation.
METHODS
All experiments and scans were performed on a 58 cm clear bore Philips 7 Tesla Achieva 
system (Philips Medical Systems, Best, The Netherlands).
Coronary artery stent safety
Coronary stents (Cobalt Alloy, Medtronic) ranging from 5 to 85.8 mm in length were 
used in this study. The longest stent (85.8 mm) consisted of four separate stents (1x30, 
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1x24 and 2x18 mm), which were combined with a small overlap between two adjacent 
stents. All stents were inflated to obtain an internal diameter of 3 mm.
The magnetically induced displacement force was assessed for each stent size using 
the deflection angle method, according to the procedure described by the American 
Society for Testing and Materials (ASTM) (12). The magnetically induced displacement 
was measured by the angular deflection using a protractor mounted on a stand with the 
zero degree mark at the 6 o’clock position. A stent was hung on the device by a 0.1 mm 
nylon thread. The angular deflection from the vertical was measured for all stent lengths 
with the protractor placed at the position where the magnetic field produces the great-
est magnetically-induced deflection. During all these measurements the air circulation 
in the scanner bore was switched off. 
Measurements of RF-induced heating were performed according to the ASTM Standard 
Test method for measurement of radiofrequency-induced heating on or near passive 
implants (13) with some necessary modifications. A tissue-mimicking phantom (149 mm x 
59 mm x 47 mm) was formulated from 1.55 g/L sodium chloride (NaCl) and 31 g/L hydroxy-
ethylcellulose (HEC) in sterile water. To obtain a gel free of air bubbles the phantom was 
ultrasonicated. The gel was positioned in the 7T scanner room for at least 24 hours prior to 
testing to obtain a transparent gel that was free of bubbles and temperature-stabilized. A 
stent was placed in the middle of the phantom, 2.5 cm from the bottom: this is comparable 
to the depth of a stent in a patient’s body. Two fiber optic temperature probes (Opsens, 
Quebec, Canada) were used to measure the temperature during MRI-induced heating. The 
first temperature probe was positioned at the tip of the stent, the site of maximum heating 
(14), the second was used as a reference and was placed well away from the stent. The 
temperature was measured every 2.1 seconds and the measurements started 30 seconds 
before the MRI heating started and ended 30 seconds after the heating stopped. 
Besides different lengths of stent, the effect of different relative positions of more 
than one stent was investigated. Two stents were used, one with a length of 42.4 mm 
and the other with a length of 19.5 mm. In the first situation, the two stents were placed 
in a straight line with each other. For the second situation, the two stents were placed at 
different angles relative to each other. In the last situation, one stent was placed on top 
of the other stent, forming a T-shape. Temperature measurements were performed in 
the gap between the two stents. The same custom-built quadrature cardiac coil as used 
for the clinical imaging experiments (see later) was used for the heating experiments. 
The phantom was placed with the stent directly below the overlap point of the two 
loops, which is the position of maximum electric field and therefore maximum heating. 
The phantom was tested with the stent both parallel and perpendicular to the main 
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axis of the coil. A multi-slice gradient echo sequence (similar to a cardiac cine-scan) was 
used. By over-riding in software the manufacturer’s signal absorption rate (SAR) limits, 
a time-averaged SAR of 5W/kg was produced, well above the regulatory limit of 2 W/kg. 
Clinical imaging protocols
All studies were conducted according to the principles of the Declaration of Helsinki 
(current version adopted by the 59th WMA General Assembly, Seoul, October 2008), in 
accordance with the Medical Research Involving Human Subjects Act (WMO) and ac-
cording to local guidelines, as specified by the local medical ethical committee. 
The MR system was equipped with a vector ECG module. Electrodes were placed at the 
anterior chest wall: Two electrodes (lead 1 [L1] and L2) at the level of the sternum, one 
electrode (L3) vertical to L1 and L2, just below the sternum, one electrode (L4) horizontal to 
L2, on the left thorax along the mid-axillary line (8). ECG triggering was effective in about 
80% of patients. All subjects were placed in the bore head first and in a supine position. 
Coronary artery MRA
Bright blood coronary MRA of the right coronary artery was performed in a twenty-
three year old female healthy volunteer. A custom-built quadrature two element surface 
transceiver (T/R) coil with two overlapping loops of 18 cm diameter was used. Scout 
images in coronal, transverse and sagittal orientations were used to plan ECG triggered, 
breath-hold transverse cine scout imaging for both determination of the period of 
minimal coronary motion and the volume targeting of the 3D stack in parallel with the 
mid-diastolic right coronary artery (RCA). The RCA was imaged by using a navigator-
gated, vector ECG triggered 3D segmented k-space gradient-echo combined with a 
spectrally selective adiabatic inversion recovery pulse for fat suppression. The in plane 
field-of-view (FOV) was 420 x 270 mm² with a coverage of 30 mm, TR was 4.06 ms, TE 1.32 
ms, FA 15º and voxel size 0.82 x 0.82 x 2.0 mm.
Vessel wall imaging left carotid artery
As described previously a flexible 15-cm diameter local surface T/R surface coil was con-
structed for vessel wall imaging (11). The coil was segmented into six sections by series 
connected non-magnetic capacitors (American Technical Ceramics) and was positioned 
at the left side of the neck. A cushion was used to fix the position of the neck. 
After acquisition of a three-dimensional (3D) time-of-flight (TOF) sequence to local-
ize the vessel bifurcation, sagittal and coronal 2D scout scans of the left carotid artery 
were acquired. The multi-contrast carotid vessel wall protocol was planned on these 
images and consisted of a T1 segmented fast gradient echo (FGE) sequence, a T2 turbo 
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spin echo (TSE) sequence and a 3D TOF sequence. At 7T BB preparation is performed 
using local saturation slabs that saturate the inflowing venous and arterial blood. For the 
T2-weighted TSE protocols no BB prepulse was used. 
Cardiac function
Scout images in coronal, transverse and sagittal orientations are used to plan ECG trig-
gered, breath-hold transverse cine scout imaging, performed using TE 1.7 ms, TR 4 ms, 
FA 15º, and reconstructed pixel size 0.88x0.88 mm. To determine systolic left ventricular 
(LV) volumes, function and mass, the LV was imaged in a short-axis orientation, as 
previously described (15). Endocardial and epicardial LV contours were manually drawn 
in the end-systolic and end-diastolic phases of the short-axis data, using software 
package MASS® (Medis, Leiden, the Netherlands). LV and right ventricular (RV) ejection 
fraction (EF), stroke volume (SV), LV and RV end-diastolic volume (LVEDV/RVEDV), LV/
RV end-systolic volume (LVESV/RVESV) and LV/RV end-diastolic mass (LVED/RVED mass) 
were assessed. Transmitral flow was measured for assessment of LV diastolic function, 
using a velocity sensitivity of 150 cm/s, TE 2.6 ms, TR 4.6 ms, FA 20º, reconstructed pixel 
size 1.5x1.5 mm. Flow velocities in early diastole (E) and at atrial contraction (A) were 
measured and their peak flow ratio was calculated (E/A ratio) using the FLOW® software 
(Medis, Leiden, the Netherlands) (16,17)
Delayed enhancement
Delayed enhancement acquisitions were performed approximately 15 minutes after 
intravenous administration of 0.1 mmol/kg Gadolinium using an inversion-recovery 
turbo-gradient echo sequence, TE 1.06 ms, TR 3.7 ms, FA 15º, reconstructed pixel size 
1.5x1.5 mm. The inversion time was determined with a Look-Locker scan to null the 
normal myocardial signal.
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RESULTS
Coronary artery stent safety
The deflection angle of stents in the length range from 5.0 mm to 85.8 mm varied between 
10° and 17°. The average deflection angle was 13° (Figure 1). The results of the RF induced 
heating are shown in Figure 2. For a stent length between 5.0 and 31.2 mm and between 
58.7 and 85.8 mm the change in temperature, and thus the heating, was very low (max 
0.1°C). However, for stent lengths between 35.2 and 51.7 mm the heating was higher (max 
1.0°C). Overall, an average temperature rise of 0.09 ± 0.28°C (parallel position) and 0.00 ± 
0.06°C (perpendicular position) was found. No large temperature change was found for the 
different relative positions of two stents. The highest temperature change (0.2°C in 6 min) 
was found for two stents that were placed in a straight line with a small gap in-between. 
Figure 2. Total change in temperature for different lengths of stents. Blue bars represent total change in 
temperature at the tip of the stent in parallel orientation with respect to the magnetic field. Purple bars 





















Length of stent (mm)  
Figure 1. Deflection angle of cobalt allow coronary artery stents, measured for length range from 5.0 mm 
to 85.8 mm.
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Cardiovascular MRI – healthy volunteers
(i) Coronary artery MRA
Figure 3 shows a section imaged with a bright blood coronary MRA sequence. Good fat 
suppression and high vessel sharpness enable a clear delineation of the RCA. Furthermore, 
anatomic details of the coronary, such as the conus and side branches, are clearly visible
.
Figure 3. MRA of the right coronary artery (RCA) in a twenty-three-year old healthy female volunteer 
obtained with a bright blood coronary MRA sequence. Several structures can be identified in this image: 
the ostium, conus and a portion of the RCA. Notice the good fat suppression and high vessel sharpness. 
RVOT = right ventricular outflow tract, Ao = aortic root, LV = left ventricle, Sb = Side branch.
(ii) Vessel wall imaging of the carotid artery
In Figure 4 the left carotid artery of a 32 year old healthy male is depicted. The top row 
represents T1-weighted images and the bottom row T2-weighted images.
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Figure 4. Left carotid artery of a thirty-two year old healthy male. The * is centered in the left carotid 
artery, the arrow points to the jugular vein. Top row represents T1-weighted images, bottom row T2-
weighted images.
(iii) Systolic function
Figure 5 shows cardiac cine images of a healthy twenty-nine year old female. Left ven-
tricular, two-chamber, four-chamber and short axis images are shown in end-diastolic 










Figure 5. Cine imaging of a twenty-nine year old healthy volunteer. The upper panels are acquired in 
end-diastole, the lower panels in end-systole. Images A and B depict 2-chamber views, B and E depict  
4-chamber views and images C and F represent the short axis view. RF penetration depth is sufficient to 
assess left ventricular and right ventricular heart function.
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Figure 6 shows more recent results acquired in a healthy twenty-five year old female 
volunteer using a transmit array of eight segmented dipoles (18). Eight custom-built 
transmit/receive switches were interfaced with the dual transmit system via four Wilkin-
son lumped element 1:2 splitters. Note the improved homogeneity of RF penetration 
and increased coverage of the heart in comparison to Figure 5. Improved coverage is 









Figure 6. Recent results from our group in a twenty-five year old healthy female volunteer using a 
transmit array of eight segmented dipoles.  The upper panels are scanned in end-diastole, the lower 
panels in end-systole. Images A and D are 2-chamber views, B and E depict  4-chamber views and images 
C and F represent the short axis view. 
Cardiovascular MRI – clinical cases
(i) Global systolic dysfunction.
In Figures 7 (A) and (B) global systolic dysfunction in a 65 year old male is shown. This 
patient was admitted to the coronary care unit with chest pain and had no previous 
medical history. His ECG showed complete left bundle branch block, and cardiac en-
zymes were negative. In order to rule out coronary artery disease, coronary catheteriza-
tion was performed and no significant coronary artery disease was found. Echocardiog-
raphy showed a dilated left ventricle with severely diminished left ventricular function, 
with a left ventricular ejection fraction (LVEF) of 23% and no significant valvular disease. 
The patient had no clinical signs of infection and detailed history taking revealed no 
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infectious episode in the recent past. Therefore, recent and acute myocarditis was not 
suspected. MRI was performed to assess cardiac function and the etiology of the cardio-
myopathy. Cardiac MRI showed a substantially dilated, globally hypokinetic left ventricle 
with an LVEF of 22%, in concordance with the echocardiographic findings. Panels A and 
B of Figure 7 distinctly show the reduced myocardial contractility. There were no signs 
of focal wall motion impairments. The most probable diagnosis was idiopathic dilated 
cardiomyopathy.
(ii) Systolic dysfunction after right coronary artery infarction
Figures 7 (C) and (D) show the short axis view at end diastole and end systole in a 52 year 
old man with a history of an occluded RCA with collateral filling via the left coronary 
artery. The patient was seen at the outpatient clinic for a second opinion concerning 
treatment of coronary artery disease. He complained of atypical chest pain despite 
appropriate cardiac medication. The echocardiographic window of this patient was 
very poor and therefore 7T MRI was performed to assess cardiac function. MRI showed 
basal, midventricular and apical hypokinesia of the inferior wall. The LV was not dilated 
and function was quantified as follows: end-diastolic volume (EDV) 176ml, end-systolic 
volume (ESV) 87ml, stroke volume (SV) 88ml and LVEF 50%. For further evaluation stress 
myocardial perfusion scintigraphy was performed, showing extensive ischemia in the 
inferior-, septal- and anterior myocardium. Coronary catheterization was performed 
and revealed significant coronary artery disease in all 3 coronary arteries for which the 
patient was treated with coronary artery bypass grafting. 
(iii) Systolic dysfunction after left anterior descending artery infarction
Figures 7 (E) and (F) show regional systolic dysfunction in a patient after partial occlu-
sion of the left anterior descending (LAD) coronary. The patient is a 60 year old male who 
was admitted with acute anterior myocardial infarction and no previous medical history. 
Two hours before admission he experienced chest pain with radiation of pain to his left 
arm. He was transported to the hospital for an emergency percutaneous coronary inter-
vention (PCI). His coronary angiogram showed an occluded ramus descendens anterior 
(RDA) after the 2nd diagonal branch. He received balloon angioplasty of the occlusion 
and a drug eluting stent (Promus 3.5 x 20 mm) was placed in the RDA en coronary blood 
flow was restored. His circumflex- and right coronary artery showed luminal narrowing 
of 30-40%, for which no intervention was required. Patient was admitted to the coro-
nary care unit, was put on medication and recovered quickly. He was discharged after 2 
days and MRI was performed after 6 days to assess LV function and infarct burden. MRI 
showed a global moderate systolic function, with profound midventricular hypokinesia/
akinesia, mainly in the anteroseptal- and anterior wall, expanding to the apex. The apical 
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segment showed dyskinesia compatible with aneurysm development. LV volumes were 









Figure 7. Three different kinds of systolic dysfunction. All images are in short axis orientation. Panel a 
and b reflect global systolic dysfunction, respectively, at end diastole and at end systole. Note impaired 
ventricular contraction comparing A and B, representing low ejection fraction. C and D reflect systolic 
dysfunction after RCA infarction, showing regional akinesia in inferior wall. Panels E and F show focal 
systolic dysfunction in the anteroseptal myocardial region, compatible with a significant coronary artery 
stenosis in the LAD.
(iv) Transmitral flow in diastolic dysfunction
Figure 8 depicts normal and abnormal diastolic heart function, assessed at 7T MRI. The 
flow curve across the mitral valve is shown. The upper panel illustrates normal diastolic 
function in a 33 year old healthy male. The lower panel demonstrates impaired diastolic 
function of a 62 year old male. This patient had diabetes mellitus and was seen at the 
cardiology outpatient clinic for evaluation of stable angina pectoris due to an occluded 
right coronary artery with collateral filling by the left coronary artery. An MRI was per-
formed to assess cardiac function. MRI showed a non dilated left ventricle with basal- 
and midventricular mild septal hypertrophy. Mild hypokinesia was seen basal inferior. 
The E/A ratio was <1 and no regurgitation of the valves was observed. 
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Figure 8. Diastolic function. Upper panel: an example of a normal flow (E>A) pattern across the mitral valve. 
Lower panel: diastolic dysfunction (E<A) in a patient with diabetes mellitus and coronary artery disease. 
(v) Delayed enhancement
The same 60 year old male (Figures 7 E and F), with systolic dysfunction after LAD infarc-
tion, also had signs of transmural delayed enhancement (Figure 9). Delayed enhance-
ment was located at the sites of wall motion abnormalities, in accordance with scar 
tissue related to the myocardial infarction. Note that the posterior wall is too dark to 
reliably assess delayed enhancement in that part of the myocardium, possibly related to 
inhomogeneous distribution of 180 degree inversion flip angles. This is clearly a case in 
which the improved image quality afforded by transmit arrays, as shown in Figure 6, will 
be critical in the future. 
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Figure 9. Transmural delayed enhancement in the anteroseptal myocardial wall. As can be appreciated 
from this figure, image quality is still insufficient to adequately assess scar tissue. 
(vi) Prominent trabecularization.
The final case is a 33 year old man who was seen at the outpatient clinic for evaluation of 
palpitations. He experienced short episodes of fast palpitations of sudden onset without 
syncope. Echocardiography was performed and showed suspicion of non-compaction 
cardiomyopathy. An MRI was performed to assess cardiac anatomy and function. The MRI 
showed prominent trabecularization in the apical inferolateral wall, with normal myocardial 
wall thickness (Figure 10). No criteria for left ventricular non-compaction cardiomyopathy 
were met. LV function was normal, with an LVEF of 57%. Patient is currently in a good 
condition and the palpitations were later attributed to AV nodal re-entry tachycardia.
B A
4 chamber short axis
Figure 10. Prominent trabecularization in a 33 year old male. Panel A shows a 4 chamber view, panel B a 
short axis view at end diastole. The trabeculae are mainly seen in the apical area. 
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DISCUSSION
Coronary artery stent safety
According to the ASTM test method a deflection angle of less than 45 degrees is con-
sidered safe. The force exerted by the magnet is then equal or less than that of gravity. 
For all tested stent lengths the deflection angle was lower than 45 degrees (max. 13 
degrees) and therefore it may be concluded that the 7T MR system did not exert an 
extra force on the stents. In general, the RF induced heating was higher for the parallel 
position (0.09 ± 0.28) compared to the perpendicular position (0.00 ± 0.06). This can be 
explained by the shape of the electric field, which couples more tightly to the test device 
in this orientation. The highest temperature change was found for a stent length of 42.4 
mm (0.93°C in 6 min). Almost no heating was induced in stents longer or shorter than 
42.4 mm, indicating that for this particular stent type the critical length lies around the 
42.4 mm. 
Patients may have multiple stents, depending on the passage or the weak places of 
the blood vessels. This leads to stents inserted close to each other or placed in a certain 
relative position. These stents can interact with each other and together they can un-
dergo an interaction with the RF-field of the MR system. To simulate this, several relative 
positions were tested. Almost no heating was seen. The highest heating (0.20°C in 6 
min) was seen for two stents placed in a straight line with a small gap in-between. The 
heating was probably induced by the largest stent (42.4 mm) because that was found to 
be the critical length. 
A rise of 1°C is generally acceptable in a normal healthy body. The highest increase 
in temperature for stents was 0.93°C. This temperature rise was only found for one stent 
length (42.4 mm). For the other stent lengths the maximal temperature rise was far 
below 1°C (max: 0.35°C). 
These results agree well with those of a recent study which also suggested that, if 
guidelines for local/global SAR are followed, extra RF heating induced by stents may be 
insignificant (19). In that study two non ferromagnetic coronary stent configurations 
with lengths of 40 mm and 27 mm were used to assess the safety of scanning of coronary 
stents at 7T MR. In this study we assessed more stent lengths, ranging from 5 to 85.8 mm. 
Our results therefore add to the existing data on safety of coronary stent scanning at 7T. 
Healthy volunteers and clinical cases
Several previous studies showed that ultrahigh field 7T CMR is feasible (9,10,20), despite 
many technical challenges. Ultrahigh field CMR is very promising (7,21), since the higher 
SNR inherent to higher magnetic field strengths is advantageous for cine CMR. Addition-
ally, the potential of enhanced spatial resolution may lead to advantages for CMR (7).
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MRA has several advantages over coronary computed tomography (CTA) and 
coronary angiography (CAG): it is non-invasive, non-irradiating and the use of a contrast 
agent is not required. At 1.5T, a number of studies on the diagnostic accuracy of MRA 
have proven that proximal coronary artery disease (CAD) can be reliably identified or 
ruled out (22,23). Higher SNR has been reported in MRA of the RCA at 7T when compared 
to 3 T (6). The increased SNR can potentially be used to increase spatial resolution with 
the potential of more accurate detection of significant coronary artery stenosis. 
Besides imaging of coronary arteries, we recently showed that ultrahigh field 7T MR 
imaging also offers potential for imaging of the carotid vessel wall (11). We demon-
strated an improved vessel wall SNR and CNR as compared to 3T MR images for both the 
T1- and T2-weighted images. In the future, this may potentially allow a more detailed 
assessment of carotid atherosclerosis or plaque morphology in patients.
Previous studies showed that assessment of LV volumes, function and mass at 7T agree 
well with 1.5T, which is the accepted reference standard in CMR (10,24). A recent study 
by Suttie et al (25) reported that steady state free precession (SSFP) and fast low angle 
shot (FLASH)  cine imaging  at  7T  is technically feasible and provides valid assessment 
of  LV  volumes and mass compared with CMR  imaging  at  lower, i.e. 1.5T  and  3T,  field 
strengths (25).
Another challenge in the field of CMR is imaging of the right ventricle (RV). The 
non-invasive imaging of function, size and anatomy of the RV is difficult, due to several 
factors, such as the asymmetric and variable shape of the RV, the mainly longitudinal 
systolic contraction, thin myocardial wall and location behind the sternum (26). As for 
LV volumes, function and mass, 1.5T is the golden standard for assessment of the RV. 
However, the accuracy of quantifying for example RV mass and characterization of myo-
cardial tissue remains uncertain. It is important to improve imaging techniques, since 
anatomy and function of the RV are known to be predictors of morbidity and mortality 
in a variety of cardiac diseases, such as arrythmogenic RV cardiomyopathy (27). The 
potential improvements in SNR and thereby spatial resolution at 7T MR could add to 
better imaging quality of RV morphology and function. Recently, the first study on RV 
imaging at 7T was published, showing that cine imaging of the RV is feasible at ultrahigh 
field MRI and achieves image quality comparable to the quality at 1.5T (26). There is little 
literature on assessment of LV diastolic function at ultrahigh field MRI. To our knowledge, 
only one previous study investigated LV diastolic filling on 7T (10). Trans-mitral flow was 
assessed with velocity-encoded (VE) MRI, and a strong agreement between trans-mitral 
stroke volume and E/A ratio at 1.5T and 7T was found. The early and atrial peak filling 
rates displayed a greater, though not significant, variation at 7T versus 1.5T. These results 
show that trans-mitral flow assessment with VE MRI is feasible at 7T.
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In previous publications it has been shown that functional cardiac scans, coronary 
magnetic resonance angiography, and vessel wall imaging are all feasible in humans 
at 7T. In this paper we show that functional and anatomic imaging, even using a simple 
RF coil setup, are useful within a clinical setting, while also highlighting some of the 
current inadequacies, mainly associated with limited RF penetration. Many other groups 
have shown that the use of multi-element transmit arrays can mitigate many of these 
penetration effects. In parallel, Figure 4 shows improved coverage using a transmit ar-
ray of eight segmented dipoles (18). Extensive B1 shimming was not performed, with 
equal phases applied to each segmented dipole, and so image quality may well be 
improved by optimizing the individual phases. Currently, these types of array require full 
characterization in terms of safety, SAR monitoring, before they can be used in “routine” 
clinical practice. The clear improvement in image quality over a single transmit system, 
combined with our demonstration of clinical potential even with the single transmit 
system, point to rapid advancements for clinical application.
In conclusion, 7T cardiovascular MRI is safe to perform in patients with cobalt alloy 
coronary stents ranging from 5 to 85.8 mm. Clinical cardiovascular MRI at 7T is feasible. 
Technical challenges have to be overcome before routine clinical application becomes 
possible. Clinical practice has to prove the benefit of ultrahigh field MRI as compared to 
lower field MRI at 1.5T and 3T.
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The first part of this thesis focuses on assessing end-organ damage in individuals with 
metabolic syndrome and diabetes mellitus using magnetic resonance imaging (MRI) 
and spectroscopy (1H-MRS). We performed cross sectional and intervention studies 
to investigate the contribution of obesity, dietary conditions, metabolic environment 
and exogenous disruptors (chemotherapy) to cardiovascular end-organ damage and 
the reversibility of this damage with a low caloric diet. The effects of interventions, 
dietary as well as non-dietary, were explored using imaging technology. As ethnicity 
is an important aspect of the pathophysiology in diabetes mellitus, we also examined 
the influence of ethnic factors on diabetes mellitus and its complications. The second 
part of this thesis focuses on safety, feasibility and implementation of innovative MR 
techniques at higher field strengths for assessment of cardiovascular disease.
Chapter 2 describes the relationship between left ventricular diastolic function and 
aortic stiffness in patients with type 1 diabetes mellitus (T1DM). T1DM is associated with 
aortic stiffening and with left ventricular (LV) diastolic dysfunction, but the relationship 
between a stiffer aorta and LV diastolic dysfunction is still largely unknown. Pulse wave 
velocity (PWV) is a marker for aortic stiffness and can readily be assessed with velocity-
encoded MRI. Speckle tracking, a relatively new echocardiographic method, is suggested 
to provide a more sensitive evaluation of global LV diastolic function than traditional 
echocardiographic Doppler techniques of mitral inflow. Furthermore, speckle tracking 
strain analysis permits a concise evaluation of left atrial (LA) compliance. PWV, LV and 
LA longitudinal strain were assessed in 41 T1DM patients. It was found that aortic PWV, 
assessed with MRI, is inversely associated with LV diastolic function indices and reduced 
LA compliance, measured with speckle tracking strain analysis in patients with T1DM. 
The more conventional echocardiographic inflow parameters of diastolic dysfunction 
were not associated with PWV. The correlation between aortic stiffness and impaired LV 
diastolic function can be caused by two possible separate mechanisms. First, increased 
aortic stiffness is associated with higher end-diastolic pressure and increased afterload, 
which can directly affect LV diastolic function (1). Secondly, advanced glycation products 
that are generated in the course of DM and cause cross-linking of collagen molecules in 
the myocardium and in vessel walls can simultaneously affect both the myocardium 
and the aortic wall (2). The results of this study suggest that aortic PWV can be used as 
an integrated marker for LV diastolic function and LA compliance in this patient group. 
Further studies are required to assess the potential clinical and prognostic implication of 
these findings. In the future, PWV or the speckle tracking diastolic function parameters 
could potentially be used to assess cardiovascular risk in patients with T1DM, which 
could eventually lead to adjustments in treatment. 
222 Chapter 13
Aortic stiffening may affect multiple end organs by decreasing end-organ perfusion, 
including the brain. 
Although T1DM is not primarily a brain disease, it is associated with brain damage, 
such as cerebral atrophy, white matter hyperintensities and decreased cognitive func-
tioning (3-5). Aortic stiffening may play a central role in the development of brain injury 
(6) and previous studies have shown that aortic stiffness is associated with generalized 
white matter atrophy in T1DM and related systemic diseases (7). In Chapter 3, the as-
sociation between PWV and white matter integrity of the brain is evaluated. Forty-two 
patients with T1DM were studied and PWV was measured using a 1.5 Tesla (T) MRI scan-
ner. Diffusion Tensor Imaging (DTI) is a validated and sensitive technique for detecting 
brain disease with MRI, which, in contrast to conventional methods, enables alterations 
in white matter microstructure to be detected. DTI is a technique that allows early de-
tection of white matter damage, even in regions that appear normal on conventional 
anatomical images. We concluded that aortic stiffness is associated with white matter 
integrity independently of other potential confounders, such as age, gender, mean arte-
rial pressure, body mass index (BMI), smoking, duration of diabetes and HbA1c levels, in 
patients with T1DM. This suggests a vascular contribution to early subtle microstructural 
deficits. Future prospective studies are needed to improve knowledge of the prognostic 
and therapeutic consequences of these microstructural changes in the brain white 
matter. An earlier recognition of microstructural brain damage might lead to earlier or 
more intense treatment, for example of vascular risk factors such as hypertension or 
hypercholesterolemia.
In Chapter 4, the effects of T1DM on cortical gray matter volume are studied. Cortical 
gray matter and the thalamus and hippocampus, two subcortical structures, are affected 
in patients with T1DM. Previous studies on hippocampal and thalamic volumes showed 
reduced volumes in patients with T1DM (8-11). However, no studies have investigated 
in-depth volume loss in gray matter areas other than the hippocampus and thalamus in 
T1DM. Voxel-based morphometry (VBM) is a relatively novel and sophisticated analysis 
technique which can be used to identify subtle gray matter alterations (12). 62 patients 
with T1DM and 62 age- and gender-matched healthy controls underwent MR imaging 
of the brain. Basal ganglia, amygdala, hippocampus and thalamus volumes were as-
sessed with VBM. In this chapter we show that in T1DM patients, volume loss occurs 
in all of these gray matter areas, except for the amygdala. In addition, our results show 
that after correcting for potential confounding factors, the thalamus, hippocampus and 
putamen were still significantly smaller in patients with T1DM. The finding that T1DM 
differentially affects specific gray matter areas is challenging, but difficult to explain. 
Potential differences in the susceptibility of the thalamus, hippocampus and putamen 
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and other graymatter structures to T1DM related factors might be involved. The clinical 
significance and underlying mechanisms remain to be elucidated. 
In Chapter 5, the effects are described of a 16-week (very) low calory diet ((V)LCD) on 
cardiovascular function and ectopic fat depositions in overweight patients with type 2 
diabetes mellitus (T2DM) and coronary artery disease (CAD).
Prolonged caloric restriction in obese patients with T2DM without established coro-
nary atherosclerosis improves myocardial function and leads to a decrease in ectopic fat, 
including myocardial and pericardial fat (13,14). The aim of this study was to evaluate 
whether T2DM patients with CAD also benefit from prolonged caloric restriction. 27 
overweight patients with T2DM and CAD were subjected to a 16-week (V)LCD.
After the diet, substantial beneficial changes in glucoregulation and cardiovascular 
function were found. These improvements were paralleled by reductions in all fat com-
partments, as well as in ectopic fat accumulation in the liver and heart. 
Myocardial triglyceride (TG) accumulation is the net result of excessive free fatty acids 
(FFA) uptake in relation to FFA oxidation. Patients with T2DM have increased myocardial 
TG content (15), which is associated with impaired myocardial function (16). Reducing 
myocardial TG leads to improved cardiac function in uncomplicated T2DM patients (13) 
and our study indicated that this also applies to patients with T2DM and CAD. Moreover, 
we also noted a decrease in pericardial fat. Pericardial fat consists of two layers, i.e., 
epicardial fat and paracardial fat, both of which are associated with insulin resistance, 
T2DM and cardiovascular disease (CVD) (17-20). The effects on pericardial fat observed 
in our study are therefore considered to be beneficial.
A further benefit was the decrease seen in left ventricular (LV) mass and heart rate, 
since both are important predictors for CVD (21,22). The finding that LV ejection frac-
tion (LVEF) increased after the (V)LCD is clinically relevant, as LVEF is one of the most 
important predictors of survival (23). Our study also revealed a decrease in PWV of 0.7 
m/s, indicating a less stiff aorta. Given the fact that PWV increases with 0.7m/s per 10 
years of aging (24), this is a significant improvement. These data show that cardiovas-
cular function and ectopic fat accumulation are susceptible to dietary intervention in 
complicated T2DM, a finding which has important clinical implications. Since T2DM is 
associated with increased cardiovascular risk (25) and CVD is the main cause of death 
in patients T2DM (26,27), the results of this study are clinically relevant and prove that 
dietary interventions, superposed on optimal pharmacological therapy, are worthwhile 
strategies, even in advanced complicated T2DM.
The effects of bariatric surgery on ectopic fat depositions and cardiovascular function 
are described in Chapter 6. Cardiac ectopic fat depositions, i.e. myocardial TG and 
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pericardial fat, are thought to play a role in the pathogenesis of CVD, the main cause of 
death in T2DM patients. While diet-induced weight loss results in a decrease in cardiac 
ectopic fat stores, it is less clear whether this also holds for surgically induced weight loss. 
Myocardial TG, pericardial fat and cardiac function were assessed in 10 obese, insulin-
dependent T2DM patients before and 16 weeks after Roux-en-Y gastric bypass (RYGB) 
surgery. After the surgery, these patients lost a considerable amount of weight and 
showed improvements in glycemic control. The loss of body weight led to a significant 
decrease in visceral and subcutaneous fat depots. Additionally, a substantial reduction 
in ectopic cardiac fat was found, with a differential response of the pericardial fat layers 
after RYGB surgery: although epicardial fat volume was found to have diminished, the 
relative decrease in paracardial fat volume was much higher. Increased epicardial fat 
volume has been associated with insulin resistance, T2DM and CVD (17-20). The role 
of paracardial fat is currently less clear. Some studies have shown that paracardial fat 
is a better predictor of cardiovascular risk than epicardial fat (28). Myocardial TG did 
not decrease and cardiovascular function did not improve after RYGB. These findings 
suggest that weight loss after RYGB in T2DM patients affects paracardial adipose tissue 
differently than epicardial adipose tissue. The clinical implications of these findings have 
yet to be determined. Studies with longer follow-up periods could help determine these 
implications.
Chapter 7 describes the effects of a 5-day high fat high caloric (HFHC) diet on cardiovas-
cular function in young, healthy South Asians and Caucasians. Twelve Dutch South Asian 
and twelve Dutch Caucasian healthy males, matched for age (19-25 years) and BMI (<25 
kg/m2), with a positive family history for T2DM were subjected to a 5-day HFHC-diet, 
consisting of the subject’s regular diet, supplemented with 375 ml of cream per day. 
Cardiovascular function was assessed with MRI. This study shows that young, healthy 
South Asians have smaller cardiac dimensions compared to matched Caucasians, even 
after adjusting for the smaller body surface area (BSA) in South Asians. Furthermore, 
diastolic cardiac function in South Asians is different. In addition, although the ejection 
fraction (EF), a gross parameter of systolic function, was similar between both groups, 
more subtle parameters of systolic function were different. A 5-day HFHC-diet did not 
increase these differences. The South Asians were also shown to have a higher PWV 
at baseline. PWV is a powerful independent predictor of cardiovascular events (29). 
Whether these differences contribute to the higher incidence of CVD in South Asians, 
however, remains to be determined. The 5-day HFHC-diet did not increase the observed 
functional cardiovascular differences between both groups, suggesting that these find-
ings cannot be explained by a different metabolic response to dietary fat consumption 
between both ethnicities at young age.
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In the study described above, the metabolic effects of the HFHC-diet were assessed, 
as well; the results are reported in Chapter 8. Previous studies showed that South 
Asians have high hepatic and intramyocellular lipid content compared to Caucasians 
(30,31). This suggests that South Asians have an impaired mitochondrial fatty acid beta-
oxidation in either skeletal muscle and/or adipose tissue, resulting in ectopic fat deposi-
tion in peripheral tissues, eventually leading to insulin resistance and other metabolic 
dysfunctions (32). South Asians may therefore be less well able to handle a Western-type 
high fat diet than Caucasians.
Recent studies have identified the nutrient and energy-sensing mammalian target of 
rapamycin (mTOR)-pathway as a modulator of both insulin sensitivity and mitochondrial 
function (33,34). We hypothesized that differences in mTOR activity between the two 
ethnicities may underlie or contribute to the increased risk of T2DM in South Asians, 
assuming that alterations in the mTOR-pathway may lead to mitochondrial dysfunction 
and subsequent impaired fatty acid handling. In addition, hepatic and peripheral insulin 
sensitivity, substrate oxidation, abdominal fat distribution and skeletal muscle insulin 
signaling and mitochondrial respiratory-chain content were assessed. As mitochondrial 
dysfunction may be unveiled by high fat load, participants were subjected to a 5-day 
HFHC-diet. The participants underwent a 2-step hyperinsulinemic euglycemic clamp 
with skeletal muscle biopsies and indirect calorimetry both prior to starting and after 
completing a 5-day HFHC-diet. 
This study revealed that a 5-day HFHC-diet is already sufficient to affect insulin-
stimulated non-oxidative glucose disposal in healthy, young, lean South Asians males, 
whereas no diet effect was found in age- and BMI-matched Caucasians, suggesting 
that healthy young South Asians might have an innate impaired metabolic adaptation 
to dietary fat overload. The mTOR-pathway does not seem to be involved, at least not 
in skeletal muscle. These findings might provide new leads for further investigations 
aimed at elucidating the pathogenesis of insulin resistance and T2DM in South Asians. 
For example, it might be interesting to investigate the role of white adipose tissue in the 
impaired glucose handling in South Asians as compared to Caucasians.
Chapter 9 presents the results of a study into the effects of an 8-day VLCD on cardio-
vascular function, ectopic fat distribution and myocardial TG in twelve middle-aged, 
overweight South Asians and twelve age-, sex- and BMI-matched Caucasians. At base-
line South Asians were more insulin resistant than Caucasians. Just as was the case in 
young healthy South Asians and Caucasians, the middle-aged participants exhibited 
smaller cardiac dimensions, despite adjusting for BSA. PWV was higher in the distal 
aorta in South Asian. No difference was seen in systolic and diastolic cardiac function, 
myocardial and pericardial fat between groups. After the VLCD body weight reduced 
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and myocardial TG increased in both ethnicities. Diastolic function had decreased to a 
similar extent in both groups. However, paracardial fat and PWV showed a differential 
effect in response to the VLCD, with a more favorable response observed in Caucasians.
The results of our study show a comparable flexibility of the heart to a VLCD in 
middle-aged overweight and insulin resistant South Asians as compared to age-, sex- 
and BMI-matched but less insulin resistant Caucasians. However, the response of South 
Asians to an 8-day VLCD appears to be less favorable with respect to paracardial fat 
volume and PWV.
Chapter 10 demonstrates that cisplatin-based chemotherapy for testicular cancer 
(TC) induces acute alterations in diastolic cardiac function, paralleled by unfavorable 
metabolic changes. Treatment with cisplatin-based chemotherapy is associated with 
an increased prevalence of cardiovascular risk factors, such as central obesity and 
metabolic disturbances, including dyslipidemia and insulin resistance. Treatment of TC 
with cisplatin, bleomycin and etoposide (BEP) combination chemotherapy is also as-
sociated with acute vascular toxicity and subacute changes in cardiac function (35,36), 
as well as with long-term cardiovascular disease. Little is known about the acute effects 
of cisplatin-based chemotherapy, defined as effects occurring 3 months after the start 
of chemotherapy, on cardiac function, body fat distribution and metabolic parameters. 
Cardiac function, fat distribution and metabolic parameters were assessed in 14 patients 
with TC prior to commencing chemotherapy and shortly after the last chemotherapy 
cycle, approximately three months after the start of the therapy. We showed that treat-
ment with cisplatin-based chemotherapy for TC induces acute alterations in diastolic 
cardiac function, which was accompanied by unfavorable metabolic changes. Although 
the predictive significance of these diastolic cardiac changes for long-term cardiovascu-
lar morbidity is not clear at present, it seems plausible that they may eventually lead to 
overt cardiovascular disease. As the detrimental metabolic changes can contribute to 
the development of cardiovascular disease, these risk factors should be monitored and 
treated if necessary. 
The study in Chapter 11 compares 3T and 7T carotid vessel wall imaging in healthy 
volunteers. MRI of the vessel wall enables determination of luminal area, vessel wall 
thickness, and atherosclerotic plaque characteristics. For clinical application, high spatial 
resolution, deriving from optimal signal-to-noise-ratio (SNR) and contrast-to-noise-ratio 
(CNR) is paramount. In many applications, ultrahigh field MRI provides higher SNR and 
CNR, which can be used to increase spatial resolution (37-40). MR imaging of the carotid 
vessel wall may therefore benefit from higher magnetic field strength. 18 volunteers 
underwent MRI-examinations at 7T (using a custom-built surface transmit/receive coil 
Summary and conclusions 227
of 15 cm diameter) and at 3T (using a commercial phased-array coil with two flexible 
oval elements, each 14 x 17 cm). MRI of the left common carotid artery vessel-wall was 
performed at 7T with the identical in-plane resolution as that of 3T MRI (0.46 x 0.46 mm2) 
providing transverse T1- and T2-weighted images. The results indicate that morphologic 
carotid vessel wall measurements (luminal area and vessel wall area) and intra- and 
inter-observer reproducibility are comparable between 3T and 7T. Furthermore, 7T MRI 
carotid vessel wall imaging improves SNRVW and CNR compared to 3T. 
This chapter highlights the potential of 7T carotid MR imaging for assessment of 
carotid luminal area and vessel wall area, since accurate delineation of the carotid artery 
vessel wall structure is crucial to detect carotid atherosclerosis and atherosclerotic 
changes of the vessel wall over time. 
The increased field strength produces a series of technical challenges for cardiovas-
cular MRI (41,42). Cardiovascular MRI requires robust compensation for heart motion, 
breathing motion and field inhomogeneity. Another challenge is obtaining a reliable 
electrocardiogram (43). Chapter 12 describes the results of a study on coronary stent 
safety at 7T MR by determining displacement and heating for cobalt alloy stents ranging 
in length from 5 to 85.8 mm in a worst-case scenario. Furthermore, it describes the initial 
clinical feasibility of 7T cardiovascular MRI in healthy volunteers and patients with CVD 
in the format of a multiple-case presentation. The results of this study show that 7T car-
diovascular MRI is safe to perform in patients with cobalt alloy coronary stents ranging 
in size from 5 to 85.8 mm and that clinical cardiovascular MRI at 7T is feasible in healthy 
volunteers and in patients with cardiovascular disease. Technical challenges have to be 
overcome before routine clinical application becomes possible. Clinical practice has to 
prove the benefit of ultrahigh field MRI as compared to lower field MRI at 1.5T and 3T.
In conclusion, patients with DM experience cardiovascular complications of their dis-
ease.
Obesity is a major risk factor for developing T2DM, and the increasing prevalence of 
obesity has led to a concomitant increase in the prevalence of T2DM. T2DM is one of the 
most common chronic diseases in the world. The pathogenesis of cardiovascular com-
plications in T2DM is multifactorial, but a major role seems to be attributable to ectopic 
accumulation of TG in skeletal muscle, liver and in and around the heart. Weight loss is 
currently considered the most effective treatment for T2DM. A reduction in ectopic fat is 
thought to be one of the responsible mechanisms for improved insulin sensitivity after 
weight loss (44). However, sustained weight loss is difficult as permanent changes in 
lifestyle are required to prevent the lost weight from being regained. Bariatric surgery is 
228 Chapter 13
another possible treatment for T2DM since it results in massive weight loss and marked 
improvement in glycemic control, or even in remission of T2DM. 
In patients with T1DM, the aorta is stiffer as compared to healthy volunteers and 
this is correlated with LV diastolic function and white matter brain integrity. T1DM also 
influences gray matter volume. 
Patients with T2DM have an increased risk of mortality due to CVD. We showed that 
even in patients with T2DM and CAD a 16-week (V)LCD can improve cardiovascular func-
tion and ectopic fat distribution. This highlights the importance of dietary interventions 
in this patient group and indicates that the cornerstone of treatment remains weight 
loss. Since the prevalence of overweight/obesity and concomitant T2DM is reaching 
epidemic proportions, the main focus should be on the prevention of obesity. In ad-
dition to the results of the 16-week (V)LCD study, a study in T2DM patients before and 
16 weeks after bariatric surgery showed a more pronounced reduction of paracardial 
fat, compared to epicardial fat. The implications of this finding need to be elucidated in 
future studies. 
Furthermore, the studies in this thesis have shown that, already at a young age, there 
are differences in cardiac dimensions and function between South Asians and Cauca-
sians. In addition, a HFHC-diet impairs insulin sensitivity in young, lean, healthy South 
Asians but not in Caucasians. The ectopic fat distribution is the same in South Asians 
and Caucasians, both in young and in middle-aged subjects. However, paracardial fat 
and PWV showed a differential response to a VLCD, with a more favorable response in 
Caucasians. Our findings contribute to a greater understanding of the increased risk of 
CVD and T2DM in South Asians. Nevertheless, more studies need to be performed to 
investigate and hopefully better understand the mechanisms behind this increased risk. 
Finally, this thesis describes the results of the feasibility of carotid vessel wall imaging 
performed at 7T. Furthermore, data on coronary stent safety at 7T and initial clinical 
feasibility of cardiovascular MRI in patients with cardiovascular disease are presented.
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Wereldwijd neemt de prevalentie van overgewicht en obesitas snel toe. Het aantal men-
sen met overgewicht is verdubbeld sinds 1980. In 2008 waren er wereldwijd meer dan 
1.4 miljard mensen met overgewicht (BMI ≥ 25 kg/m2), waarvan er 500 miljoen mensen 
zelfs ernstig overgewicht (obesitas, BMI ≥ 30 kg/m2) hadden. Geschat wordt dat deze 
aantallen in 2030 verder toegenomen zijn tot 2.2 miljard mensen met overgewicht, 
waarvan 1.1 miljard met obesitas. 
Diabetes mellitus (DM) is een ziekte waarbij de glucoseregulatie in het lichaam 
verstoord is. Insuline is een hormoon dat gemaakt wordt in de alvleesklier en het is van 
belang voor het reguleren van de glucoseconcentratie in het bloed. Bij gezonde mensen 
zorgt insuline ervoor dat te hoge glucosespiegels weer omlaag gaan, doordat insuline 
onder andere de opname van glucose in de perifere weefsels stimuleert. Diabetes is een 
van de meest voorkomende chronische ziektes ter wereld. Er zijn meerdere types DM, 
de onderzoeken beschreven in dit proefschrift betreffen type 1 en 2. Type 1 diabetes 
mellitus (T1DM) is de variant die al op jonge leeftijd ontstaat en niet geassocieerd is met 
overgewicht. Daarentegen is overgewicht wel een belangrijke risicofactor voor type 2 
diabetes mellitus (T2DM), en het is dus niet verwonderlijk dat tegelijk met de prevalen-
tie van overgewicht ook de prevalentie van T2DM toeneemt. De geschatte prevalentie 
T2DM in 2030 is tussen de 4.4% en 6.4%, wat aangeeft hoe groot het probleem is voor 
de volksgezondheid. DM heeft negatieve effecten op bijna alle weefsels en organen in 
het lichaam. Bekende complicaties van zowel T1DM als T2DM worden gezien in hart en 
bloedvaten, het (centrale) zenuwstelsel, de nieren en de ogen (‘eindorgaanschade’). 
De pathogenese van T2DM is nog niet geheel opgehelderd, maar is in ieder geval 
multifactorieel. Bij T2DM is er sprake van een verminderde functie van de cellen in de 
alvleesklier die insuline produceren, de bètacellen. Tevens is er een verminderde gevoe-
ligheid van de weefsels voor insuline, wat ook wel insulineresistentie wordt genoemd 
en leidt tot verhoogde glucosespiegels. Dit wordt deels genetisch bepaald. Zo hebben 
bepaalde etniciteiten, zoals Hindostanen, een verhoogd risico op T2DM. Bij overgewicht 
neemt de hoeveelheid vetweefsel toe. Teveel vetweefsel veroorzaakt een chronische 
staat van laaggradige ontsteking, wat weer kan leiden tot T2DM. Ook ectopische vetsta-
peling speelt een belangrijke rol in de pathogenese van T2DM. Ectopische vetstapeling 
is vetstapeling (triglyceriden (TG) stapeling) in organen die niet primair bedoeld zijn 
voor de opslag van vet, zoals het hart, de lever en de skeletspieren. Door de opslag van 
vet in deze weefsels, zijn ze minder gevoelig voor insuline. Ook exogene factoren kunnen 
de glucosehuishouding verstoren door de gevoeligheid voor insuline te verminderen. 
Hierbij kan gedacht worden aan exogene toxiciteit door bijvoorbeeld chemotherapie.
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Patiënten met DM hebben een verhoogd risico op hart- en vaatziekten. Ongeveer 
50% van de patiënten met T2DM sterft aan hart- en vaatziekten. De pathogenese van de 
cardiovasculaire complicaties is ingewikkeld, maar ook hier lijkt een belangrijke rol toe 
te schrijven aan ectopische vetstapeling. 
Meer dan 80% van de T2DM patiënten heeft overgewicht en daarom blijft gewichts-
vermindering de hoeksteen van hun behandeling. Gewichtsverlies kan bewerkstelligd 
worden door middel van diëten, met lichamelijke activiteit of met behulp van bariatri-
sche chirurgie. Daarnaast bestaat de behandeling van T2DM uit glucose-, lipiden- en 
bloeddruk verlagende medicatie. Behandeling is gericht op het verlichten van de 
klachten en het voorkomen van complicaties. 
Magnetic Resonance Imaging (MRI) technieken zijn uiterst geschikt om de anatomie 
van hart en bloedvaten en de hersenen goed in beeld te brengen. Tevens kunnen ecto-
pische vetdeposities met behulp van MRI technieken goed in beeld worden gebracht. 
De toenemende incidentie van T2DM wordt, ook in Westerse landen, met name 
gezien bij mensen van Zuid Aziatische afkomst. De wereldbevolking bestaat voor een 
vijfde uit Zuid Aziaten. In Nederland noemen we deze bevolkingsgroep, die oorspron-
kelijk afkomstig is van het Indiase subcontinent (India, Pakistan, Bangladesh, Nepal en 
Sri Lanka) Hindostanen. Niet alleen is de prevalentie van T2DM hoger bij Hindostanen, 
maar T2DM ontstaat bij hen op jongere leeftijd en bij een lager lichaamsgewicht in 
vergelijking tot blanke Kaukasiërs. Bovendien verloopt de ziekte vaak ernstiger bij Hin-
dostanen. Daarnaast hebben Hindostanen een verhoogd risico op hart- en vaatziekten 
in vergelijking tot blanke Kaukasiërs. De gemiddelde leeftijd van een eerste hartinfarct 
is bij Hindostanen lager en de mortaliteit van hart- en vaatziekten is hoger. Een goede 
verklaring hiervoor is nog niet gevonden en is een onderwerp van veel wetenschap-
pelijk onderzoek.
Het doel van dit proefschrift is het in beeld brengen en onderzoeken van eindor-
gaanschade bij mensen met het metabool syndroom en DM door middel van MRI. 
Bovendien worden de veiligheid, uitvoerbaarheid en implementatie van innovatieve 
MRI technieken met hogere veldsterktes voor het onderzoeken van cardiovasculaire 
ziekten geëvalueerd. We hebben cross-sectionele en interventie studies uitgevoerd 
om te onderzoeken wat de invloed is van overgewicht, dieet en exogene invloeden 
(chemotherapie) op cardiovasculaire eindorgaan schade. Tevens onderzochten we de 
omkeerbaarheid van deze cardiovasculaire schade met dieetinterventies. De invloed 
van etniciteit op DM (gericht op Hindostanen) en de complicaties daarvan werden ook 
onderzocht in dit proefschrift. 
Hoofdstuk 2 beschrijft de relatie tussen de diastolische functie van de linker ventrikel 
(LV) en de stijfheid van de aorta in patiënten met T1DM. T1DM is geassocieerd met een 
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stijvere (minder elastische) aorta en met diastolische disfunctie van de LV. Of er een re-
latie is tussen een stijvere aorta en LV diastolische disfunctie is echter niet bekend. Pulse 
wave velocity (PWV) is een indicator voor aorta stijfheid en is een goede onafhankelijke 
voorspeller voor hart- en vaatziekten. PWV kan goed gemeten worden met behulp van 
MRI technieken. 'Speckle tracking' is een relatief nieuwe echocardiografische methode 
die globale LV diastolische functie beter kan vaststellen dan traditionele Doppler echo-
cardiografie van de mitralisklep. Bovendien kan met speckle tracking de compliantie 
van het linker atrium (LA) goed worden geëvalueerd. Met speckle tracking kan de strain 
van het LV en het LA worden bepaald. Strain is een maat voor snelheid van deformatie 
van het myocardweefsel. De PWV, LV en LA longitudinale strain werden bepaald bij 41 
patiënten met T1DM. Deze studie toont aan dat een hogere PWV in de aorta, gemeten 
met MRI, geassocieerd is met verminderde LV diastolische functie en LA compliantie, 
gemeten met speckle tracking in patiënten met T1DM. De meer conventionele echocar-
diografische instroom parameters van diastolische disfunctie waren niet geassocieerd 
met PWV. De correlatie tussen een stijvere aorta en een verminderde diastolische functie 
kan door twee mogelijke mechanismen verklaard worden. Ten eerste kan de verhoogde 
aorta stijfheid direct de LV diastolische functie beïnvloeden door hogere eind-diastoli-
sche druk en verhoogde afterload. Ten tweede kunnen de 'advanced glycation products' 
(AGEs) die worden gevormd bij diabetes, cross linking van collageen moleculen in het 
myocard en in vaatwanden veroorzaken. AGEs zijn eiwitten of lipiden die beschadigd 
zijn na blootstelling aan hoge glucoseconcentraties, zoals bij patiënten met DM Deze 
AGEs kunnen de stijfheid van zowel het myocard als van de aortawand beïnvloeden. De 
resultaten van deze studie suggereren dat de PWV van de aorta gebruikt kan worden 
als een geïntegreerde marker voor LV diastolische functie en LA compliantie in deze 
patiëntengroep. Vervolgstudies zijn nodig om de klinische en prognostische implicaties 
van deze bevindingen te onderzoeken. In de toekomst kunnen PWV of de diastolische 
functie parameters verkregen met speckle tracking mogelijk gebruikt worden om een 
inschatting van het cardiovasculaire risico te maken bij patiënten met T1DM. Dat zou 
mogelijk kunnen leiden tot veranderingen in de behandeling van deze patiënten. 
Toegenomen stijfheid van de aorta kan invloed hebben op de perfusie van verschillende 
eindorganen, waaronder de hersenen. Alhoewel T1DM niet een primaire hersenaan-
doening is, is T1DM wel geassocieerd met hersenschade, zoals cerebrale atrofie, witte 
stof afwijkingen en verminderd cognitief functioneren. Mogelijk speelt toegenomen 
stijfheid van de aorta een rol in het ontstaan van hersenschade. Eerdere studies heb-
ben aangetoond dat stijfheid van de aorta geassocieerd is met gegeneraliseerde witte 
stof atrofie in patiënten met T1DM. In hoofdstuk 3 wordt de associatie tussen PWV van 
de aorta en witte stof integriteit van de hersenen geëvalueerd. Bij 42 patiënten met 
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T1DM werd de PWV van de aorta gemeten met een 1.5 Tesla (T) MRI. Diffusion Tensor 
Imaging (DTI) is een gevalideerde en sensitieve techniek om hersenschade op te sporen 
met MRI. In tegenstelling tot conventionele methoden, kunnen met DTI veranderingen 
in de microstructuur van de witte stof opgespoord worden. DTI maakt het mogelijk 
om witte stof schade vroeg op te sporen, zelfs in gebieden die er normaal uitzien op 
conventionele anatomische opnames. We stelden vast dat aorta stijfheid geassocieerd 
is met witte stof integriteit, onafhankelijk van leeftijd, geslacht, gemiddelde arteriële 
polsdruk, BMI, roken, ziekteduur en HbA1c waarden bij patiënten met T1DM. Dit wijst 
op een vasculaire component van vroege subtiele microstructurele beschadigingen. 
Prospectieve studies zijn nodig om de prognostische en therapeutische consequenties 
van deze microstructurele veranderingen in de witte stof van de hersenen vast te 
stellen. Het eerder ontdekken van microstructurele hersenschade, kan leiden tot een 
vroegere of intensievere behandeling, bijvoorbeeld van vasculaire risicofactoren zoals 
hypertensie of hypercholesterolemie.
In hoofdstuk 4 hebben we de gevolgen van T1DM op het volume van de corticale grijze 
stof bestudeerd. Corticale grijze stof en de thalamus en hippocampus, twee subcorticale 
structuren, kunnen aangedaan zijn bij patiënten met T1DM. Eerdere studies toonden 
verminderde volumes van hippocampus en de thalamus bij patiënten met T1DM. Er is 
echter beperkt onderzoek gedaan bij patiënten met T1DM naar volume verlies in grijze 
stof gebieden, anders dan de hippocampus en de thalamus. Voxel-based morphome-
try (VBM) is een relatief nieuwe en geavanceerde analyse techniek, waarmee subtiele 
grijze stof veranderingen vastgesteld kunnen worden. Bij 62 patiënten met T1DM en 
62 op leeftijd en geslacht gematchte gezonde controles werd een MRI van de hersenen 
gemaakt. Volumes van de basale ganglia, amygdala, hippocampus en thalamus werden 
onderzocht met VBM. In dit hoofdstuk tonen we aan dat patiënten met T1DM volume 
verlies hebben van al deze grijze stof gebieden, met uitzondering van de amygdala. 
Bovendien laten onze resultaten zien dat na correctie voor andere factoren (waaronder 
leeftijd, geslacht, roken, BMI en hypertensie), de thalamus, hippocampus en putamen 
nog steeds significant kleiner zijn bij patiënten met T1DM. Een verklaring voor het feit 
dat T1DM geen uniforme invloed heeft op de verschillende grijze stof gebieden is niet 
direct voor handen. De klinische relevantie en onderliggende mechanismen moeten 
nog worden opgehelderd.
In hoofdstuk 5 worden de effecten besproken van een 16 weken durend (zeer) laag ca-
lorisch dieet ((Z)LCD) (~450-1000kcal/dag) op de cardiovasculaire functie en ectopische 
vetdeposities bij patiënten met overgewicht, T2DM en coronairlijden. Eerdere studies 
hebben uitgewezen dat langdurige calorische restrictie in patiënten met overgewicht 
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en T2DM zonder coronairlijden leidt tot verbetering van de myocardiale functie en 
vermindering van ectopisch vet, waaronder myocardiaal en pericardiaal vet. Het doel 
van onze studie was om te onderzoeken of patiënten met overgewicht en T2DM met 
coronairlijden ook baat hebben bij een 16 weken durend (Z)LCD. 27 patiënten met 
overgewicht, T2DM en coronairlijden volgden 16 weken een (Z)LCD. Na het dieet werd 
een substantiële verbetering van de glucoregulatie en van de cardiovasculaire functie, 
gemeten met MRI, gevonden. Deze verbeteringen gingen gepaard met reductie van 
de volumes van alle vetcompartimenten en van ectopische vet accumulatie in de lever 
en het hart. Myocardiale TG accumulatie is het netto resultaat van overmatige opname 
van vrije vetzuren in relatie tot de oxidatie van vrije vetzuren. Patiënten met T2DM 
hebben een toegenomen stapeling van TG in het myocard. Dit is geassocieerd met een 
verminderde myocardiale functie. Vermindering van TG in het myocard resulteert in een 
verbetering van de hartfunctie in patiënten met ongecompliceerde T2DM en volgens 
de huidige studie ook bij patiënten met T2DM en coronairlijden. Bovendien vonden we 
een afname van pericardiaal vet. Pericardiaal vet bestaat uit twee lagen, epicardiaal en 
paracardiaal vet. Toegenomen epicardiaal vet volume is geassocieerd met insulineresis-
tentie, T2DM en hart- en vaatziekten. De rol van paracardiaal vet is momenteel minder 
duidelijk. Sommige studies hebben aangetoond dat paracardiaal vet een betere predic-
tor is voor cardiovasculair risico dan epicardiaal vet. Om deze redenen beschouwen we 
de reductie van pericardiaal vet in deze studie als gunstig. LV massa en de hartfrequentie 
verminderden, wat een positief effect is, aangezien beide belangrijke voorspellers zijn 
van hart- en vaatziekten. Daarnaast nam de LV ejectiefractie (LVEF) toe na het (Z)LCD, 
wat klinisch relevant is, omdat de LVEF een van de belangrijkste voorspellers van over-
leving is. Ook werd een verlaging van de PWV van de aorta van 0.7m/s gevonden, wat 
wijst op een minder stijve aorta. Aangezien PWV met elke 10 jaar ouder worden 0.7m/s 
toeneemt, is de afname van PWV in deze studie een significante verbetering. Deze 
data tonen aan dat cardiovasculaire functie en ectopische vet accumulatie gevoelig 
zijn voor dieetinterventies in gecompliceerde T2DM en dat heeft belangrijke klinische 
implicaties. Aangezien T2DM geassocieerd is met een verhoogd cardiovasculair risico 
en hart- en vaatziekten de belangrijkste doodsoorzaak zijn in patiënten met T2DM, 
zijn de resultaten van deze studie klinisch relevant. Tevens bewijzen de resultaten dat 
dieetinterventies, naast optimale farmacologische therapie, nuttig zijn, ook in patiënten 
met T2DM met coronairlijden. 
De effecten van bariatrische chirurgie op ectopische vetdeposities en cardiovasculaire 
functie worden beschreven in hoofdstuk 6. Cardiale ectopische vetdeposities, te weten 
myocardiaal en pericardiaal vet, spelen een rol in de pathogenese van hart- en vaatziek-
ten. Gewichtsverlies door dieetinterventies resulteert in een afname van het cardiale 
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ectopische vet, maar het is onduidelijk of dit ook geldt voor gewichtsverlies na baria-
trische chirurgie. Myocardiale TG accumulatie, pericardiaal vet en hartfunctie werden 
onderzocht bij 10 patiënten met overgewicht en insuline-afhankelijke T2DM voor en 16 
weken na een Roux-en-Y gastric bypass (RYGB) operatie. Na de operatie vielen de pati-
enten veel af en er was sprake van een verbeterde glucoregulatie. Het gewichtsverlies 
ging gepaard met een afname van visceraal en subcutaan vet. Daarnaast werd na RYGB 
een substantiële afname in het ectopische cardiale vet gevonden. In deze studie nam 
het epicardiale vet volume af, maar de relatieve afname in het paracardiale vet volume 
was veel hoger. 
De myocardiale TG accumulatie nam niet af en de cardiovasculaire functie verbeterde 
niet na RYGB. Deze bevindingen suggereren dat gewichtsverlies na RYGB in patiënten 
met T2DM andere effecten heeft op paracardiaal vet weefsel dan op epicardiaal vet 
weefsel. De klinische implicaties van deze bevindingen moet nog vastgesteld worden. 
Hiervoor dienen studies met langere follow-up duur te worden uitgevoerd. 
Zoals eerder genoemd, hebben Hindostanen een hoger risico op hart- en vaatziekten 
dan blanke Kaukasiërs. Het is niet bekend of er reeds op jonge leeftijd verschillen in 
cardiale dimensies en/of cardiovasculaire functie zijn tussen de etniciteiten. Het 
verhoogde risico op hart- en vaatziekten zou kunnen samenhangen met een ander 
metabolisme of andere verdeling van ectopische vetdeposities. In Hoofdstuk 7 staan 
de effecten van een 5 dagen durend hoog vet hoog calorisch (HVHC) (~3775kcal/dag) 
dieet op cardiovasculaire functie beschreven bij jonge, gezonde Hindostanen en blanke 
Kaukasiërs. Met deze studie wilden wij onderzoeken of er een verschil is in cardiale 
dimensies en cardiovasculaire functie tussen jonge Hindostanen en blanke Kaukasiërs 
en of er een andere respons is op een hoog vet dieet. Twaalf Nederlandse Hindostanen 
en 12 Nederlandse Kaukasische gezonde mannen, gematcht voor leeftijd (19-25 jaar) 
en BMI (<25 kg/m2), met een positieve familie geschiedenis voor T2DM, ondergingen 
een 5 dagen durend HVHC dieet, bestaande uit het normale dieet aangevuld met 375 
ml slagroom per dag. De cardiovasculaire functie werd gemeten met behulp van MRI. 
Deze studie toont aan dat jonge, gezonde Hindostanen kleinere cardiale dimensies 
(afmetingen) hebben, vergeleken met gematchte blanke Kaukasiërs, zelfs na correctie 
voor hun kleinere lichaamsoppervlakte. Ook is de diastolische hartfunctie van Hindos-
tanen anders, de cardiale relaxatie is verlengd in Hindostanen. Hoewel de ejectie fractie 
(EF), een grove parameter voor systolische functie, gelijk was binnen de twee groepen, 
waren meer subtiele parameters van systolische functie verschillend tussen beide 
groepen, wijzend op een verlengde cardiale contractie in Hindostanen. Een 5 dagen 
HVHC dieet vergrootte deze verschillen niet. Hindostanen hadden een hogere PWV 
voor start van het dieet. Na het dieet was er geen significant verschil meer tussen de 
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PWV in beide etniciteiten. PWV van de aorta is een krachtige onafhankelijke voorspeller 
van cardiovasculaire events. Of deze verschillen bijdragen aan de hogere incidentie van 
hart- en vaatziekten in Hindostanen moet nog worden vastgesteld. Het 5 dagen HVHC 
dieet vergrootte de gevonden verschillen in cardiovasculaire functie niet. Dit suggereert 
dat onze bevindingen niet verklaard kunnen worden door een verschillende metabole 
respons op vet in de voeding tussen de twee etnische groepen op jonge leeftijd.
In de hierboven beschreven studie werden tevens de metabole effecten van het HVHC 
dieet geëvalueerd; deze resultaten worden beschreven in hoofdstuk 8. Eerdere studies 
tonen aan dat Hindostanen hogere vet waarden hebben in de lever en spieren dan blan-
ke Kaukasiërs. Dit kan erop wijzen dat Hindostanen een slechtere mitochondriële vrije 
vetzuur bèta-oxidatie hebben in skeletspier en/of vetweefsel, waardoor er ectopische 
vetdepositie plaatsvindt in perifere weefsels, uiteindelijk leidend tot insulineresistentie 
en andere metabole disfuncties. Hindostanen zouden daardoor mogelijk minder goed 
in staat zijn om het Westerse hoog vet dieet te verwerken dan blanke Kaukasiërs.
Recente studies hebben de 'nutrient and energy-sensing mammalian target of rapa-
mycine (mTOR)-pathway' aangemerkt als modulator van zowel insuline gevoeligheid als 
mitochondriële functie. Onze hypothese was dat verschillen in mTOR activiteit tussen 
de twee etniciteiten mogelijk ten grondslag liggen of bijdragen aan het verhoogde 
risico op T2DM in Hindostanen. Hierbij gingen wij ervan uit dat veranderingen in de 
mTOR-pathway kunnen leiden tot mitochondriële disfunctie en de daarop volgende 
slechtere verwerking van vrije vetzuren. Daarnaast werden gevoeligheid van de lever 
voor insuline en perifere insuline gevoeligheid, substraat oxidatie, abdominale vetver-
deling, insuline verwerking in de skeletspier en mitochondriële functie onderzocht. 
Omdat mitochondriële disfunctie mogelijk aan het licht gebracht kan worden door 
hoge vet belasting, ondergingen de deelnemers een 5 dagen durend HVHC dieet. Ze 
ondergingen een 2-staps hyperinsulinemische euglycaemische clamp met biopten van 
de skeletspier en indirecte calorimetrie voor en na het dieet. De hyperinsulinemische 
euglycaemische clamp wordt gezien als de gouden standaard voor het vaststellen van 
insulinegevoeligheid.
Deze studie toont aan dat een 5 dagen HVHC dieet al voldoende is om insu-
line gestimuleerde non-oxidatieve glucose verwerking te beïnvloeden in jonge, slanke 
Hindostanen, terwijl geen effect van het dieet werd waargenomen in leeftijd en BMI 
gematchte blanke Kaukasiërs. Dit suggereert dat jonge gezonde Hindostanen mogelijk 
een aangeboren verminderde metabole adaptatie voor hoge vetbelasting in het dieet 
hebben. 
De mTOR-pathway in de skeletspier lijkt, in deze studie, geen verklaring voor de 
gevonden verschillen in insuline gevoeligheid. Deze bevindingen kunnen nieuwe 
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aanknopingspunten geven voor verder onderzoek gericht op het ophelderen van de 
pathogenese van insulineresistentie en T2DM in Hindostanen. Zo zou het interessant 
zijn om de rol van vetweefsel te onderzoeken in de verminderde glucose verwerking in 
Hindostanen in vergelijking met blanke Kaukasiërs.
In hoofdstuk 9 worden  de effecten beschreven van een 8 dagen durend zeer laag 
calorisch dieet (ZLCD) in 12 Hindostanen van middelbare leeftijd met overgewicht en 
12 voor leeftijd en BMI gematchte blanke Kaukasiërs op de cardiovasculaire functie, 
ectopische vetverdeling en myocardiale TG. Het doel van deze studie was te onderzoe-
ken of er een verschil is in metabole en functionele cardiovasculaire flexibiliteit op een 
kortdurend ZLCD tussen Hindostanen en blanke Kaukasiërs. Voor het dieet waren de 
Hindostanen reeds meer ongevoelig voor insuline dan blanke Kaukasiërs. Net als bij de 
jonge gezonde Hindostanen en blanke Kaukasiërs, waren de cardiale dimensies kleiner 
bij Hindostanen van middelbare leeftijd dan in blanke Kaukasiërs, ook na correctie voor 
lichaamsoppervlakte. De PWV was hoger in het distale deel van de aorta in Hindostanen. 
Systolische en diastolische cardiale functie, myocardiaal en pericardiaal vet waren niet 
verschillend tussen beide groepen. Na het ZLCD daalde het lichaamsgewicht en steeg 
de myocardiale TG accumulatie in beide etnische groepen. Bovendien verminderde de 
diastolische functie in dezelfde mate in beide groepen. Echter, het paracardiale vet en 
de PWV lieten een verschillende respons zien op het ZLCD, met een gunstiger respons 
in de Kaukasische groep.
De resultaten van onze studie tonen een vergelijkbare respons van het hart ten aan-
zien van TG accumulatie in reactie op een ZLCD in Hindostanen van middelbare leeftijd, 
met overgewicht en insulineresistentie in vergelijking met op leeftijd en BMI gematchte, 
maar minder insuline resistente, blanke Kaukasiërs. Er lijkt echter een minder gunstige 
respons te zijn op het 8 dagen durend ZLCD in Hindostanen ten aanzien van het para-
cardiale vet volume en de PWV.
Behandeling met op cisplatinum gebaseerde chemotherapie is geassocieerd met een 
verhoogde prevalentie van cardiovasculaire risicofactoren, zoals centrale adipositas 
en metabole verstoringen, zoals dyslipidemie en insulineresistentie. Behandeling van 
testiskanker (teelbalkanker) met cisplatinum, bleomycine en etoposide (BEP) chemothe-
rapie is ook geassocieerd met acute vasculaire toxiciteit en subacute veranderingen in 
hartfunctie en met, op de lange termijn, cardiovasculaire ziekte. Er is echter weinig be-
kend over de acute effecten van op cisplatinum gebaseerde chemotherapie op cardiale 
functie, lichaamsvetverdeling en metabole parameters. Acute effecten worden gedefi-
nieerd als de effecten die ontstaan binnen 3 maanden na start van de chemotherapie. 
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Hoofdstuk 10 toont aan dat op cisplatinum gebaseerde chemotherapie voor tes-
tiskanker acute veranderingen in diastolische cardiale functie induceert, wat gepaard 
gaat met ongunstige metabole veranderingen. Cardiale functie, vetverdeling en me-
tabole parameters werden onderzocht in 14 patiënten met testiskanker voor start van 
chemotherapie en kort na de laatste chemotherapie, dit was ongeveer 3 maanden na 
start van de therapie. Wij toonden aan dat behandeling met op cisplatinum gebaseerde 
chemotherapie voor testiskanker, acute veranderingen in diastolische hartfunctie 
induceert, die gepaard gaan met ongunstige metabole veranderingen. Alhoewel de 
voorspellende betekenis van deze diastolische cardiale veranderingen voor cardiovas-
culaire morbiditeit op de lange termijn op dit moment nog niet duidelijk is, lijkt het 
aannemelijk dat ze uiteindelijk daadwerkelijk kunnen leiden tot hart- en vaatziekten. 
Aangezien de nadelige metabole veranderingen bij kunnen dragen aan het ontwik-
kelen van hart- en vaatziekten, moeten deze risicofactoren worden gemonitord en zo 
nodig worden behandeld.
Met behulp van MRI van de vaatwand kan onderscheid gemaakt worden tussen het 
lumen, de dikte van de vaatwand en de karakteristieken van atherosclerotische plaques. 
Voor klinische toepasbaarheid is hoge spatiële resolutie, verkregen door optimale sig-
naal-ruis ratio en contrast-ruis ratio, noodzakelijk. In vele toepassingen geeft ultra-sterk 
veld MRI een betere signaal-ruis ratio en contrast-ruis ratio, welke gebruikt kunnen wor-
den om de spatiële resolutie te verhogen. Naar verwachting kan MRI beeldvorming van 
de vaatwand van de carotiden dus profiteren van een hogere magneet veldsterkte. Het 
onderzoek beschreven in hoofdstuk 11 vergelijkt de beeldvorming van de vaatwand 
van de carotiden van gezonde vrijwilligers op 3T en 7T, dus op een lagere respectievelijk 
hogere magneet veldsterkte. Achttien vrijwilligers ondergingen MRI onderzoeken op 
7T (waarbij gebruik werd gemaakt van een zelfgebouwde zend/ontvang coil van 15 cm 
diameter) en op 3T (waarbij gebruik gemaakt werd van een commerciële coil met twee 
flexibele ovale elementen, elk van 14 x 17 cm). MRI van de vaatwand van de linker carotis 
werd uitgevoerd op 7T met identieke in-plane resolutie als op 3T MRI (0.46 x 0.46 mm2). 
Hiermee werden transversale T1 en T2 gewogen afbeeldingen verkregen. De resultaten 
laten zien dat zowel de morfologische metingen van de carotis vaatwand (zowel de 
luminale als de vaatwand regio) als de intra- en inter-observer reproduceerbaarheid 
vergelijkbaar zijn tussen 3T en 7T. Bovendien verbetert beeldvorming van de carotis 
vaatwand op 7T MRI ten opzichte van op 3T de signaal-ruis ratio van de vaatwand en de 
contrast-ruis ratio.
Dit hoofdstuk illustreert de mogelijke waarde van 7T MRI voor de beoordeling van 
het lumen en de vaatwand van de arteria carotis, aangezien accurate afgrenzing van de 
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vaatwand van de arteria carotis van belang is om atherosclerose en atherosclerotische 
veranderingen van de vaatwand op te sporen.
De hogere veldsterkte brengt een reeks technische uitdagingen voor cardiovasculaire 
MRI met zich mee. Cardiovasculaire MRI vereist goede compensatie voor de beweging 
van het hart en de ademhaling en voor veldinhomogeniteit. Een andere uitdaging is 
het verkrijgen van een betrouwbaar elektrocardiogram. Hoofdstuk 12 beschrijft de 
resultaten van een studie naar veiligheid van stents in de coronairvaten (kransslagaders) 
op 7T MRI, door het bepalen van verplaatsing en opwarming van cobalt alloy stents, een 
type coronairstent, met een lengte van 5-85.8 mm in een 'worst-case' scenario. Daarbij 
worden ook de initiële resultaten beschreven van de klinische uitvoerbaarheid van 7T 
cardiovasculaire MRI in gezonde vrijwilligers en patiënten met hart- en vaatziekten. De 
resultaten van deze studie tonen aan dat cardiovasculaire MRI op 7T veilig is in patiën-
ten met cobalt alloy coronair stents met een lengte tussen 5 en 85.8mm. Verder laten 
de resultaten zien dat klinische cardiovasculaire MRI op 7T uitvoerbaar is bij gezonde 
vrijwilligers en bij patiënten met hart- en vaatziekten. Technische uitdagingen moeten 
nog overwonnen worden voordat 7T routinematig klinisch gebruikt kan worden. In de 
klinische praktijk zal het voordeel van een ultra-hoge veldsterkte MRI boven een lagere 
veldsterkte MRI, zoals 1.5 of 3.0T, moeten blijken.
Concluderend: DM leidt tot cardiovasculaire complicaties. Overgewicht en obesitas 
zijn een belangrijke risicofactor voor het ontwikkelen van T2DM en de toenemende 
prevalentie van overgewicht en obesitas heeft geleid tot een daarmee samengaande 
toename in de prevalentie van T2DM. T2DM is een van de meest voorkomende chro-
nische ziekten in de wereld. De pathogenese van de cardiovasculaire complicaties in 
T2DM is multifactorieel, maar een belangrijke rol lijkt toe te schrijven aan de ectopische 
accumulatie van TG in skeletspier, de lever en in en rondom het hart. Gewichtsverlies 
wordt momenteel gezien als de meest effectieve behandeling van T2DM. Een afname 
in ectopisch vet wordt beschouwd als een van de mechanismen voor toegenomen 
insuline gevoeligheid na gewichtsverlies. Echter, blijvend gewichtsverlies is moeilijk, 
aangezien permanente leefstijlveranderingen nodig zijn om te voorkomen dat er weer 
gewichtstoename plaatsvindt. Bariatrische chirurgie is een andere mogelijke behande-
ling voor T2DM, aangezien dit resulteert in fors gewichtsverlies, duidelijke verbetering 
in de glycemische controle en zelfs tot remissie van T2DM.
Patiënten met T1DM hebben een stijvere aorta dan gezonde vrijwilligers en dit is 
gecorreleerd met LV diastolische functie en witte stof integriteit in het brein. T1DM heeft 
ook gevolgen voor het volume van de grijze stof.
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Wij hebben aangetoond dat bij patiënten met T2DM en coronairlijden een 16 weken 
durend (Z)LCD de cardiovasculaire functie en ectopische vet distributie kan verbeteren. 
Dit benadrukt het belang van dieetinterventies in deze patiëntengroep en onderstreept 
dat gewichtsverlies de hoeksteen van de behandeling blijft. 
Aangezien de prevalentie van overgewicht/obesitas en van T2DM een epidemische 
omvang bereikt, dient de nadruk te liggen op preventie van overgewicht. Naast de 
resultaten van het 16 weken (Z)LCD, toonde een studie in T2DM patiënten voor en 16 
weken na bariatrische chirurgie een sterkere afname in paracardiaal vet, in vergelijking 
tot epicardiaal vet. De implicaties van deze bevindingen moeten worden onderzocht in 
toekomstige studies. 
Verder tonen de studies in dit proefschrift aan dat al op jonge leeftijd verschillen 
bestaan in cardiale dimensies en functie tussen Hindostanen en blanke Kaukasiërs. 
Daarnaast verslechtert een HVHC dieet de insuline gevoeligheid in jonge, slanke, 
gezonde Hindostanen, maar niet in blanke Kaukasiërs. De ectopische vetverdeling is 
vergelijkbaar tussen Hindostanen en blanke Kaukasiërs, zowel in de jonge groep als in 
de groep van middelbare leeftijd. Echter, paracardiaal vet en PWV lieten een verschil-
lende respons zien op een ZLCD, met een gunstiger respons bij blanke Kaukasiërs.
Onze bevindingen dragen bij aan een beter begrip van het verhoogde risico op hart- 
en vaatziekten en T2DM in Hindostanen. Desalniettemin zijn er meer studies nodig om 
de mechanismen, die leiden tot een verhoogd risico, te onderzoeken en hopelijk nog 
beter te begrijpen. Tot slot beschrijft dit proefschrift de resultaten van de toepasbaarheid 
van de beeldvorming van de carotis vaatwand op 7T MRI. Bovendien worden data over 
veiligheid van coronairstents op 7T en de initiële toepasbaarheid van cardiovasculaire 
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